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Abstract 
 
Stable telomeres play a key role to the survival of cancer cells; therefore, 
different cancer chemotherapeutic approaches have been developed in order to 
disrupt or destabilise telomeres or telomerase. One of the newest methods is 
the disruption of vital protein–protein interactions in the telomere, such as that 
between shelterin components TRF1 and TIN2. The principal aim of this 
project was to obtain a novel peptide-like molecule, an analogue of a key 
interacting region of TIN2 that could compete effectively for the binding sites 
on TRF1 and so lead to the destabilisation of telomere structure. Molecular 
modelling and simulations were undertaken as the starting point of the project. 
Structure-based drug design was applied, starting from the available crystal 
structure data. A library of peptide analogues of the TRF1-binding motif in 
TIN2 was designed using the MM-GBSA simulation method to predict binding 
affinities. Then, a number of the peptide analogues were selected from the 
library for further investigations. 
 
The secondary goal was to investigate the accuracy of the predicted ΔGbinding 
values and try to optimise them; the latter aim was set out after finding a 
significant difference in the predicted binding free energy values after 
repeating the identical protocol for the same complex system. Therefore, 
different approaches were applied to optimise the predicted ΔGbinding values. 
Subsequently, selected TIN2 peptide analogues were synthesised in the 
laboratory using Fmoc solid-phase peptide synthesis. Then, the hTRF1 protein 
	 II 
was expressed and purified in preparation for the development of the in vitro 
assay. Finally, biophysical evaluations and screening of the peptide analogues 
were performed using fluorescence polarisation assay.  
 
One of the peptide analogues developed in this study was identified as an early 
lead compound. In addition, the findings of this research showed that the 
ΔGbinding values of the peptide analogues have significantly improved accuracy 
after optimisation. As a result of these investigations, suggestions were 
identified for future research. 
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1. Introduction 
1.1 Telomeres and Telomerase Enzyme 
 
Eukaryotic chromosomes are composed of linear DNA molecules, condensed 
around histone proteins in the nucleus of the cells. Generally, chromosome 
ends face two specific challenges: the first is how to ensure that they are not 
mistaken for DNA double strand (ds) breaks and processed by a cell’s DNA 
damage repair systems, and the second is how to preserve genomic integrity 
during the DNA replication process of cell proliferations 1. As will be 
discussed in more detail below, the existence of telomeres at the end of the 
linear DNA could answer both of the mysteries 2.  
 
Telomeres can be defined as specialised nucleoprotein structures at the ends of 
chromosomes (Figure 1.1) to protect both ends of a chromosome from all 
events that can cause cell death 3. The nucleic acid part is repetitive sequence 
tract of TTAGGG/AATCCC double stranded sequences ending with a single-
stranded (ss) G-rich 3' overhang. The G-rich strand of telomeric DNA is 
oriented 5'–3' towards the terminal part of the chromosome 4. The 3' single-
strand overhang is approximately 200 nucleotides, bending backward to create 
a large loop structure known as a “T-loop” that sequesters the chromosome 
terminus 5. The overhang invades the double-stranded telomeric region and 
replaces one of the telomeric strands to generate a small loop called 
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displacement loop (D-loop) (Figure 1.1B). The structure produced seals the 
chromosome end and prevents it being recognised as a double-strand break 6. 
 
 
 
Figure 1.1 Telomeres location and structure in the cells. (A) Telomeres at the end of 
chromosomal DNA in the nucleus of the cell (taken from Hubbart 2014) 7. (B) The 
produced T-loop and D-loop structure in the telomeres (taken from Deng et al., 2008) 
8. 	
Human and other eukaryotes telomeres have virtually the same structure 9 and 
function 5. Telomere shortening can induce cancer and aging issues 10. Loss of 
the telomeric regions occurs slowly with each cell division 4. In humans, 
(TTAGGG)-n repeats at birth are about 15–20 kb (kilo base pairs) length, 
whereas they become 8–10 kb in adults because each cell division leads to the 
loss of some of the (TTAGGG)-n tracts, and occasionally the tracts loss are 
arising from exonuclease activities or deletion 5. Conversely, tract lengthening 
may occur either by the telomerase enzyme or by recombination mechanism. 
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The essential pathway of telomere length maintenance is through the 
telomerase enzyme, a reverse transcriptase, which adds further copies of the G-
rich repetitive sequences to the 3' end of telomeres, after which DNA 
polymerase finalises the complementary strand. This enzyme is generally only 
activated in stem cells and gametes and permits them to proliferate indefinitely. 
As a result, in human somatic cells, replication potential is limited to 50–70 
cell divisions because without active telomerase, telomeres shortening 
gradually lead to a permanent proliferation arrest (senescence), proliferating 
cells beyond senescence limits (crisis) and cell death subsequently. In contrast, 
the proliferation potential of most cancer cells is unlimited because the 
telomerase enzyme is also activated to maintain the stability of the short 
individual telomeres; hence, any approach that could inhibit the enzyme and 
thus promote telomeric attrition has the potential for the selective killing of 
cancer cells 11,12. 
 
1.2 History of Telomere Discovery 
 
The importance of chromosome ends was first recognised by Muller (1938) 
and McClintock (1941) who established that the terminus of eukaryotic 
chromosomes has a different structure 13. Then, Leonard Hayflick discovered 
that cultured normal human cells have limited capacity for division; afterward, 
they reach the state of senescence; a phenomenon now defined by the 
‘Hayflick limit’. This achievement has enabled other researchers to obviously 
progress in understanding the molecular mechanisms of ageing 14. Later on, 
Alexey Olovnikov hypothesised that some mechanism had to be available to 
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repair and maintain the ends of chromosomes or the continuing replication of 
linear DNA by polymerase enzymes would gradually cause the loss of terminal 
sequences; and, in 1971, Olovnikov described the existence of the DNA end-
under replication problem 13. Finally, the Nobel Prize in medicine or 
physiology 2009 was awarded to Elizabeth Blackburn, Carol Greider and Jack 
Szostak because of their role in the discovery of telomere and the telomerase 
enzyme 15. 
 
1.3 Telomeric Proteins 
 
A telomere contains many copies of each of six key protein components, 
known collectively as “shelterin” or the “telosome”, as shown in Figure 1.1B 
16. Shelterin has at least three key functions in the telomeres, which are: 
regulating the structure of the telomeric end, contributing to the creation of T-
loops for protecting telomeres and restraining the synthesis of telomeric DNA 
by telomerase 17. All of the shelterin proteins can perform their functions in 
conjunction with associated proteins (Table 1-1). 
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Table 1-1 The full name, main binding site, function and dysfunction of shelterin and 
shelterin-associated proteins that regulate telomeric length 16,18,19.  
 
Protein Full name Binds to Normal function Dysfunction 
 
Binding directly with telomeres 
 
TRF1 Telomere 
repeat 
binding 
factor 1 
Ds DNA Negative regulator 
of TL: telomerase 
repressor  
 
Inhibition (↓) lead 
to TL increase (↑) 
 
TRF2 Telomere 
repeat 
binding 
factor 2 
DsDNA Negative regulator 
of TL and ATM 
inhibitor  
 
↓ lead to G-
overhang ↓; 
hRAP inhibition; 
DNA damage 
factors ↑ 
 
POT1 Protection 
of telomeres 
1 
Ss DNA Connecting ss to 
dsDNA 
POT 1 ↓ cause G- 
overhang ↓ and 
TL↑ 
TPP1 Stimulating the 
activity of 
helicase, and 
preventing re-
annealing 
 
 
Indirect binding through TRF1 or TRF2 
 
TPP1 Tripeptidyl 
peptidase 1 
POT1 Binding POT1 to 
TRF1 
 
↓ lead to TL ↑ 
 
 TIN2   
TIN2 TRF1 
interacting 
nuclear 
factor 2 
TRF1 Control poly 
(ADP-ribose) 
polymerase 
activity tankyrase 
↓ lead to TRF1/2 
↓, which cause 
hRAP1 ↓ and TL 
↑ 
 
TRF2 Connecting TRF1 
and TRF2 
 
 
TPP1 Tethering TRF1 
complex to TPP1 
 
 
RAP1 Repressor 
activator 
protein 1 
 
TRF2 Negative regulator 
TL and 
component of the 
DNA repair 
↓ lead to TL ↑ 
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response  
Associated proteins 
 
Apollo  TRF2 Protection of 
telomere during 
and after 
replication 
 
↓ lead to DNA 
damage signal 
 
pinX1   TRF1  ↓ of telomerase 
activity 
↑ lead to 
telomerase 
activity ↓ and 
TL ↓ 
 
pinX3 ↑ lead to TL ↑ 
 
Tankyrase 1 TRF1-
interacting 
ankyrin-related 
ADP-ribose 
polymerase 1 
and 2 
TRF1 TRF1 down-
regulation 
 
Tankyrase ↑ 
lead to TRF1 ↓ 
and cause TL ↑ 
Tankyrase 2 Cell division 
 
1.3.1 TRF1 and TRF2 Proteins 
 
Both of the TRF1 and TRF2 proteins are fundamental, directly binding double-
stranded telomeric DNA 20 and then recruiting most of the other telomere-
associated proteins. However, their molecular mechanism remains unknown. 
The two proteins share the same molecular architecture, characterised by a C-
terminal Myb/SANT DNA binding domain, which is responsible on binding 
with telomeric DNA, and an N-terminal TRFH (Telomere Related Factor 
Homology) domain, which mediates homodimerisation and recruits other 
telomeric proteins 21. The N terminus of TRF2 contains a glycine and arginine 
(GAR) domain, while the N terminus of TRF1 encompasses aspartic acid and 
glutamic acid (DE) domain (Figure 1.2a). 
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Figure 1.2 Schematic representation of the shelterin proteins in the telomere, their 
binding domains and their interactions. (a) Interactions of the components of human 
shelterin (b) Shelterin position in the telomeric DNA (taken from Palm and de Lange, 
2008) 19. 
	
As shown in Figure 1.3, TRFH domains of both TRF1 and TRF2 have virtually 
the same protein docking sites (F142 in TRF1 and F120 in TRF2); however, in 
vivo, TRF1 interacts with TIN2 through TRFH domain, while TRF2 interacts 
with TIN2 in a region outside of the TRFH domain, through a C-terminal 
domain, and TRF2TRFH recruits Apollo protein (shelterin-associated protein), 
instead; it is clear that the differences in recruiting proteins by TRF2TRFH and 
TRF1TRFH result from some structural differences 21. Structural analysis shows 
that sequences FxLxP and YxLxP are the target sites for the TRF1 F142 and 
TRF2 F120 docking sites, respectively (x is any amino acid). In addition to 
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TIN2 and Apollo, other TRF1 and TRF2 interacting proteins might also use the 
F/YxLxP motif to interact with the TRFH docking site. Indeed, a number of 
non-shelterin proteins that are suggested to interact with TRF1 and TRF2 have 
a conserved F/YxLxP motif; for example, Ataxia Telangiectasia Mutated 
(ATM) protein. Nevertheless, several accessory proteins make interactions 
outside of the TRFH domains. For example, tankyrase1 interacts with the N-
terminal domain of TRF1 (D/E rich area) (Figure 1.3a); also, WRN and ORC1 
bind with the N-terminus of TRF2 (Figure 1.3b) 19. 
 
 
 
Figure 1.3 TRF1 and TRF2 binding proteins. (a) Proteins that are associated with 
TRF1. (b) Proteins associated with TRF2 (taken from Palm and de Lange 2008) 19. 
	
Regarding the roles of the two proteins, TRF1 has a crucial role to maintain 
telomeric length and shelterin component stability in the telomeres of the 
chromosomal DNA 22, and TRF2 protects telomeres through keeping T-loops 
stable and inhibiting DNA Damage Response (DDR) 23; any disruption of these 
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proteins causes telomeric instability and may lead to direct apoptosis of the 
cells 24. 
 
1.3.2 TIN2 Protein 
 
TIN2 is one of the shelterin proteins; it creates a bridge and assembles shelterin 
proteins by directly interacting with TRF1, TRF2 and TPP1/POT1; moreover, 
it tethers double stranded and single stranded telomeric DNA, stabilise TRF2 
protein through attaching TRF1 and it is essential for the stability and function 
of the complex 25,26 (Figure 1.2). As discussed above, TIN2 binds to the 
TRF1TRFH through the C-terminal motif, whereas, it connects to the TRF2 and 
TPP1 through the N-terminal domain. Depletion or the release of mutant 
variants of this protein has a destabilising effect on shelterin 27,28.  
 
1.3.3 RAP1 Protein 
 
Another key shelterin proteins is RAP1; it’s a crucial binding partner of TRF2; 
each RAP1 interacts with one TRF2, therefore, this protein’s stability is related 
to the TRF2. It has three detectable domains; a Myb domain that mediates 
interactions of the protein with an unknown partner, an N-terminal BRCT 
motif, which binds with a phosphorylated peptide, and a C-terminal domain 
that confers the interaction with short helical region of the TRF2 hinge domain 
(Figure 1.2) 19.  
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1.3.4 TPP1 Protein 
 
TPP1 protein links the POT1 protein with TIN2 through its centrally located 
POT1 interaction domain and C-terminal TIN2 interaction domain (Figure 
1.2), thus recruiting POT1 to the shelterin proteins TRF1 and TRF2. It has a 
Ser-rich region with an unknown function. It is presumed that TPP1 interacts 
with the telomerase enzyme due to the presence of an OB-fold domain at the N 
terminus (Figure 1.2a). Mutants of TPP1 protein, chiefly those with disturbed 
binding to POT1, lead to the removal of POT1 protein from telomeres, 
telomere deprotection and the triggering of a DNA damage response 2,19.  
 
1.3.5 POT1 Protein 
 
POT1 is one of the shelterin-complex proteins that bind directly to the 
telomeric DNA, connecting the single-stranded 3` extension at the end of 
chromosomes and TPP1 protein, as shown in Figure 1.2b.  The N-terminus of 
this protein contains two OB folds, which have the ability to recognise the G-
strand telomeric sequence in vitro. The OB-folds are composed of a common 
protein domain, originally identified as an oligonucleotide or oligosaccharide-
binding domain, and can recognise single-stranded telomeric overhangs. 
Moreover, according to sequence analysis, a third OB-fold is located in the C-
terminus of POT1 (Figure 1.2a) 19. Genetic studies in humans, mice, plants, 
yeast and Tetrahymena have documented that POT1 plays a basic role in 
telomere integrity, since POT1 knockout stimulates damaging of the DNA, 
initiated by the ataxia telangiectasia related protein kinase (ATR). Inhibition of 
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the activity of ATR by POT1 is probably due to POT1 binding to telomeric 
ssDNA and inhibiting ATR activation by blocking access of the ss binding 
protein RPA (replication protein A), by which ATR is recruited to the telomere 
28. In addition, repression of POT1 may lead to increase in the telomere length 
16.  
 
1.4 Tumourigenesis and Telomeres 
 
A set of genetic modifications, which lead to disturbed growth and 
differentiation of normal cells, define cancers. As described in the literature, 
tumourigenesis can arise from various cornerstones and is characterised by 
distinctive hallmarks. The alterations can be rationalised as inhibitions of 
tumour suppressor genes and improperly activated normal cellular genes 29. 
According to Hanahan and Weinberg (2011), six distinctive signs characterise 
cancer from normal cells, these are: escaping growth suppressor signals, 
avoiding DNA damage responses or resisting apoptosis (automatic cell death), 
incorrect signaling of cells to proliferate, production of angiogenesis, infinite 
cell replicative potential and invasive character 30-32. 
 
Intact telomeres have a profound impact on the division and survival of cells. 
Telomeric shortening or attrition contributes to chromosomal instability that 
may promote tumourigenesis 33,34. Shammas has suggested telomeric 
dysfunctions are highly associated with head, neck, gastrointestinal, renal cell, 
bladder and lung cancers due to a sequence of biochemical reactions in vivo 35.  
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Normally, any critical shortening or erosions of the telomeres in stem, somatic 
and epigenetic cells can deprotect the telomeric cap and lead to a DNA damage 
response, which activates the tumour suppressor p53 protein, resulting in 
replicative senescence and cell apoptosis. In contrast, deficiencies related to the 
lack of p53 protein or incompetency of the cells’ checkpoint mechanisms can 
trigger continuous telomere shortening until the cells reach crisis and genomic 
instability; the consequence will be chromosomal end-to-end fusions that either 
produce cell apoptosis or developing oncogenes (Figure 1.4) 36,37.  		
Telomere erosion 
 
 
               Intact checkpoint                                                       Compromised checkpoint 
 
 
 
 
 
 
           ATM/ATR                                                                    Telomere fusions 
 
 
 
 
                    p53/p16                                                       Chromosomal instability 
 
 
 
 
 
 
 Replicative senescence         Mitotic catastrophe       Gene amplification, 
                                               Apoptosis                      Loss of heterozygocity, 
                                                                                     Oncogenic translocation          
                                                                                                                                                   
                  
                     Tumour suppression                            Tumour promotion                                                                                    		
Figure 1.4 Consequences of the telomere attrition in the eukaryotic cells (adapted from 
Xu et al., 2013) 37.  
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1.5 Telomere Disruption and Destabilisation for 
Cancer Treatment 
 
Cancer cells prevent their telomere shortening and cell death through two 
mechanisms. The first pathway involves activating the telomerase enzyme as a 
maintenance factor to prohibit further telomere shortening because it adds 
multiple copies of the 5'-GGTTAG-3' to the telomeric end (G-strand of the 
telomere). Telomerase activity is overexpressed in about 85–90% of tumours 
and it is absent in only 10–15% of those cells. The second pathway of 
lengthening telomeres in cancer cells lacking telomerase is sustaining telomeric 
length through recombination-based mechanism, known as alternative 
lengthening of telomere (ALT) 38,39. Since stable telomeres are essential to the 
survival of cancer cells, different chemotherapeutic approaches have been 
developed in order to disrupt or destabilise telomeres or telomerase 40. Most of 
the research has been focused on targeting the activity of the telomerase 
enzyme by directly inhibiting telomerase or by preventing telomerase access to 
the telomeres; however, more recently the approach of directly targeting 
telomeric proteins has developed as a pathway to cancer chemotherapy 41-43. 
 
1.5.1 Targeting Telomerase Enzyme 
 
The strategy of targeting telomerase enzyme for cancer treatment has been the 
focus of most researchers because telomerase overexpression is the most 
obvious characteristic of most cancer cells 44 and it could be an attractive target 
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for cancer therapy as a consequence of the persuasive link between cellular 
immortalisation and reactivation of telomerase. Any compound able to inhibit 
the telomerase enzyme would theoretically return cancerous cells to the normal 
situation of a (finite) potential for replication. Furthermore, molecules targeting 
telomerase enzyme are characterised by selectivity for cancer cells over normal 
somatic cells. However, therapeutic strategies for shortening telomeres through 
administration of telomerase inhibitors are practically challenging because 
significant telomere shortening would require continuous treatment of the 
patient for multiple population doublings of tumour cells and the population 
doubling time of most solid tumours is several days to weeks; thus, telomerase 
inhibitors may take months to have an effect on the patient. These obstacles 
have hampered the release of these drug candidates into the market and clinic.  
40,41,45. 
 
1.5.2 Targeting Telomeric DNA (G-quadruplexes) 
 
This approach directly targets the guanine rich sequences of the telomeric ends 
and modifies telomeric structures 46 by guanine–guanine base pairing of the 3` 
sequences to form a particular structure called G-quadruplex or G4 DNA that 
makes a protective cap which is no longer recognised by the telomerase 
enzyme. The new G-quadruplex structures consist of two or more G-tetrads 
(quartets), and each quartet comprises four guanine bases, linked together by 8 
hydrogen bonds in a cycle (Figure 1.5A), when a central cation can improve 
the stability of the structure. G-quadruplexes can assemble either through 
intermolecular bonding (Figure 1.5B) or intramolecular bonding (Figure 1.5C), 
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but human telomeric DNA can fold to generate an intramolecular G-
quadruplex structure, depicted as a basket, having three G-tetrads, each 
stabilised by Hoogsteen base pairing (Figure 1.5D). The stabilised G4 DNA in 
cancerous cells prevents the ability of telomeres to lengthen after cell division, 
and eventually cancer cells will die 47.  
 
Primarily, the aim of targeting the 3' DNA sequence through G-quadruplex 
inducing ligands was to mitigate telomerase enzyme effects on the telomeres 
48,49, but a series of studies on a variety of diverse G-quadruplex ligands, 
confirmed unexpected outcomes, specifically the apoptosis of the cells after 
just a few days of ligand exposure, before significant telomere shortening 
could have taken place. These results have been interpreted as due to ligand 
induced telomeric cap opening and structural disruptions, which finally 
produce chromosomal end-to-end fusions 50-52. These arguments have support 
from a number of observations and the conclusion is that the target of G-
quadruplex ligands is in effect telomeres rather than telomerase 41. Hence, 
based on these results, the formation of G-quadruplex promoting ligands could 
be a novel therapy for cancer treatment 53.  
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Figure 1.5 Structures of G-tetrad and G-quadruplexes. (A) G-tetrads are 4 guanine 
residues forming a planar structure (B) A parallel model of G-quadruplexes. (C) A 
model of intermolecular G-quadruplexes  (D) A model of intramolecular basket of G-
quadruplexes (taken from Rezler et al., 2003) 47,54. 
 
1.5.3 Targeting Shelterin Proteins 
 
The shelterin targeting approach is the strategy of targeting compounds that 
have destabilising, disrupting and/or inhibiting effects on the shelterin proteins, 
on the basis that they may have antitumour effects through disruption and 
apoptosis of the cells (Figure 1.6); for example, inhibition of TRF2 protein can 
induce massive telomere dysfunction and apoptosis of tumour cells by 
uncapping of the telomere ends, end-to-end fusions and activation of ATM/p53 
DDR pathway 55; another example is the telomeric damage induced by TPP1 
knock down due to inhibiting the associations between POT1 with TRF1 and 
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TRF2 proteins 56. Furthermore, Pal et al. (2015) explained that inhibiting TRF1 
and TRF2 proteins can produce a telomere disruption and cell apoptosis in 
renal cell carcinoma through arresting the progression of cell cycle in Phase S 
and G1/S, respectively 57. 
 
 
 
Figure 1.6 Different approaches for inhibiting telomeres (adapted from Folini et al., 
2009) 58. 
 
The latest publication on mouse TRF1 ablation by Garcia-Beccaria et al. 
(2015) has examined the effect of TRF1 abrogation in lung cancer cells with 
inactivated p53 suppressor proteins; significant positive results have been 
Chapter One                                                                                                                  Introduction 
	 18 
obtained on the number and size of the malignant cells in the first generation, 
disregarding the length of the telomeres; this reveals that disturbing TRF1 
could potentially stop cancer progression and metastasis in both mouse models 
and human. In addition, this approach may retain selectivity for cancer over 
normal cells (a worry when targeting telomeres rather than telomerase), as it 
has proved to have a minimal effect on the growth and activity of other organs 
when used long-term, just a slight reversible inhibition of bone marrow and 
blood cells was noticed. The promising results could become a possible new 
chemotherapy for lung cancer. Furthermore, this strategy could be effective for 
diverse types of cancer because it follows a universal mechanism of telomere 
inhibition (telomeres uncapping) 59. 
 
In conclusion, integrity of the shelterin proteins and protein–protein 
interactions (PPIs) has a significant effect in telomere maintenance 60. In 
addition, the structure and accessibility of telomeres in cancer cells seems to 
vary considerably from that of normal cell telomeres, which might lead to 
specific cytotoxicity 41. Also, the promising results of the G-quadruplex 
compounds (as discussed in Section 1.5.2) might increase the chance of 
cytoselectivity in shelterin inhibitors. However, the individual shelterin 
components have not so far been studied greatly as targets for small-molecule 
drugs, and the challenge remains to discover novel compounds, which 
selectively interfere with protein–protein and protein-DNA interactions to 
destabilise shelterin components.  
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1.6  Drug Discovery Process 
 
The sequence of steps from candidate molecule identification to market release 
of a new medication is termed the drug discovery process. In medicinal 
chemistry the term “hit” describes a molecule able to modulate and affect the 
specific target with sufficient activity 61; while a “lead compound” is a 
molecule that has therapeutic and pharmacological activities, but requiring 
chemical optimisation to improve physicochemical characteristics and so be 
suitable for use as a drug 62. Normally, the drug discovery process is an 
expensive and time consuming (12–15 years). It starts with a hit and lead 
identification; after that, lead optimisation is achieved. Then, the expensive 
processes of preclinical and clinical studies follow (Figure 1.7). Target 
identification and validation is realised either before or after a ‘hit’ 
identification. In classical drug discovery, lead identification comes before 
target validation 63-65, while, in most more contemporary approaches, target 
identification and validation precedes hit and lead finding 66. 
  
Significantly, 90% of molecules identified at the start of the drug discovery 
process fail somewhere along the pipeline. Within the clinical phases, on 
average, 38% of candidates are abandoned in phase I because of their toxicity, 
lack of efficacy and bioavailability hurdles. Next, phase II causes 63% of the 
remaining to leave the process, and only 45% of the molecules that have 
succeeded in previous phases, can pass phase III clinical trials. On the basis of 
this data, the most obvious difficulties in developing new drugs are clearly 
issues of efficacy, bioavailability and toxicity 67. Two main factors are 
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contributing to increase costs of research and development (R&D) in the 
pharmaceutical industries; the first is the new regulation by the authorities to 
confirm a drug with high efficacy, safety and quality; the second is the 
increased efforts of governments to decrease medicine costs and compensating 
brands by generic companies 68.  
 
It is clear therefore that both of the high failure rate of new drug development 
projects and high costs of R&D cause risen costs of new medicine in the 
market, which may not be affordable for the consumers and the companies 69. 
Therefore, pharmaceutical companies to be profitable and competitive, have to 
reduce costs through improving efficacy and bioavailability and decrease 
toxicity of the candidate molecules. 
 
 
 
Figure 1.7 Main steps of drug discovery and development process. 
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1.7 Lead Compound Identification 
 
Different approaches are available to first identify a hit or lead compound 70. 
Prior knowledge on the receptor or ligand is crucial for developing and 
optimising a lead compound. In the modern drug discovery processes, 
structural information on the protein or any targets plus familiarity with the 
ligand’s structural, physicochemical and pharmacokinetic properties (e.g. from 
identified hits) are important factors to improve the success of the process 71. It 
can be used with the aid of in silico approaches to develop a lead molecule 
72,73.  
 
Most of the methods are based on target molecules. After target identification 
or validation, various experiments are performed to find a hit compound, 
perform hit-to-lead development and lead optimisations 65 and usually the 
target is a protein, gene, gene product, or the modulation of a molecular 
mechanism 74. The advantage of this approach is the direct identification of an 
effective molecule against the specific well-known target, whose role in the 
disease is presumed well established; however, in reality the target may not 
provide a promising result due to a poor correlation with the disease state or an 
insufficient therapeutic window 75. On the other hand, sometimes the 3D 
structure of the target molecule is not identified or the approach is not 
dependent on the target structure, such as phenotypic screening. Most of the 
approaches are illustrated below: 
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1.7.1  Phenotypic Screening 
 
The traditional method of hit and lead compound discovery in classical 
pharmacology is the phenotypic screening approach. All of the serendipitous 
discoveries are related to this method. The technique is based on testing 
compounds in vivo, consequences on the cells, tissues, organs and the whole 
body system can be seen through physiological changes and modifications to 
the disease state. After confirming the results, investigations are undertaken to 
identify the molecular target 76. The advantage of this method is that one 
obtains directly disease responses to the tested compounds, which are closer to 
reality than proxy readout and there is no need for the prior knowledge of the 
molecular mechanism of the disease 65. However, the limitations are low 
throughput screening and potentially significant challenges to optimise the 
candidate molecules without the target information 75. 
 
1.7.2 High Throughput Screening  
 
High throughput screening (HTS) involves a robotic assay process for mass 
screening of compound libraries in the early stages of drug discovery to 
identify hit molecules, development to a lead molecule and optimisation of a 
lead 77. In the early days of HTS, thousands of compound were screened per 
day, after several years this evolved to 100,000 per day in ultra HTS (uHTS) 78, 
and recently, a paper published in 2010 by Agresti et al., has described a new 
uHTS technique that can screen 100,000 assays per only 10 hours 79. The first 
published work on HTS dates from the 1990s; now, it is an essential part of 
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most drug discovery projects in the pharmaceutical realm 80 because of 
screening large compound libraries during a limited time and miniaturised 
format of the assays through advances of liquid handling, microplate reader 
sensitivity and wells availability as 96, 384 and 3456 78,81. However, more 
recently the use of this technique has been cut back by several companies, due 
to the low rate of the molecules success to be a drug 82. Typically, HTS is 
achieved by big Pharma companies; in addition, it is of interest to academic, 
government and non profit institutions with a smaller scale of running 83.  
 
1.7.3 Fragment-Based Drug Discovery 
 
Fragment-based drug design (FBDD) is considered to be a promising new 
strategy for screening compounds to find a lead compound 84. The principle of 
this technique is the screening of small fragments, following the “rule of 
three”: the fragments molecular weight (MW) < 300 Da, calculated log P 
(ClogP) ≤ 3 and both hydrogen (H) bond donors and acceptors should be ≤ 3 
85,86. Individually the small fragments are low affinity molecules, but after 
combining several fragments, high-affinity ligands are produced. This 
approach require a dramatically smaller library than HTS method and it can be 
used as a complementary method of drug discovery 87. 
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1.7.4 Computer-Aided Drug Discovery 
 
Computer-aided drug design (CADD) is also called in silico drug design. It is 
based on computationally synthesising molecules and analysing molecular 
interactions to assist and speed up hit molecule identification, lead selection 
and optimisation and also to predict potential pharmacokinetic difficulties 88. 
CADD can considerably reduce the time, cost and workload in drug discovery 
projects; for example, selecting compounds from a library of molecules 
through virtual screening before experimental tests could produce the same 
level of lead identification at much reduced time and cost. Furthermore, it has 
the potential to improve efficacy, reduce toxicity and optimise pharmacokinetic 
activities of the selected molecules. In addition, it may be applied to design 
new molecules or modify existing structures to produce a novel compound 
82,89. Figure 1.8 outlines the role of CADD in drug discovery process, which 
the first step is identifying a target. Then, according to the availability of 3D 
receptor structure, choosing between ligand-based or structure-based drug 
design strategies. After in silico screening of the compounds to find a lead 
compound, lead optimisations step is achieved, followed by in vivo assays to 
confirm that if the compound can be a drug candidate and ready for the new 
steps of preclinical tests 82. 
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Figure 1.8 The role of CADD in the drug discovery processes 82.  
 
1.7.4.1 Structure-Based Drug Design 
 
Structure-based drug design (SBDD), which can also be described as a 
receptor-based drug design, encompasses identifying a lead compound and 
optimising it on the basis of knowledge of the 3D crystal or nuclear magnetic 
resonance (NMR) structure of the potential target. Docking and screening are 
applied to a library of selected molecules to find the most appropriate molecule 
as a novel compound to activate or inhibit (as required) the target receptor 
through predicting interaction energies between them. Detailed structural 
information on the target is the basis for designing ligand molecules and then 
docking. A major factor driving the development of SBDD has been the 
proteomic and genomic evolution, which has resulted in the production of 
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hundreds of new proteins and availability of their high-resolution X-ray crystal 
structures that can be used as potential drug targets 90-93. Most of the high-
resolution crystal structures of approximately one hundred thousand proteins 
are published in the Protein Data Bank (PDB) and Cambridge Crystallographic 
Data Centre that can be used as potential sources for SBDD 94,95.  
 
Formerly, static structures of the proteins were used in SBDD, but in reality, 
protein samples are ensembles of various conformation states, each 
conformation has a different free energy. Usually, proteins occupy a low 
energy state that their structures may be significantly different from the crystal 
structure; consequently, docking ligands to a single, specific conformation of 
the receptor may well lead to incorrect predictions, as it may not be the ligand 
bound conformation. However, now molecular dynamics and molecular 
modelling computational tools are helping solve these issues, as they can 
simulate and estimate a protein’s conformational space as a collection of 
snapshots for each protein structure describing their fluctuations due to 
conformational sampling 96,97. The essential steps of SBDD are illustrated in 
Figure 1.9. 
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Figure 1.9 Structure-based drug discovery process to find a lead compound (taken 
from Babine and Bender 1997) 98. 
 
1.7.4.2 Ligand-Based Drug Design 
 
Ligand-based drug design (LBDD) is one of the approaches of in silico drug 
design to find a lead molecule and optimise it when the 3D structure of the 
potential target is typically unknown; therefore, structural investigations of the 
ligand molecule and its pharmacophore are performed 99. Because LBDD is a 
ligand knowledge-based technique, previous information from active ligands is 
used to build up a picture of the similarity of the active sites and functional 
groups 82. 
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1.8 Molecular Recognition 
 
Molecular recognition deals with the investigations and analyses of the non-
covalent binding interactions between two or more molecules in the biological 
systems. In addition, it is essential to investigate various receptor–ligand 
binding interactions 100. Advances in biological, chemical and technical 
sciences have caused the evolution of this subject, especially those techniques 
that reveal 3D structural information of the molecules. In the drug discovery 
arena, all of the interactions and contacts between cell–cell, antigen–antibody, 
enzyme–substrate, hormone–receptor and drug–receptor are realised and 
analysed in terms of molecular recognition 101. In addition, it provides a 
theoretical framework to evaluate and optimise specificity, potency and 
stability of the ligands 61,102. Most of the non-covalent binding interactions are 
elucidated below. 
 
1.8.1  Hydrophobic Contacts 
 
Hydrophobic or lipophilic molecules are nonpolar molecules that do not 
optionally interact with water. In aqueous solution, these molecules tend to 
self-associate and form clusters to decrease their surface area and exclude 
water molecules 103. The hydrophobic molecules in the aqueous medium form 
a ‘hole’, which is surrounded by water molecules to produce a cage-like 
structure. The cages decrease the entropy of the systems due to aggregating the 
hydrophobic groups and producing a cluster to decrease the contact surface 
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area with the aqueous medium. Contacts between hydrophobic molecules are 
known as hydrophobic interactions; they are relatively stronger than other 
types of non-covalent interactions, such as hydrogen bonds and van der Waals 
forces 104. The strength of hydrophobic interactions is affected by several 
factors; for instance, aliphatic organic molecules have a stronger interaction 
than those of aromatic organic molecules. Additionally, a stronger interaction 
is produced through linear carbon chains rather than branched chains because 
the latter produce steric hindrance and cannot repel water molecules so 
effectively. Furthermore, increasing numbers of carbons in the molecule and 
temperature are directly correlated with interaction strength 105. Importantly, 
hydrophobic effects have a dynamic function in folding and energy-minimising 
protein structures to keep them biologically active, decreasing their surface 
area and so protecting them from undesirable reactions with water.  
 
Globular proteins in aqueous solutions are arranged in a such way that 
hydrophobic amino acids are positioned in the interior, which might be a 
ligand-binding site in a druggable protein, whereas hydrophilic amino acids 
often cover the surface of proteins 103. Hydrophobic contacts between the 
ligands and proteins can be rationalised as entropic or enthalpic gain because 
water molecules are no more positionally restricted (free) after establishing 
hydrophobic interactions between the ligands and the proteins; also, the 
displaced water molecules allow an established hydrophobic contact between 
the ligands and the receptors; in addition, the liberated water molecules, which 
previously could not interact with hydrophobic groups, can form hydrogen 
bonds with the bulk of solvent molecules and lead to enthalpic gain 106,107. 
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1.8.2  Van der Waals Interactions 
 
The intermolecular attractive and repulsive forces are known as van der Waals 
forces; the attractive forces are owing to the favourable interactions between 
electronic multipoles, while the repulsive forces are due to spatial overlap of 
the electron orbitals 108,109. There are three types of van der Waals forces. The 
first is the attraction between two molecules with induced dipoles (induced 
dipole–induced dipole). The second and stronger type is between a 
permanently polar pole and a momentarily polar pole (dipole–induced dipole). 
The last van der Waals force is dipole–dipole interactions, which are produced 
between two molecules with permanently polar poles 110. Van der Waals forces 
are generally considered as a weak non-covalent interactions between 
molecules, while summation of them can produce strong binding interactions 
and it is one of the most significant interactions in protein molecules 111.  
 
Van der Waals attractive forces between a protein and a ligand occur over a 
very short distance range and have a distance dependence of 1/r6 (r is a 
distance between two nuclei). Therefore, optimised van der Waals attraction of 
a protein–ligand complex can occur when they have shape complementarity, 
which occasionally happens; however, the ligand or the protein might change 
their conformation to provide a complementary structure. Nevertheless, van der 
Waals attraction remains favourable and can stabilise a complex if the ligand 
atoms are not too close to the protein atoms 98.  
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1.8.3  Hydrogen Bonds 
 
Aruna et al. in 2011 states that “a hydrogen bond is an attractive interaction 
between a hydrogen atom from a molecule or a molecular fragment X–H in 
which X is more electronegative than H, and an atom or a group of atoms in 
the same or a different molecule, in which there is evidence of bond formation” 
112. Typically, hydrogen bonds exert a fundamental role in various biological 
interactions like proteins interactions 113. Hydrogen bond strength is typically 
between that of covalent and van der Waals interactions; the energy of 
hydrogen bonds is directly related to donor–acceptor separation and the 
linearity of the donor atom and acceptor lone pairs 114. Universally, hydrogen 
bonds favour specific distances between heteroatoms (donor–acceptor atoms) 
that lead to different energy outcomes, in such a way that strong bonds distance 
range are 2.2–2.5 Å with energy in the range 40–14 kcal/mol, moderate 
strength bonds are 2.5–3.2 Å with 15–4.0 kcal/mol energy and weak bonds are 
3.2–4.0 Å with energy < 4.0 kcal/mol 115. 
 
1.8.4  π effects 
	
The interaction of π systems of aromatic rings in different molecules can have 
energetic consequences. Three types of π effects are defined: π–π interactions, 
cation-π interactions and anion-π interactions. Regarding the π–π clouds of two 
aromatic rings, three interaction arrangements may be defined, displaced, T-
shaped edge-to-face and sandwich bindings (Figure 1.10) 116. In proteins, these 
interactions occur between the aromatic side chains of adjacent amino acids 
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like Phe and Tyr, as well as between the side chain aromatic rings of proteins 
and ligands possessing aromatic groups 117. 
 
 
 
Figure 1.10 Stacking conformations between aromatic groups. (A) T-shaped π– π 
interaction. (B) Sandwich shaped π– π interaction. (C) Staggered or parallel-displaced 
π– π interactions. 
 
Another class of π interactions is those with cations or anions. Various 
investigations on proteins and proteins with ligands have proved this type of 
contact as very common between charged side chain amino acids and π-
electron clouds of the aromatic rings of Phe, Trp and Tyr. Almost always, this 
interaction type is considered as strong 118-120. 
 
1.8.5 Salt Bridges 
 
Adjacent molecules of opposite charges may interact non-covalently through 
salt bridges, in which the interacting atoms have separation in the hydrogen 
bond range 121. They can have an essential function in protein stability and 
protein–ligand interactions 122-124 because they are a combination of 
A) B) C)
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electrostatic and hydrogen bonds. Ordinarily, in protein structures, the bridges 
are created between the side chain carboxylate anions (RCOO–) of Glu or Asp 
and the positive ammonium (RNH3+) or guanidinium charges of Lys and Arg, 
respectively 116. In addition, other amino acids like His, Ser and Tyr may 
produce salt bridges depending on their ionisation state, related to the 
environmental pH. However, if the distance between the two interacting atom 
is greater than 4.0 Å, it can not be consider as a salt-bridge 124. 
 
1.9 Therapeutic Molecule Sizes  
1.9.1 Small Molecules 
 
Drug molecules with a size < 900 Dalton (Da) are considered as small 
molecules. Generally, they can pass biological barriers such as cell membranes 
because of their tiny sizes and they can easily reach the required destinations 
125,126. Most of these drugs were discovered by different methods such as 
rational drug design, screening tests or serendipity and they were released to 
the market during the last century 65,127. The molecules are typically 
synthesised in chemical laboratories 128. To improve permeability and 
absorption of the small molecules, they can follow Lipinski’s rule of five: the 
molecule should have less than 10 hydrogen bond acceptors and 5 hydrogen 
bond donors, MW < 500 Da and ClogP < 5 129.  
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1.9.2 Protein-Based Drugs 
 
Recently, we see more compounds derived from biological sources coming to 
the market, biosynthesised in molecular biology laboratories through a protein 
expression and purification processes; they are termed biologics 130. These 
medicines may contain protein, nucleic acids and sugars. Unlike small 
molecules, they have a massive size (roughly > 5000 Da) and are characterised 
by increased specificity and less toxicity because size of biologics can 
significantly inhibit “off-target” issues. Nevertheless, the biologics huge size 
have a serious disadvantages, such as metabolic instability, poor membrane 
permeability, significantly low bioavailability and highly prone to immune 
response 131.  
 
1.9.3 Peptide-Based Drugs 
 
Therapeutic peptides are sequences of 2–50 amino acids or similar 
peptidomimetics with agonistic or antagonistic activities on receptors 132,133. 
Peptides can be produced through either chemical synthesis or biosynthetic 
methods 134,135. The size of the desired peptide is the major factor that 
determines the method of production; small and medium sized peptide (2–50 
amino acids), and peptides involving unnatural amino acids are constructed by 
chemical synthesis 136, while the recommended method for producing large and 
complicated peptides is biosynthesis because chemical synthesis is expensive 
and provides low yields. 
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Peptide drugs have several advantages over small molecule ligands; the first is 
the ability of peptides to inhibit PPIs because small molecules to a large extent 
could not inhibit them due to a wide interacting area of most proteins. 
Moreover, peptides typically have high target specificity and efficacy because 
of the significantly higher biological and chemical diversity compared with the 
small molecules 133,137. Furthermore, in vivo, peptides are metabolised into 
amino acids, which decrease the probabilities of drug–drug interactions and 
systemic toxicity 138. Finally, the short duration of action of peptides may 
decrease the risk of accumulating metabolites in the various tissues and 
producing complications 133.  Peptides can also have potential benefits over 
biologics like antibodies and recombinant DNA therapies because due to their 
smaller sizes, they are less capable of producing immunogenic reactions; 
additionally, they have a significantly better cell penetration, lower 
manufacturing costs and greater stability 136,139,140.  
 
However, low bioavailability and pharmacokinetic issues, especially in the 
linear peptides are considered as the two inevitable difficulties associated with 
developing peptide therapeutics. The low bioavailability problem is due to the 
peptides easily degradation by protease enzymes; and pharmacokinetic 
problems are due to the absorption limitations, easily metabolism and their low 
plasma residence time. Therefore, various approaches have been applied to 
overcome the mentioned hurdles, such as choosing alternative route of drug 
administration, applying new strategies of chemical synthesis and chemical 
modifications to circumvent pharmacokinetic and bioavailability issues of the 
peptides 136.  
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1.10 Inhibiting PPIs as a Therapeutic Approach 
 
PPIs play vital functions in the body, as they are responsible for regulating an 
enormous variety of biological processes and cellular activities. The binding 
partners interact via a patch on the accessible surface area of each protein, 
termed the protein interface area, which repels solvent molecules 141. 
Interestingly, improper or disrupted interactions between the two proteins at 
the interface can result in abnormality and diseases 142; therefore, it is not 
surprising that intervening at these interfaces and grooves may offer an 
attractive therapeutic target 143. Almost invariably, proteins interact with each 
other through a large interface area, but most of the binding affinity values are 
associated with a limited number of residues in the critical region of PPIs 
interface, which is called the “hot spot” 144.  
 
The aim of PPI inhibitors is modulating the functions of interacting proteins to 
bring about a therapeutic effect; the modulations are typically achieved through 
molecules targeting the proteins host spot 145; and importantly, small size hot 
spots are favourable targets for inhibitor molecules, as they are commensurate 
with the sizes of typical small molecule drug structures 143,144,146.  
 
In the past, some of the pharmaceutical industries avoided inhibiting PPIs 
projects, concerning about technological difficulties and the immaturity of the 
area. Generally, inhibiting PPIs is a challenging process compared with the 
traditional drug targets; the essential hurdle of these targets is the large surface 
area of the typical protein–protein interface, which makes targeting PPIs 
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through a small molecule hit compound is a difficult process; it could be solved 
through increasing the size of the hit molecules in order to cover the target 
surface area of the proteins; however, it is at the cost of pharmacokinetic 
properties 143.  
 
Despite the difficulties of targeting PPIs, recently several factors have 
encouraged pharmaceutical industries to get involved and invest intensively in 
project related to PPIs and their inhibitors. The first is advances in the 
recognition and crystallisation of interacting proteins, thus revealing and 
defining hot spots and druggable pockets that biophysicists, biologists and 
chemists can evolve novel hits against 147. In addition, there are documented 
successes with emerging peptide-based inhibitors. Also, the genomics and 
proteomics revolution has resulted in the identification of a huge number of 
new targets. Finally, the growth in computational methods and combinatorial 
synthesis approaches have supplied new tools to apply to this type of project 
148. 
 
Without doubt, as stated in Section 1.6, the major factors in increasing drug 
discovery costs and failure rates are the problems of efficacy, and toxicity of 
the candidate molecules due to off-target issues with the small molecules. To 
overcome these obstacles, larger and more target–specific molecules may 
require, which are either biologics or peptides 131. In the specific case of PPI 
inhibitors, likewise most of the hurdles are linked to small molecules because 
the protein interface may require a considerably larger ligand with more 
binding interactions to cover the interface. Small molecules typically can not 
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cover the flat and extended surface area of the “undruggable” protein interface 
area because they are characterised by restricted size, physicochemical 
properties and surface area 149. Given this, the contrasting properties of 
peptide-based molecules make them an attractive choice for the targeting of 
protein interfaces. 
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1.11 Aims and Objectives 
 
This project aims to find novel peptide-like molecules, analogues of a key 
interacting region of TIN2, that can compete effectively for the binding sites 
for TIN2 on TRF1 and so lead to the destabilisation of telomere structure; 
along the way, a subsidiary aim is the investigation and optimisation of the 
accuracy of ΔGbinding predictions, made using the MM-GBSA molecular 
modelling method for the TIN2 peptide analogues. The aims were achieved 
through the following objectives: 
 
1. Design of a library of peptides, analogues of the TRF1-binding motif in 
TIN2, using the X-ray crystal structure of the TRF1–TIN2 complex, and 
prediction of their likely activity as competitive inhibitors of the TRF1–
TIN2 PPI through the calculation ΔGbinding for the peptide analogues. 
 
2. Extensive investigation and optimisation of molecular modelling strategies 
to predict the ΔGbinding values of the TIN2 peptide analogues. 
 
3. Chemical synthesis of the TIN2 peptide and selected peptide analogues 
using solid-phase peptide synthesis methods and preparation of them for 
experimental tests. 
 
4. Biophysical evaluation of the peptide analogues as inhibitors of TRF1–
TIN2 interaction (IC50 values), through the development and application of 
a Fluorescent Polarisation (FP) assay. 
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5. Correlation of ΔGbinding results (before and after optimisations) with IC50 
values to confirm the validity and accuracy of the computational methods 
and results. 
 
Detailed background description for each method is provided at the start of 
each chapter. 
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2. The Application of Molecular Modelling to Ligand 
Design 
2.1 Introduction  
 
Molecular modelling is a term associated with molecular structure and can be 
defined as a computational technique to simplify the process of mathematical 
calculation. It is crucial to model, explain, recognise and evaluate the 
behaviour of molecules or molecular systems, thus significantly facilitating 
teaching and research 150. Generally, molecular models can show molecules as 
three-dimensional structures and permit molecular manipulations, not only of 
small molecules, but also of large biomolecules. Calculations in molecular 
modelling are used to predict molecular energy, vibrational frequencies and the 
behaviour of the molecule in the presence of other molecules 151. 
 
Molecular modelling calculations can be performed by either quantum 
mechanical or molecular mechanical methods. Quantum mechanics (QM) 
approaches are extensively used due to the relative accuracy with which they 
represent structural and thermodynamic changes 152. QM energy calculations 
rely on the Born-Oppenheimer approximation, when nuclear motions are 
separated from the electronic motions and assume that the nuclei do not move 
because nuclei motion is significantly slower compared with the speed of 
electrons. This approximation is to simplify the Schrodinger equation; 
therefore, it is known as “electronic Schrodinger equation” 153. This method is 
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very computationally expensive and is usually limited to small systems with 
hundreds of atoms 154. Molecular mechanics (MM) calculations, on the other 
hand, rely on a simple model of interactions relative to QM, and encompass 
four key forces or components, which are bond stretching, angle opening and 
closing, bond rotations and non-bonded interactions, such as van der Waals 
forces and electrostatic interactions (Equation 2.5). This approach uses force 
field parameters to model molecular systems, and typically considers an 
individual atom as a point charge with an associated mass while neglecting the 
electronic motions. MM calculations are applicable to small as well as large 
biological systems 151. 
 
2.2 Molecular Dynamic Simulation  
 
Investigating molecular and atomic motions and interactions, specifically in 
biomolecules, can be achieved by a Molecular Dynamics (MD) simulation 
technique. MD simulations, a rapidly developing field with diverse 
applications such as providing insights into natural dynamics on different time 
scales of biomolecules in solution, can provide the thermal averages of 
molecular properties and explores the thermally accessible conformations of 
the molecule or complex (Figure 2.1).  
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Figure 2.1 A scheme representing the process of molecular dynamic simulations 97. 
 
This technique can be applied to the exploration of the conformational spaces 
and dynamical evolution of the molecular systems 155 using Newtonian 
dynamics (Newton’s second law of motion) to simulate the movement of 
interacting atoms and molecules (Equation 2.1).  
 
F = ma                                                                              Equation 2.1 
 
where F is the external force on the particle, m is the mass of the particle and a 
is the acceleration of the particle. Before MD simulations can be initiated, 
energy minimisation of the initially-constructed molecular model is frequently 
required to obtain a molecular geometry with low potential energy, thus 
protecting the molecule from fracture due to large initial forces in the system 
Advance(simula.on(.me(by(1(or(2(fs(
Move(each(atom(according(to(those(forces(
Calculate(molecular(forces(ac.ng(on(each(atom(
Ini.al(atomic(model(
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during MD simulation 156. Two important issues with MD simulations are the 
sometimes uncertain reliability of the force field and the high computational 
demands for execution of the extensive calculations 97. 
 
2.3 In silico Calculations of Binding Free Energy 
 
The application of molecular modelling in the field of drug design mostly 
involves the realisation of 3D structures and the calculation of attraction and 
repulsion forces between ligands and receptors or within biological systems. 
Typically, the calculation of ΔGbinding value is a valuable tool across different 
areas of computational biochemical research, for example, in protein structure 
determination and drug design processes through the estimation of binding 
affinities of drug-candidate compounds 157. Many computational approaches 
are available to estimate free energies, ranging from rapid but relatively 
inaccurate techniques such as linear interaction energy analysis (LIE) 158 and 
Molecular Mechanics-Poisson Boltzmann Surface Area/Generalized Born 
Surface Area (MM-PBSA/GBSA) calculations 159, to more accurate but 
extremely slow methods including free-energy perturbation (FEP) 160,161, 
umbrella sampling (US) 162 and thermodynamic integration (TI) 163,164. These 
methods can analyse trajectories produced by MD or Monte Carlo (MC) 
simulations to calculate free energies.  
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2.4 MM-PBSA/GBSA Method 
 
The MM-PBSA method is the well-known end-point implicit free energy 
calculation approach, which was applied for the first time in 1998 165. It is a 
consolidation of molecular and continuum solvent models 166 that has been 
used widely in many drug discovery projects for calculating the ligand–
receptor binding free energy, determining the structural stability and evaluating 
the docking poses 157. It is a particularly popular method for evaluating 
differences in free energy between the bound and unbound states of solvated 
molecules, or for comparing the free energy of the same solvated molecule in 
different conformations 167.  
 
This method is of increasing interest to the researchers in drug discovery 
projects for estimating relative binding free energies, due to its acceptable 
accuracy compared to experimental data 168, broad applicability to diverse 
systems, efficient computation and calculation of free energy by a more refined 
mechanism when compared to common scoring functions 159. However, 
diverse limitations are a feature of this computational method; the first is force 
field accuracy and partial charge models 169 followed by inadequacy of 
sampling within a large conformational space 170. The sampling problem can 
be exacerbated if it traps systems in a local minima for a prolonged period of 
simulated time 171. Ultimately, the limitations can affect the accuracy of MM-
PBSA/GBSA results. 
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The following equation (Equation 2.2) can be used to illustrate the binding free 
energy of a protein–ligand complex applying MM-PBSA/GBSA methods: 
 
∆Gbinding = Gcom – Grec – Glig                                                                                  Equation 2.2 
                                 
where ∆Gbinding is the binding free energy of protein–ligand, Gcom is complex 
energy, Grec is receptor energy and Glig is ligand energy 172,173. 
 
The free energy of each G from Equation 2.2 is predicted by Equation 2.3: 
 
G = H – TS                                                                               Equation 2.3 
 
where H denotes enthalpy, T is the absolute temperature and S is the entropy of 
the molecule. Equation 2.4 explains H as follows: 
 
H = EMM + Gsolv                                                                                                         Equation 2.4 
 
where EMM represents the molecular mechanics energy of the molecule and 
Gsolv is the free energy of solvation in MM-PBSA method. Both Equations 2.5 
and 2.6 clarify EMM and Gsolv separately: 
 
EMM = Einternal  + Eelectrostatic + Evdw                                                               Equation 2.5 
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where Einternal is the summation of all internal energies, which are bond, angle 
and dihedral energies. Eelectrostatic and Evdw are used respectively to represent the 
electrostatic and van der Waals interaction energies 172.  
 
Gsolv = GPB/GB  + GSA                                                                                                   Equation 2.6 
 
where Gsolv is the summation of the polar (GPB/GB, electrostatic) and nonpolar 
(GSA, nonelectrostatic) components, GPB/GB is the polar contribution of 
solvation energy of the molecule, and GSA is the non-polar solvation free 
energy. Poisson-Boltzmann (PB) and Generalized Born (GB) models are 
implicit solvation models used to compute the polar contribution of solvation 
169.  
 
As illustrated in Figure 2.2 and Equation 2.7, ΔGbinding of the molecular 
systems in the MM-PBSA/GBSA approach are calculated through the 
summation of their gas-phase energy, Gsolv and a configurational entropy of the 
solute (–TΔS) 174. The gas-phase energy is the MM energy of the molecules 
(EMM). Furthermore, as shown in Equation 2.6, Gsolv is the polar and nonpolar 
contribution of the solvation free energy; the polar contribution (GPB/GB) is 
dependent on the transfer of a charged molecules from a homogenous medium 
(gas-phase) with dielectric constant = 1 to the solvent with dielectric constant = 
78–80, which is estimated by the implicit solvent models 175. The PB equation 
was initially used (and still is still widely applied) to calculate the polar 
contribution energy of Gsolv 176; however, an alternative implicit solvent model 
is mostly used at present, based on the GB theory and a computationally more 
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efficient approximation compared with PB approximation 177,178. On the other 
hand, the nonpolar solvation free energy (GSA) is the energy required to form a 
cavity for the solute by the solvent and is proportional to the surface area or 
solvent accessible surface area (SASA) of the solute. The final term is the 
configurational entropy (S) of the solute in the gas-phase, which is calculated 
using either quasi-harmonic 179 or normal mode analysis 180. In conclusion, the 
ΔGbinding value in the implicit solvent is equivalent to the summation of EMM in 
the gas-phase, the difference of Gsolv between the complex and the nonbonded 
molecules and the configurational entropy related to the complex formation in 
the gas-phase at a specific temperature (TΔS).  
 
    Implicit solvent                                                Gas-phase 
 
Figure 2.2 Calculating binding free energy of the receptor–ligand complex, using 
MM-PBSA/GBSA method 157. 
ΔGsolv (receptor)	
ΔGsolv (ligand)	
ΔGsolv (complex)	
ΔGbinding	 ΔEMM – T ΔSconfig	
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∆Gbinding =ΔEMM + (ΔGsolv complex – ΔGsolv receptor – ΔGsolv ligand) – TΔS  
                                                                                                                                                            Equation   2.7 
 
Calculation of MM-PBSA/GBSA between a receptor and a ligand can be 
achieved using either multiple or single trajectory approaches. In terms of 
multiple (separate) trajectory approach, MD simulations are carried out for 
unbound receptor, unbound ligand and the complex, separately; then, the 
energy terms are calculated from the snapshots of the individual trajectories 181. 
On the other hand, in the single trajectory approach, MD simulations are 
performed only for the complex system, after which snapshots of the single 
trajectory are taken to create conformations of the receptor and ligand and 
calculate their free energies 182,183. In the single trajectory approach, cancelling 
the Einternal of the ligand, receptor and complex has a significant effect on 
decreasing the noise 181,184. Using the single trajectory approach is more 
common compared with the separate trajectory approach because it requires 
less effort and it is not as expensive as the separate approach. In addition, it can 
provide relatively accurate results for the greatest applications of protein–
ligand interactions 170. However, in such cases, the single trajectory approach 
results are less accurate than the separate trajectory approach results owing to 
neglecting the explicit structural relaxation of the protein and ligand before 
binding 185. 
 
The starting structure for the calculations is usually a crystal or minimised 
structure; the conformational ensembles are compared to the reference 
structure in order to calculate the energy of the conformers and average the 
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output. Therefore, conformational changes in the system components 
determine the final energy 157.  
 
2.5 The Balance Between Enthalpy and Entropy  
 
As explained in Section 2.4 (above), the energy of the molecule (G) can be 
defined as a summation of enthalpy (H) and entropy (S) at a constant 
temperature (T); hence, ΔGbinding is a function of changing enthalpy (ΔH) and 
entropy (ΔS) and is the determinant of the binding affinity between a receptor 
and a ligand. Therefore, the potency of lead compounds can be improved 
through favourable improvement of the enthalpy and entropy 186 (Equation  
2.8). 
 
ΔGbinding = ΔH – TΔS                                                                       Equation 2.8   
 
In early drug discovery process and medicinal chemistry, to increase the 
binding affinity of ligands, the functional groups are typically modified to 
establish more and stronger favourable binding interactions between the ligand 
and the receptor (increase -ΔH); however, the greatest modifications could not 
improve the potency of the ligand because the enthalpic gain may be cancelled 
totally or further inhibit a favourable ΔGbinding value due to an unfavourable 
entropy (decrease -TΔS). The causes of unfavourable entropy are 
conformational entropy loss and/or inhibiting desolvation 187. Therefore, a 
combination of favourable enthalpy and entropy can produce a highly potent 
lead compound 188. 
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2.6 Molecular Recognition in the TRF1–TIN2 and 
TRF2–Apollo Crystal Structures 
 
X-ray crystallography, the most important technique for the determination of 
protein structure, provides atomic-level clarification of biological structure and 
function across multiple fields of research. This valuable tool can be applied in 
different areas such as SBDD, the elucidation of enzyme mechanisms, the 
design and interpretation of site directed mutagenesis studies and the 
elucidation of the specificity of protein–ligand interactions 189.  
 
In terms of the sizes of the different proteins investigated in this study, mature 
TRF1 and TRF2 proteins are comprised of 438 and 542 residues, respectively. 
Furthermore, the full chain of the TIN2 protein is 450 amino acids in length, 
while the Apollo consists of 532 residues 190. Nevertheless, crystallising the 
full-length structures of these proteins is difficult as they include structural and 
functional domains which are flexibly linked together 191. Hence, the crystal 
structure of the TRF1–TIN2 complex (PDB code 3BQO) was determined at 2 
Å resolution and composed of residues 62–268 and 256–268 for the TRF1 and 
TIN2 respectively; the crystal structure of TRF2–Apollo (PDB code 3BUA) 
was determined at 2.5 Å resolution and shown to include only residues at 
position 44–245 of TRF2 and 499–510 of the Apollo peptide.  
 
As illustrated in Figure 2.3, both TRF1 and TRF2 proteins form a homodimer 
in solution, with each dimer comprised of two monomers in an antiparallel 
arrangement, thus forming a symmetrical complex whose overall structure 
Chapter Two                        The Application of Molecular Modelling to Ligand Design 
	 52 
resembles a twisted horseshoe 192. The proteins share virtually the same 
architecture of the C-terminal Myb/SANT domains. Moreover, the TRFH 
domains of both proteins are highly superimposable; they produce almost 
identical 3D structures, which are essential for binding telomeric DNA 192,193. 
 
The TRF1 and TRF2 monomers are structurally composed of nine α helices in 
an elongated helix bundle formation. The helices are divided into two sections, 
the first of which includes α helices 1, 2 and 9, arranged into what is known as 
the dimer interface. The second section includes α helices 3 and 8, forming the 
‘arms’ of the horseshoe. The remaining helices 4, 5, 6 and 7 are located 
adjacent to helices 3 and 8. Extended protein–protein interaction surfaces are 
provided by a six-α helix bundle dimerisation interface (helices 1, 2 and 9 from 
each monomer) (Figure 2.3B). In addition to dimerisation, TRF1 and TRF2 
proteins also bind with their partner proteins through their TRFH domains 
(Section 1.3.1). Despite the observation that the dimerisation domains of both 
shelterin proteins feature a conserved common architecture, several different 
residues are located at the surfaces, thus enabling the recognition of different 
telomere-associated proteins and preventing the formation of TRF1/TRF2 
heterodimers 194. 
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Figure 2.3 Structure of TRF1 and TRF2 dimerisation domains and TRF1 helices. A 
ribbon representation is used to display structures. (A) Superposition of TRF1 and 
TRF2 dimerisation domain. The grey colour is characterising TRF1 and the pink is 
depicting TRF2 protein. (B) The TRFH monomer structure of TRF1. Number and 
colour are used to mark all of the α helices (adapted from Fairall et al., 2001) 194. 
 
Regarding the interactions between the TRF1 and TIN2 proteins, the C-
terminus of the TIN2 protein, termed the TIN2-TRFH binding motif (TBM) or 
TIN2TBM, is recognised by TRF1TRFH domains 195. TRF1TRFH exists in vivo as a 
homodimer, with each TRF1TRFH protein interacting with one TIN2TBM 
peptide.  
 
As demonstrated by Chen et al. (2008) and illustrated in Figure 2.4 and 2.5, the 
crystal structure of the TRF1–TIN2 complex reveals the interactions of amino 
acids between TRF1TRFH and TIN2TBM. The electron density map demonstrates 
that residues 257 to 268 of TIN2TBM assume a well-defined conformation. The 
TIN2TBM peptide is composed of 13 residues (S256-H-F-N-L-A-P-L-G-R-R-R-
V268); it interacts with TRF1TRFH through its C and N-termini in unison. The 
Chapter Two                        The Application of Molecular Modelling to Ligand Design 
	 54 
C-terminus of TIN2TBM consists of L263-G-R-R-R-V268, forming an 
antiparallel β sheet on the surface of loop L34. Hydrogen bond (H-bonds) can 
occur between Q141 of TRF1 and both L263 and G264 of TIN2. Furthermore, 
R265 of TIN2 interacts with D139 of TRF1 and R266 of TIN2 peptide 
interacts with L138, D139, R147 and E192 through a combination of H-bonds 
and salt bridge interactions. Lastly, R267 of TIN2 attracts the E146 side chain 
of TRF1. In contrast, the N-terminus of TIN2TBM, which is composed of H257-
F-N-L-A-P262 and has an extended conformation, stabilised by intermolecular 
hydrogen bonding and hydrophobic contact with TRF1TRFH residues 192.  
 
 
 
Figure 2.4 The TRF1–TIN2 crystal structure. The grey color is TRF1 and the brown 
sequence is TIN2. 
 
The hydrophobic groove of TRF1TRFH, consisting of I109, L115, L120, I123 
and Y124, recruits F258 of TIN2TBM. In addition, N259 undergoes an 
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intermolecular hydrophilic interaction with F142 and an intramolecular 
hydrophilic interaction with A261. The oxygen atom of the N259 main-chain 
attracts both Q127 and R131 of TRF1. Furthermore, L260 side chain inserts 
the concave hydrophobic pocket of TRF1TRFH and its backbone N-H group has 
a H-bond interaction with the E106 carboxylic acid side chain. The next 
residue of TIN2 is A261; it undergoes only a H-bond interaction through its 
backbone N-H group with the side chain carboxylic acid group of E106 (Figure 
2.5) 192. The last residue of the N-terminus is P262; according to the crystal 
structure analysis, it has not any contact with the TRF1 protein. 
 
 
 
Figure 2.5 Interactions between TRF1TRFH protein and TIN2TBM peptide. Green ovals 
and square boxes symbolise the side chain and main-chain portions of TRF1TRFH 
amino acids, respectively. Circles denote the primary chain atoms of TIN2TBM: blue 
circles represent nitrogen atoms, orange circles represent α carbon atoms, β carbon 
atoms are yellow and oxygen atoms are represented by red circles. Straight magenta 
lines represent hydrophilic interactions, curved red lines show hydrophobic contacts 
and pale yellow arrows denote intermolecular β sheets (taken from Chen et al., 2008) 
192. 
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As stated in Section 1.3, one of the telomere-associated proteins is known as 
Apollo 196; it is recruited by TRF2 and contributes to the protection of 
chromosomes 197. The region of TRF2 responsible for attracting Apollo protein 
is called TRF2TRFH and the TRF2 interacting segment of Apollo is termed the 
Apollo–TRFH binding motif (ApolloTBM), consisting of amino acids 498–509. 
The C-terminal region of ApolloTBM (Y504-L-L-T-P-V509) is essential for 
interacting with TRF2TRFH (Figure 2.6) 192. Structural similarities exist between 
the TRF1TRFH-TIN2TBM and the TRF2TRFH-ApolloTBM complexes, in that both 
segments share an identical conformation and preserve virtually the same 
hydrogen bonds. Furthermore, the TBMs of TIN2 and Apollo share the 
sequence Y/F-X-L-X-P (where X is a non-conserved amino acid). However, 
several differences exist between TIN2TBM and ApolloTBM; the highly 
interacting region of TIN2TBM localises at the N-terminal, but is located at the 
C-terminal of ApolloTBM 19. Additionally, the C-terminus of TIN2TBM consists 
of a polyarginine residue extension and creates a β sheet, while the N-terminus 
of ApolloTBM forms a short helix and is an extension of six amino acids (R498-
G499-L500-A501-L502-K503). Finally, to allow efficient binding with 
TRF2TRFH, a more hydrophilic amino acid such as Tyr is preferred in the Y/F-
X-L-X-P motif of ApolloTBM, whereas, for binding with TRF1TRFH, a more 
hydrophobic residue such as Phe is preferred in the Y/F-X-L-X-P motif of 
TIN2TBM (Figures 2.5 and 2.6) 192. 
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Figure 2.6 A scheme denoting TRF2TRFH-ApolloTBM interactions. All symbols and 
colours are as for Error! Reference source not found., except for the yellow lines 
denoting the N-terminal helix of Apollo (taken from Chen et al., 2008) 192. 
 
2.7 In silico Design of TIN2 Peptide Inhibitors 
 
Specific amino acid residues of TIN2 peptide were computationally mutated in 
an attempt to identify the optimal sequence of a synthetic peptide that might 
functions as a competitive inhibitor of the TRF1–TIN2 protein–protein 
interaction. Two different strategies were used to obtain a novel TIN2 peptide 
analogue with a significantly higher binding free energy and potential as an 
early lead compound.  
 
2.7.1 TIN2–Apollo Cross-Matching Mutations 
 
The first strategy used to design peptide analogues was the mutation of 
selected TIN2 peptide amino acid residues to the corresponding amino acid in 
the Apollo peptide within the shared sequence (F/Y-X-L-X-P). This approach 
was selected due to the structural similarities between the host TIN2 and 
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Apollo molecules and the close resemblance of the two-peptide TBM 
sequences, especially the N-terminal of TIN2 and the C-terminal of Apollo. As 
stated in Section 2.6, the peptides share the same conformation and virtually 
the same H-bonds (Figures 2.5, 2.6 & 2.7) 192. 
 
 
 
 
 
Figure 2.7 Overlapping 3D structures of the TIN2 and Apollo peptides.  
 
As shown in Figure 2.8, three amino acids in the shared sequence of TIN2 
peptide differ from their matched Apollo peptide structure and were thus 
selected for mutation. An additional mutation outside of the shared amino acid 
residues was selected as a negative control. Hence, the first peptide analogue 
was a mutation of F258 to Y amino acid (F258Y) in TIN2 peptide; this peptide 
analogue was identical to the TIN2 structure with a hydroxyl (-OH) group 
Apollo 
TIN2 
F/Y-X-L-X-P 
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added to the side chain phenyl ring of F258. The second and third peptide 
analogues were generated through mutating N259 to L and A261 to T, 
respectively. R266 to P was selected as a negative control as the crystal 
structure 192 demonstrates the critical role of R266 in TIN2 interactions with 
TRF1. All four TIN2 peptide analogues and TIN2 peptide were named in order 
to facilitate their definition (Table 2-1). 
 
 
 
Figure 2.8 The shared sequence of the C-terminal of Apollo peptide and the N-
terminal of TIN2 peptide. Arrows denote the amino acid residues of TIN2 selected for 
mutation to the corresponding amino acids in the Apollo peptide. 
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2.7.2 Mutation of Selected TIN2 Residues Based on the Crystal 
Structure of TRF1–TIN2 
 
The second strategy for the design of TIN2 peptide analogues utilised SBDD 
198. The structures of TRF1TRFH and the TRF1–TIN2 interactions are well 
characterised through crystal structure records 194 (Figures 2.5 & 2.9) 192. 
Through careful analysis of these structures, mutations of TIN2 were predicted 
that might increase binding interactions between the peptides and the TRF1 
protein. 
 
Mutations of the TIN2 residues were selected based on their role in interactions 
with TRF1. One of the determining factors for recognising the role of each 
residue was the per-residue decomposition result (Figure 2.10), which shows 
the contribution of each residue in binding with TRF1. According to these 
results, S256 has an unfavourable effect and inhibit the binding free energy 
value (ΔGbinding = 8.56 kcal/mol); in addition, both H257 and V268 have the 
lowest binding free energy values (Figure 2.10). Therefore, these three residues 
were deleted or modified to an alternative amino acid residues in most of the 
designed peptide analogues to improve favourable binding free energy and 
decrease molecular weight of the peptide analogues.  
 
Mutation of the TIN2 residues was not only dependent on the per-residue 
result, but also on the 3D visualisation of the TRF1–TIN2 crystal structure and 
the equilibrated MD trajectories as this can show the conformation of each 
residue and its distance from the nearby TRF1 residue functional groups; 
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hence, an expected better amino acid alternatives were selected to improve 
ΔGbinding. For example, per-residue decomposition results show the 
unfavourable effect of S256 residue on ΔGbinding and, according to the MD 
simulations, the S256 side-chain cannot form interactions with TRF1 residues. 
S256 was therefore truncated in most of the peptide analogues or mutated to 
Q256 to have a longer side-chain for creation of a H-bond with the N144 side-
chain of TRF1 because, according to the MD simulations, the N144 side-chain 
amide group distance from the side chain hydroxyl group of S256 is 
approximately 6 Å, which cannot form a stable H-bond.  
 
As shown in Table 2.2, A261 and L263 of the TIN2 peptide were mutated in 
most of the peptide analogues, while the per-residue decomposition data shows 
that the ΔGbinding contribution of A261 is -2.17 kcal/mol and -3.81 kcal/mol for 
L263. The purpose of these mutations was that the side chains do not 
participate in the binding interactions with the TRF1 residues. Therefore, 
mutations were performed to such residues that may form favourable binding 
interactions with the TRF1 residues. Another mutation, which was achieved in 
20 of the peptide analogues, is F258Y; this was performed to preserve the 
hydrophobic contact between the Y258 side-chain and the residues of TRF1 
and to create a H-bond between the side-chain hydroxyl groups of Y258 and 
Y124. 
 
Despite the previously mentioned factors used for selecting the TIN2 
mutations, data from the literature was also considered. For instance, according 
to the crystal structure and MD trajectories, P262 cannot form a favourable 
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binding interaction with the TRF1 residues, although all proteins that bind with 
TRF1 through the TRFH domain have a preserved P262 residue 21. Therefore, 
this residue was also preserved in the peptide analogues in this project, except 
in one (P03) which was mutated (P262F) to form a π–π stacking between F262 
and F142 side chain of TIN2 and TRF1, respectively; however, the result was 
the inhibition of binding free energy. Thus, a library of peptide analogues was 
designed, comprised of 49 analogues of TIN2 peptide; ΔGbinding energies were 
subsequently predicted for each peptide analogue bound to TRF1 protein 
(Table 2-2).  
 
 
 
Figure 2.9 The interactions of TIN2TBM peptide with TRF1TRFH protein as determined 
from the crystal structure. 
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2.8 MD Simulations of the Protein–Peptide Complexes  
 
As described above, through mutation of selected amino acid residues of TIN2 
peptide from the crystal structure of the TRF1–TIN2 complex (3BQO), novel 
analogues were designed. Each TRF1–TIN2 analogue was then parameterised 
and prepared for MD simulation by producing topology and coordinate files; 
subsequently, the complex systems were minimised and 10 nanoseconds (ns) 
MD simulations were performed to produce trajectory files.  Finally, 500 
snapshots of the trajectory files were used to determine ΔGbinding energy and 
investigate the molecular motions and conformations of the peptide analogues 
(See Section 6.1).  
 
2.9 ΔGbinding Prediction of TRF1–TIN2 Peptide 
Analogues  
 
Binding free energies were calculated for all complex systems using the MM-
GBSA method and the single trajectory approach was applied for the 
calculations. The aim of ΔGbinding calculations in this study was to determine 
and compare the relative binding affinity between TRF1 protein and TIN2 
peptide analogues. As the relative binding free energies of similar ligands are 
required in this project, the entropy term was disregarded in order to decrease 
the noise and error associated with entropy changes 157,199. 
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The reason of selecting MM-GBSA method rather than MM-PBSA was due to 
that MM-GBSA could display a competitive computational efficiency 200 and 
better performance in predicting relative binding free energy when compared 
to the MM-PBSA approach 183. Theoretically, however, the MM-PBSA 
method demonstrates a higher accuracy in estimating absolute binding free 
energy 184. Data from the first strategy, the TIN2–Apollo cross matching 
mutations, are shown in Table 2-1. 
 
Table 2-1 Predicted binding free energies of TIN2 peptide and four analogues derived 
from cross mutation with the Apollo peptide.  
	
TIN2 peptide 
mutation 
Number of 
amino acids 
Name of TIN2 
analogue 
Calculated ΔGbinding 
(kcal/mol) 
TIN2 13 TS01 -75.01 ± 0.49 
TIN2–F258Y 13 TS02 -89.83 ± 0.20 
TIN2–N259L 13 TS03 -85.42 ± 0.19 
TIN2–A261T 13 TS04 -82.55 ± 0.25 
TIN2–R266P 13 TS05 -59.49 ± 0.37 
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Figure 2.10 Per-residue decomposition of the TRF1–TIN2 complex system, which 
shows the binding free energy contribution of each TIN2 residue with TRF1. 
 
The second strategy used to design the peptide analogues was based on the 
protein and the peptide structures. As shown in Table 2-2, ΔGbinding values for 
49 protein-peptide analogue complexes were determined and eight of the 
peptide analogues were selected according to their competitive ΔGbinding values 
(> -90 kcal/mol) because investigation of all analogues was prohibitively 
expensive. Two estimated negative controls were designed; the estimated 
negative control used in the first strategy was TS05 (R266P) and the estimated 
negative control, which designed in the second strategy, was the P25 (L260G–
R266P) molecule.  
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Table 2-2 The ΔGbinding values of 49 TIN2 peptide analogues. Blue rows represent the 
selected molecules to be chemically synthesised. 
	
Name Sequence 
Residue 
No. 
ΔGbinding 
(kcal/mol) 
P01 S256-H-F-N-L-A-P-L-G-R-R-R-V 13 -75.01 ± 0.49 
P02 Q256-H-F-N-L-A-P-L-G-R-R-R-V 13 -79.00 ± 0.57 
P03 S256-H-F-N-L-A-F-L-G-R-R-R-V 13 -71.32 ± 0.47 
P04 S256-H-F-N-L-R-P-L-G-R-R-R-V 13 -102.31 ± 0.68 
P05 S256-H-F-N-L-A-P-L-G-R-R-R-L 13 -92.32 ± 0.35 
P06 H257-F-N-L-A-P-L-G-R-R-R-V 12 -86.90 ± 0.41 
P07 H257-F-N-L-A-P-N-G-R-R-R-V 12 -83.84 ± 0.80 
P08 H257-F-N-L-A-P-L-G-K-R-R-V 12 -87.04 ± 0.61 
P09 H257-F-N-L-A-P-N-G-K-R-R-V 12 -66.97 ± 0.85  
P10 H257-Y-N-L-A-P-N-G-K-R-R-V 12 -67.66 ± 1.00 
P11 H257-F-N-L-A-P-N-G-K-R-S-V 12 -70.52 ± 0.76 
P12 H257-F-N-L-N-P-N-G-K-R-S-V 12 -101.75 ± 0.53  
P13 H257-F-N-I-A-P-L-G-R-R-R-V 12 -84.33 ± 0.57 
P14 H257-F-N-L-N-P-L-G-R-R-R-V 12 -86.01 ± 0.80 
P15 H257-F-N-L-Q-P-L-G-R-R-R-V 12 -83.47 ± 0.55 
P16 H257-Y-N-L-N-P-N-G-K-R-S-V 12 -91.3 ± 0.70 
P17 H257-Y-N-I-N-P-N-G-K-R-S-V 12 -70.26 ± 0.66 
P18 H257-F-N-L-A-P-L-G-K-R-S-V 12 -67.14 ± 0.70 
P19 H257-F-N-L-A-P-L-G-R-R-S-V 12 -83.4 ± 0.69 
P20 H257-F-N-L-N-P-L-G-K-R-S-L 12 -90.99 ± 0.49 
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P21 H257-F-N-L-N-P-N-G-R-R-R-V 12 -100.12 ± 0.86 
P22 H257-F-N-L-N-P-N-G-R-R-S-V 12 -86.32 ± 0.96 
P23 H257-F-N-L-N-P-N-G-K-R-S-L 12 -98.40 ± 0.76 
P24 H257-Y-N-L-I-P-N-G-G-R-R-L 12 -62.47 ± 0.40 
P25 H257-F-N-G-A-P-L-G-R-P-R-V 12 -50.37 ± 0.49 
P26 H257-F-N-L-A-P-L-G-R-R-R 11 -81.64 ± 0.35 
P27 H257-F-N-L-A-P-N-G-R-R-R 11 -80.01 ± 0.43 
P28 H257-F-N-L-A-P-N-G-K-R-R 11 -70.89 ± 0.46 
P29 H257-Y-N-L-A-P-N-G-K-R-R 11 -74.04 ± 0.62 
P30 H257-F-N-L-N-P-N-G-K-R-S 11 -81.69 ± 0.46 
P31 H257-Y-N-L-N-P-N-G-K-R-S 11 -70.58 ± 0.59 
P32 H257-F-N-L-N-P-N-G-K-R-K 11 -67.40 ± 0.32 
P33 F258-N-L-N-P-N-G-K-R-S-V 11 -77.12 ± 0.48 
P34 Y258-N-L-N-P-N-G-K-R-R 10 -80.18 ± 0.48 
P35 Y258-N-L-N-P-N-G-K-R-S 10 -80.04 ± 0.43 
P36 Y258-N-L-N-P-G-N-K-R-S 10 -58.90 ± 0.50 
P37 F258-N-L-N-P-N-G-K-R-S 10 -71.21 ± 0.45 
P38 F258-N-L-A-P-L-G-R-R 9 -64.95 ± 0.35 
P39 Y258-N-L-A-P-L-G-R-R 9 -55.07 ± 0.37 
P40 Y258-N-L-D-P-L-G-R-R 9 -59.82 ± 0.39 
P41 Y258-N-L-D-P-N-G-R-R 9 -58.13 ± 0.38 
P42 Y258-N-L-D-P-N-N-R-R 9 -59.19 ± 0.46 
P43 Y258-N-L-D-P-N-N-K-R 9 -62.40 ± 0.34 
P44 Y258-N-L-D-P-N-N-G-R 9 -55.46 ± 0.32 
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P45 L258-N-L-D-P-N-N-G-R 9 -53.85 ± 0.40 
P46 Y258-N-L-N-P-Q-N-G-R 9 -52.54 ± 0.34 
P47 F258-N-L-N-P-N-G-K-R 9 -72.80 ± 0.43 
P48 Y258-N-L-N-P-N-G-K-R 9 -67.57 ± 0.47 
P49 Y258-N-L-Y-P-N-G-K-R 9 -65.66 ± 0.36 
P50 Y258-N-L-A-P-N-G-K-R 9 -55.65 ± 0.38 
 
As shown in Table 2-2, P01 is the wild-type (TIN2) peptide, and the 
subsequent four analogues (P02–P05) were designed with an identical number 
of TIN2 residue numbers, two of which (P04 and P05) had a significant higher 
predicted binding free energy relative to the TIN2 peptide. Starting from P06, 
the analogues designed were truncated TIN2 molecules; residue numbers were 
decreased in order to improve the likely pharmacokinetic characteristics of the 
ligand molecules and reduce manufacturing costs 133. P06 is a TIN2 peptide, 
truncated at S256 to produce 12 amino acid residues. The next 19 peptide 
analogues (P07–P25) are composed of 12 amino acid sequences, only five of 
which (P12, P16, P20, P21 and P23) produced ΔGbinding value > -90 kcal/mol. 
Numbered P26 to P33, the next eight peptides were sequences of 11 amino 
acid residues, with P26 produced by truncating S256 and V268 in the wild–
type and the remaining seven analogues as mutants of P26.  
 
According to the data, none of the analogues were observed to have a binding 
free energy > -90 kcal/mol. The four peptides denoted by P34 to P37 were 10 
residue sequences, truncated at S256, H257 and V268 of TIN2, respectively. 
Finally, P38-P50 was a set of 9-mer analogues in which the truncated amino 
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acid residues were S256, H257, R267 and V268. Upon shortening of the amino 
acid residues to 9-mer, the observed ΔGbinding values were significantly 
lowered. Peptide analogues with a significantly higher binding free energy, 
relative to the wild-type TIN2 peptide (ΔGbinding > -90 kcal/mol), were selected 
for the chemical synthesis. These peptides are represented by blue rows in the 
Table 2-2 and are peptide analogues with higher predicted binding free 
energies relative to P01, except for P25, which was considered a negative 
control.  
 
In summary, 13 peptides were selected for chemical synthesis. These were 
TIN2, the four peptide analogues designed by the first mutation strategy 
(TIN2–Apollo cross-matching mutations) and the eight peptide analogues from 
the second mutation strategy (P04, P05, P12, P16, P20, P21, P23 and P25) 
based on their binding free energies. The chosen peptide analogues were 
named according to the first strategy format, as shown in Table 2-3.  
 
2.10 Replicating MD Simulations 
 
It was initially assumed that single MD simulations for each TRF1-peptide 
complex would suffice. Following repeated MD simulations of the identical 
complex (TRF1–TIN2 complex), trajectories were yielded that individually 
seemed to satisfy the standard equilibration and sampling metrics but differed 
markedly in predicted MM-GBSA binding affinities (Table 2-3) 171.  Although, 
all replicates were simulated from the same starting structure and using the 
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same protocols (except for the choice of initial velocities), the predicted 
energies of each replicate were significantly different (Figure 2.11).  
 
Regarding the accuracy of the MM-PBSA approach and the running single and 
multiple replicates, Sadiq et al. (2010), investigated the predicted relative 
binding free energy between the HIV-1 proteases and their inhibitors, running 
single MD simulations for 50 ns; after that, 50 replicates of MD simulations 
were run for 1 ns and 4 ns using MM-PBSA approach for calculating binding 
free energies. After plotting the predicted and experimental values, the results 
observed that the long MD simulation correlation coefficient value = 0.62, 
while the correlation coefficient of the 50 x 1 and 50 x 4 ns simulations = 0.98. 
These results demonstrated that the ensemble MD simulations could 
significantly improve the accuracy of the predicted values 170. A more recent 
study by Marc Adler and Paul Beroza (2013) on the polo-like kinase-2 
receptors and their inhibitors reported that, when single MD simulation was 
achieved for each system; then, multiple MD simulations (10 replicates) were 
used, the results of the replicate MD trajectories were more accurate than the 
single instances, as the single MD trajectory coefficient of determination (r2) 
was 0.36, while r2 for the average of 10 replicates was improved to 0.47 167. 
According to this method, the same starting velocity was used but the 
coordinates were randomly perturbed by 0.001 Å. MM-PBSA was used as a 
post-processing method and the predicted results compared with the IC50 
values.  
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It is likely that individual, single MD simulations produce inaccurate results 
due to inadequate sampling of the conformational space 170 and long periods of 
simulated time spent trapped in local minima. These observations suggest that 
computational optimisation of ΔGbinding values through multiple MD 
simulations could be used to address this limitation (Table 2-3).  
 
Table 2-3 Binding free energies of the single MD simulation and average of 50 
replicates MD simulations. Within the sequences, mutated amino acid residues are 
highlighted in red. 
	
Name Sequence Single predicted 
ΔGbinding (kcal/mol) 
Average predicted 
ΔGbinding (kcal/mol) 
TS01 S256-H-F-N-L-A-P-L-G-
R-R-R- V268 
-75.01 ± 0.49 -85.07 ± 0.72 
TS02 S256-H-Y-N-L-A-P-L-G-
R-R-R- V268 
-89.83 ± 0.20 -84.61 ± 0.81 
TS03 S256-H-F-L-L-A-P-L-G-
R-R-R- V268 
-85.42 ± 0.19 -82.69 ± 0.77 
TS04 S256-H-F-N-L-T-P-L-G-
R-R-R- V268 
-82.55 ± 0.25 -87.98 ± 0.95 
TS05 S256-H-F-N-L-A-P-L-G-
R-P-R- V268 
-59.49 ± 0.37 -60.99 ± 0.77 
TS06 H257-F-N-G-A-P-L-G-R-
P-R-V268 
-50.34 ± 0.49 -51.42 ± 0.68 
TS07 H257-F-N-L-N-P-N-G-K- -98.4 ± 0.76 -81.95 ± 1.03 
Chapter Two                        The Application of Molecular Modelling to Ligand Design 
	 72 
R-S-L268 
TS08 H257-F-N-L-N-P-N-G-R-
R-R-V268 
-100.12 ± 0.86 -94.94 ± 1.11 
TS09 H257-F-N-L-N-P-L-G-K-
R-S-L268 
-90.99 ± 0.49 -88.92 ± 0.86 
TS10 H257-F-N-L-N-P-N-G-K-
R-S-V268 
-101.75 ± 0.53 -82.96 ± 1.26 
TS11 S256-H-F-N-L-R-P-L-G-
R-R-R-V268 
-102.31 ± 0.68 -95.49 ± 1.21 
TS12 H257-Y-N-L-N-P-N-G-K-
R-S-V268 
-91.30 ± 0.70 -81.99 ± 1.20 
TS13 S256-H-F-N-L-A-P-L-G-
R-R-R- L268 
-92.32 ± 0.35 -89.00 ± 0.70 
 
 
2.11 Optimising the Accuracy of Predicted Results  
 
Different approaches were implemented in order to improve the accuracy of 
the predicted ΔGbinding values. The first was optimising the replicate number of 
MD simulations and the second was optimising the time required for execution 
of MD simulations. 
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2.11.1 Optimising the Replicate Number of MD Simulations 
 
In this section, data from an in-depth analysis of the convergence of such 
systems are presented. The output from up to 50 replicates and 10 ns 
simulations of the protein–peptide systems was subjected to a rigorous 
statistical analysis of the replicate values in order to identify the quantity of 
replicate runs required. In order to reach a defined level of accuracy and 
precision 201, the optimum number of independent simulations should be 
performed. Determining the sample size is critical, as samples that are too large 
may waste time, resources and money, while samples that are too small may 
lead to inaccurate results. Analysis of sample distribution is required to 
confirm that the assumptions of the parametric test are met prior to its 
application.  
 
Histograms of binding free energies calculated from the replicate simulations 
of the protein–peptide complexes do not show a typical bell shape (Figure 
2.11) but might still be applicable if it shown to be likely produced from an 
underlying normal distribution. A variety of tests were performed to test for 
normality, such as the Kolmogorov-Smirnov, D’Agostino and Pearson 
omnibus and Shapiro-Wilk tests, with the variables shown to be that normally 
distributed for the replicates as a consequence (p-value > 0.05). In addition to 
considering this indicator when determining the number of replicates, the 
application of standard statistical methods was necessary to estimate the 
number of replicates required to obtain a value of ΔGbinding to within defined 
confidence limits with acceptable probability. A method for determining the 
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sample size of the TRF1–TIN2 complex and its analogues was achieved using 
the sample size equation (Equation 2.9): 
 𝐧 =  𝐙 𝛂/𝟐  𝛅𝐄 𝟐                                                                Equation 2.9 
 
where n is the minimum sample size, E is margin of error (kcal/mol), Z α/2 is a 
critical value, which is 1.96 in the 95% confidence calculation and δ is the 
population standard deviation 202. The outcomes of using Equation 2.6 to 
statistically calculate the sample size for the complex systems are detailed in 
Table 2-4, with the standard deviations taken from Figure 2.11. 
 
Table 2-4 Standard deviation and calculated sample size for the complex systems with 
different margins of error. 
 
Complex 
systems 
Standard 
deviation 
 N (E=1 
kcal/mol)  
 N (E=2 
kcal/mol)  
 N (E=3 
kcal/mol) 
N (E=4 
kcal/mol) 
TS01–TRF1 5.108  100   25   11   6  
TS02–TRF1 5.711  125   31   14   8  
TS03–TRF1 5.453  114   29   13   7  
TS04–TRF1 6.731  174   44   19   11  
TS05–TRF1 5.447  114   28   13   7  
TS06–TRF1 4.783  88   22   10   5  
TS07–TRF1 7.315  206   51   23   13  
TS08–TRF1 7.868  238   59   26   15  
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As illustrated in Table 2-4, two factors affect the sample size (i.e., number of 
replicates). Firstly are different margins of error; for example, calculating the 
sample size using 1, 2, 3, or 4 kcal/mol as a margin of error resulted in diverse 
outcomes. In TS01–TRF1 complex, for instance, the minimum sample size was 
approximately 100 replicates when 1 kcal/mol was selected as the margin of 
error, with 25 replicates for 2 kcal/mol, 11 replicates for 3 kcal/mol and 6 
replicates for 4 kcal/mol margins of error. Secondly, minimum sample sizes 
differ among the diverse complex systems, as each system has a specific 
standard deviation, which directly affects the n value. Different standard 
deviation values relate to the distribution of ΔGbinding values for different 
replicates of the system. Therefore, increased standard deviations lead to 
greater numbers of replicates required.  
 
As shown by Equation 2.9 and Table 2-4, the standard deviation value is 
directly proportional to the number of replicates. For example, when E =1 
kcal/mol, the highest number of replicates was required for TS10–TRF1 
complex (304 replicates), as it had the highest standard deviation (8.899). 
Hence, if all systems applied 1 kcal/mol as the margin of error, 304 replicates 
would be required for all systems in order to obtain reliable and consistent 
TS09–TRF1 6.072  142   35   16   9  
TS10–TRF1 8.899  304   76   34   19  
TS11–TRF1 8.579  283   71   31   18  
TS12–TRF1 7.919  241   60   27   15  
TS13–TRF1 4.924  93   23   10   6  
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results, a highly expensive computational undertaking. Due to the limited 
computing capacity in this study, 3 kcal/mol was selected as the margin of 
error, with TS10–TRF1 complex subsequently requiring the highest number of 
replicates at 34. Thus, the minimum replicate number for each system was 34, 
and it was presumed that the selection of 50 replicate calculations for each 
system (a figure significantly above the minimum replicate number) would 
provide consistency across all complex systems. 
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Figure 2.11 Histograms showing the distribution frequency of ΔGbinding of the protein–
peptide complex replicates. The numbers on the histograms represent the numbers of 
the complex systems. 
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After running 50 replicates for each complex system, a relative comparison of 
the replicate clusters for each system was performed. Using this approach, 
comparisons were made between the wild-type and all mutated systems to 
determine the predictive binding affinity of each, relative to the wild-type 
complex system. One-way ANOVA was performed using GraphPad Prism 
V6.0 (GraphPad Software Inc., San Diego, CA; www.graphpad.com). As 
shown in Figure 2.12, the ΔGbinding values of the replicates for each complex 
system are distributed broadly, with small lines representing the mean ΔGbinding 
value of each system. The lines can be relatively compared, with each system 
coloured differently. TS01 is represented by blue line; TS05 and TS06 (orange 
and black, respectively) are negative controls with a markedly lower ΔGbinding 
value compared to the blue line. All remaining lines show relatively close 
values of binding free energy relative to TS01, except for TS08 (dark blue) and 
TS11 (dark green), displaying significantly higher binding free energies. 
Hence, TS08 and TS11 were proposed as an early lead compounds, particularly 
TS11 with the highest ΔGbinding value. 
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Figure 2.12 Distribution of replicate clusters for each TRF1-peptide analogue complex 
system. The lines represent mean value. 
	
2.11.2 Optimising MD Simulation Time  
 
An essential step in any molecular modelling study is the determination of the 
optimum time for MD simulations (the equilibration time after which no 
further simulation of the system is required). Two approaches were applied to 
obtain the optimum time for MD simulations. The first determined the 
equilibration time for the wild-type system by calculating ΔGbinding values of 
the set of 50 replicates at each time point over the course of the simulations. As 
demonstrated in Figure 2.13, the curve plateaus after about 4 ns, suggesting 
that the 10 ns simulations applied in this study should be of sufficient duration. 
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Figure 2.13 Mean ΔGbinding values calculated across 50 replicates of TS01–TRF1 
complex at each MD simulation time point. 
 
The second approach is to measure root mean square deviation (RMSD) with 
respect to MD simulation time. RMSD is the metric applied in drug design to 
compare the geometry of different models and/or the deviation of the predicted 
models from the ideal structure. This approach can be used in MD analysis as a 
basic tool to monitor the equilibration process, estimate the quality of the 
simulation, the extent of sampling of different conformations, and the 
variations between structural conformations 203.  
 
In this project, RMSDs were calculated for all 50 replicate of the 13 protein–
peptide complexes, for the ligands and TRF1 atoms or residues at a distance of 
≤ 5 Å from the peptide ligands. Computed RMSDs were produced for all 500 
snapshots, calculated at each 20 ps over 10 ns of MD simulations with respect 
to the starting conformation (first frame), the closest to the crystal structure. 
RMSD plots were then used to display structural conformation changes in each 
trajectory over time from the initial MD snapshot, the reference structure. 
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RMSDs of each replicate of the complex system versus the time of MD 
simulations were recorded. The goal of this process was to identify system 
equilibrations. As illustrated in Figure 2.14, equilibration of the TRF1–TIN2 
complex was assumed after approximately 3–5 ns for almost all 50 replicates. 
 
 
 
 
 
 
 
 
This approach is not entirely solid, however, as each replicate conserves a 
distinctive RMSD equilibration value in the range 3–5 Å. Therefore, the 
average RMSDs values of each snapshot for all replicates of a complex system 
were calculated and plotted against time to denote equilibration time (Figure 
2.15). When compared between Figure 2.14 and TS01 of Figure 2.15, both 
graphs represent the RMSD of the same complex system with different 
approaches. Nevertheless, the trends in both graphs are virtually identical; 
however, significant RMSD fluctuations were observed in replicates of Figure 
2.14, while minor RMSD fluctuations were shown in Figure 2.15 due to the 
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Figure 2.14 RMSDs plot of 50 replicates versus time for TS01-TRF1 complex during 
a simulation time of 10 ns. 
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average RMSD calculated for all replicates in each time point. Most of the 
complex systems in Figure 2.15 equilibrated after running approximately 5 ns 
MD simulations; however some of the complexes trend gradually increasing 
RMSDs values with respect to MD simulation time, i.e., increased 
conformational changes with increasing time. In addition, TS06–TRF1 
(negative control) was significantly different from the other systems, as it was 
not equilibrated, which could be due to the inhibition of the binding affinity. 
 
It is challenging, however, to analyse the trajectories of the complex system 
solely by using RMSDs analysis 204; it is generally considered as a crude tool 
for comparing conformations and monitoring system convergence. Additional 
analysis of the systems is therefore required 205. Factors typically related to the 
poor convergence of MD simulations of the complex systems are incorrect 
selection of force field parameters, which may lead to inaccuracies in the 
comparison to the crystal structure 169, insufficient sampling of the 
conformational spaces and deficiencies in energy functions. 206.  
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Figure 2.15 Average RMSDs of 50 replicates for each snapshot of the complex 
systems. The graph number represents the complex system name. 
 
2.12 Analysis of Key Interactions  
 
Chen et al. in 2008 192 identified the essential binding interactions between 
TRF1 protein and TIN2 peptide, on the basis of the crystal structure of the 
TRF1–TIN2 complex (3BQO.pdb). Through our MD simulations, several 
interactions between TRF1 and TIN2 were identified that they were not 
obvious in the crystal structure. In addition, MD simulations of TRF1–TIN2 
analogues were shown to either promote or abrogate the original binding 
interactions between the ‘hot spot’ of TRF1TRFH and the peptide analogues, as 
discussed below.  
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In this study, the most significant conformational changes were determined for 
each protein–peptide complex system using principal component analysis 
(PCA). This method is used for reducing a large number of independent 
variables to a smaller number of collective principal components.  The PCA 
technique was implemented in this project to analyse the snapshots of the MD 
trajectories for all replicates of each complex system 207 using an in-house 
produced tool known as pyPcazipgui, developed by Dr Gareth Shannon in 
2015 as a derivative and developed version of PCAZIP software 208. The 
results of PCA analysis illustrate the cluster analysis and 2D histogram of the 
snapshots of 50 replicates in each complex system to reveal the distribution of 
the molecules in the conformational space, depending on projections 0 and 1. 
In addition, this analysis shows a graph representing the percentage of 
occupancy of each cluster versus time-frame (500 frames) for the complex 
systems revealed the presence of more than one cluster.  
 
Interactions between the peptide analogues and the TRF1 protein in each of the 
complex systems are clarified below. The complex systems that are located at 
one region of the conformational space are illustrated by a single figure, while 
the systems located at a different region of the conformational space are shown 
as a figure either representing conformation of the molecule at the highest 
occupancy percentage at the equilibrium state or overlapping different 
conformations of the molecule (appendix A3 shows the cluster analysis, 2D 
histogram and the percentage occupancy for each of the peptide analogues).  
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2.12.1 TS01–TRF1 Binding Interactions 
 
In addition to the binding interactions in the crystal structure, the MD 
simulations identified additional interactions between TIN2 and TRF1 proteins. 
TIN2TBM peptide preserves three salt-bridges with TRF1 protein, which were 
confirmed through MD simulations; the first bridge is between the side chains 
of R265 and D139, the second is between the side chains of R266 and E192 
and the last is the interaction of the R267 and E146 side chains. These salt-
bridges are described as the hydrophilic interactions by Chen et al. (2008). We 
observed additional interactions of S256 and H257 of TIN2TBM with TRF1TRFH 
that were not previously discussed 192; the first is an unstable binding 
interaction between the side chain hydroxyl group of S256 and the side chain 
amide group of N144 (Figure 2.16). 
 
 
 
 
 
 
The next residue from the N-terminus of TIN2 peptide is H257. Following 
system equilibration during the MD simulations, it was shown to produce a 
strong and stable H-bonding interaction (through its backbone carbonyl group) 
Figure 2.16 The distance between the oxygen atom of the S256 side-chain and the 
nitrogen atom of the amide side-chain of N144 during 10 ns MD simulations. 
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with the amide side chain of Q127 in TRF1TRFH (Figure 2.17). According to the 
PCA analysis, all of the replicates are distributed at one region of the 
conformational space (See A3.1). 
 
 
Figure 2.17 H-bond interaction between H257 and Q127 in TS01–TRF1 complex. A) 
A snapshot showing interaction of H257 of TIN2 with Q127 of TRF1 during the MD 
simulations. B) H-bond distance between the two residue atoms with respect to MD 
simulation time. 
 
As shown in Figure 2.18, the conformations of S256 and H257 during the MD 
simulations are significantly different from the crystal structure, which result in 
the new H-bonds. 
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Figure 2.18 Overlapping the TRF1–TIN2 crystal structure and an equilibrated MD 
snapshot. The red and green colours are TIN2 of the MD snapshot and the crystal 
structure, respectively. The wheat color is TRF1 of the crystal structure and the orange 
is TRF1 of the MD snapshot. 
 
2.12.2 TS02–TRF1 Binding Interactions 
 
TS02 is the F258Y mutation of the wild-type peptide. As illustrated by the 
crystal structure, F258 has a crucial role in binding the TIN2TBM molecule with 
TRF1TRFH. F258 located on the concave surface of TRF1TRFH, it forms a 
hydrophobic interaction with a number of TRF1TRFH residues, in particular 
I109, L115, L120, I123 and Y124. Following mutation of this residue to a Tyr 
amino acid, hydrophobic contact with a group of protein residues is retained, 
but conformational change compared to F258 is observed to form a new 
favourable H-bond between the side-chain phenoxyl group of Y258 and the 
side-chain amide group of Q127 (Figure 2.19A). This H-bond is a strong 
H257	
S256	
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bonding interaction after 5 ns MD simulations as the distance between the 
interacting atoms is approximately 2 Å (Figure 2.19B).  
 
A)                                                                    B) 
 
Figure 2.19 Binding interactions of Y258 in TS02 peptide with TRF1 protein. A) 
Overlapping TS01 and TS02, which show conformations and the hydrophobic 
interactions of F258 and Y258, in TS01 and TS02, respectively. In addition, it 
indicates H-bonding between the side-chain hydroxyl group of Y258 and the side-
chain amide group of Q127. B) A graph illustrating the distance of the H-bond 
between the Y258 hydroxyl group side-chain and the Q127 amide side-chain during a 
10 ns MD simulation. 
 
TS02–TRF1 preserves the three salt-bridges as in TS01–TRF1. Despite 
generating a new H-bond after mutating F258Y, the ΔGbinding value is not 
significantly higher than that of TS01–TRF1 (Table 2-3) because the N-
terminus of the peptide changes its conformation and cancels the hydrogen 
bond between H256 and Q127. In addition, changing the conformation (Figure 
2.20) may affect the van der Waals and electrostatic interactions between the 
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protein and the ligand. PCA analysis shows distribution of the snapshots of all 
replicates in the one conformational region (See A3.2). 
 
Figure 2.20 Overlapping the entire structures of TRF1–TS01 and TRF1–TS02 to show 
the difference in the conformations of TS01 and TS02. 
	
2.12.3 TS03–TRF1 Binding Interactions 
 
TS03 is the sequence of TS01 with mutating N259L. PCA analysis indicates 
four clusters of the conformational space for all of the 50 replicates (See A3.3); 
however, only two of the conformations were taken because the percentage of 
occupancy of the selected two clusters is 80% during the equilibrium state of 
the system. As illustrated by the crystal structure and MD simulations, N259 of 
TIN2TBM has three binding interactions with TRF1 protein (Figure 2.21A). MD 
simulations revealed that L259 of TS03 abolishes two of these binding 
interactions, with only one H-bond remaining. In one of the TS03 
conformations (red), H-bond exists between the main-chain carbonyl group of 
TS01	
TS02	
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L259 and the side-chain guanidinium group of R131, but in the second 
conformation cluster of TS03 (green), H-bond exist between the main-chain 
carbonyl group of L259 and the side-chain amide group of Q127 (Figure 
2.21B). Most other interactions of TS03 with the residues of TRF1TRFH remain, 
but ΔGbinding inhibits at around 2.5 kcal/mol less than the wild–type complex, 
an observation presumably related to the elimination of the H-bonds. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.21 N259 of TS01 and L259 of TS03 interactions with TRF1. A) Interactions 
between N259 of TS01 with TRF1. B) Interactions of L259 of TS03 with TRF1. 
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2.12.4 TS04–TRF1 Binding Interactions 
 
PCA analysis of TS04 reveals four clusters, meaning that the snapshots of the 
50 replicates are distributed in the four major regions of the conformational 
space. The percentage of occupancy is around 30% for three of the clusters and 
10% for one of them, in the equilibrium state (See A3.4). Therefore, the 
interactions between TS04 and TRF1 are represented as overlapping four 
different figures. 
 
A261 of TIN2 typically has a single H-bond with the carboxylic acid side-
chain of E106 through its main-chain N-H group. Following mutation of A261 
to Thr in compound TS04, the bonding interaction between A261 and E106 
changed to T261–E106; however, T261 binds with E106 carboxylic acid side-
chains not only through the main-chain N-H group, but also through the 
hydroxyl group side-chain and establishes a new favourable H-bond (Figure 
2.22B). 
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Figure 2.22 Comparing the binding interactions of T261–E106 in TS04–TRF1 
complex with A261–E106 of TS01–TRF1 complex. A) Interactions between the A261 
of TS01 with the E106 of TRF1 B) Overlapping the TS04 conformations to illustrate 
bonding interactions between T261 and E106. 
 
The difference in the predicted binding free energy of TS01–TRF1 and TS04–
TRF1 is less than 3 kcal/mol, with TS04–TRF1 complex displaying a higher 
binding free energy (Table 2-3). This difference contributes to the calculated 
margin of error; therefore, TS04–TRF1 complex cannot be considered as 
having a higher binding free energy. MD simulations predicted that a salt-
bridge between R265 and D139 is eliminated in TS04–TRF1 complex and that 
only two of the salt-bridges are conserved (R266–E192 and R267–E146).  
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2.12.5 TS05-TRF1 Binding Interactions 
 
The aim of this mutation was the significant inhibition of ΔGbinding, given that 
R266 of TIN2 peptide has a critical role in binding with TRF1 protein; it 
interacts with four residues of the TRF1TRFH domain (L138, D139, R147 and 
E192) via its side and primary chains. Following mutation of R266P, all four 
interactions abolish (Figure 2.23) and the salt-bridge between R266 and E192 
eliminates. This process leads to a reduction in the calculated binding free 
energy from -85 to -61 kcal/mol. PCA analysis shows that virtually all of the 
snapshots are located at one region of the conformational space (See A3.5). 
 
 
 
Figure 2.23 Overlay of TS01–TRF1 and TS05–TRF1 complexes to demonstrate the 
effects of R266P mutation on the binding interactions in the TS05 peptide. 
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2.12.6 TS06–TRF1 Binding Interactions 
 
Compound TS06 was designed to be a second negative control peptide; it is 
related to the TS01 peptide with two amino acid mutations, the first being 
L260G and the second R266P. As shown for TS05–TRF1, TS05 peptide 
significantly inhibits the predicted binding free energy through the mutation of 
R266P and the ΔGbinding value further reduces in TS06–TRF1 (-51.42 kcal/mol) 
due to more disruption of the interactions between the peptide and TRF1 
protein by the additional mutation of L260G. The side-chain of the L260 
residue is situated in a deep hydrophobic pocket of the TRF1TRFH domain, as 
illustrated by the crystal structure and MD simulations. Following the mutation 
of L260G, the hydrophobic contact abolishes, most likely contributing to the 
further decrease in the ΔGbinding value (Figure 2.24). Moreover, the R266–E192 
salt-bridge abrogates in this complex compared to TS01–TRF1 complex. All of 
the replicates snapshots are presented as one cluster in the conformational 
space (See A3.6). 
 
Figure 2.24 Binding interactions of L260 in TS01 and G260 in TS06, with TRF1 
protein. A) L260 of TIN2 peptide located in a hydrophobic pocket of the TRF1TRFH 
domain. B) G260 of TS06 peptide inhibits hydrophobic interactions with the TRF1 
protein. 
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2.12.7 TS07–TRF1 Binding Interactions 
 
The structure of TS07 is significantly different from TS01, since S256 is 
deleted and five amino acid residues are mutated, namely A261N, L263N, 
R265K, R267S and V268L. As illustrated in Figure 2.19, in terms of 
interactions between TIN2 and TRF1, the backbone N-H group of A261 has a 
H-bond interaction with E106, but N261 of the TS07 peptide produces a 
weaker binding interaction. Furthermore, the mutation of L263N leads to the 
elimination of the hydrophilic interaction between the main-chain N-H group 
of L263 and the main-chain carbonyl group of Q141. A new weaker, but 
favourable H-bond creates, however, between the amide group side-chain of 
N263 and the main-chain carbonyl group of E143.  
 
Moreover, the R265K substitution causes the abolishment of a H-bond between 
R265 and D139 side-chains and K265 does not make contact with TRF1 
residues. Further along the peptide chain, the R267S mutation results in a new 
binding interaction between the side-chain hydroxyl group of S267 and E146, 
whereas in the wild-type peptide, R267 maintains two hydrophilic interactions 
with E146. Also, V268L does not appear to produce any new bonding 
interactions. Finally, after determining the salt-bridges, only the R266–E192 
salt-bridge shows to be conserved for TS07–TRF1. PCA analysis indicates two 
clusters, but the occupancy of one of the clusters is 60% (See A3.7), which 
presented in Figure (2.25B). 
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Figure 2.25 Comparison of the binding interactions of TS07 and TS01 with TRF1 
protein. A) Interactions between selected residues of the TS01 molecule with TRF1 
protein. B) Interactions of mutated residues of TS07 peptide with TRF1 protein. 
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2.12.8 TS08–TRF1 Binding Interactions 
 
TS08–TRF1 complex has a significantly higher estimated binding free energy 
(-94.94 kcal/mol) than TS01–TRF1 complex. This peptide analogue has 
A261N and L263N mutations. MD simulations demonstrated new interactions 
between N261 and both R102 and E106, as well as H-bonding between the 
main-chain N-H group of N263 and the main-chain carbonyl group of Q141 
(Figure 2.26). Moreover, the three salt-bridges of TS01-TRF1 are conserved. 
According to the PCA analysis, two conformation clusters are available. Figure 
2.26 represents one of the clusters, which has 60% occupancy in the 
equilibrium state (See A3.8). 
 
 
 
Figure 2.26 Interactions between the TS08 mutant residues (N261 and N263) with the 
TRF1 protein. 
E106	
R102	
N261	
Q141	
N263	
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2.12.9 TS09–TRF1 Binding Interactions  
 
The mutations of TS09 are A261N, R265K, R267S and V268L. Amino acid 
modifications in TS09 are identical to those of TS07, except that L263 does not 
mutated. The calculated ΔGbinding value increases slightly to -88.92 kcal/mol. 
With respect to the mutant residues of TS09 peptide, N261 produces H-
bonding interactions through the side-chain amide group with the side-chain 
carboxylic acid group of E106 and the side-chain guanidinum group of R102. 
Unlike the TS07 peptide and like R265 of the TIN2 peptide, the amino group 
side-chain of K265 creates a H-bond with the D139 side-chain carboxyl group. 
S267 and L268 are free from any bonding interactions with TRF1 protein, 
while the C-terminal carboxylic acid produces an unstable H-bond with the 
N189 side-chain of the TRF1 molecule (Figure 2.27). This complex system 
displays a single salt-bridge between R266 and E192. PCA analysis reveals 
that the snapshots are distributed into two clusters. Figure 2.27 represents 65% 
occupancy of the conformational space (See A3.8). 
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Figure 2.27 Binding interactions between the mutated residues of TS09 peptide and 
the TRF1TRFH protein. 
 
2.12.10 TS10–TRF1 Binding Interactions 
 
TS10 is similar to TS07, excluding the V268L modification. The amino acid 
residue mutations are A261N, L263N, R265K and R267S. The binding free 
energy (-82 kcal/mol) is slightly less than that of TS01–TRF1 complex. R266–
E192 and K265–D139 are the salt-bridges between the ligand and the protein. 
As shown in Figure 2.28, N261 is bound to the side-chain carboxylic acid 
group of E106 through both the backbone N-H and the side-chain amide). 
During MD simulations, N263 and S267 are shown to be free from any contact 
with TRF1 protein. PCA analysis provides one cluster for all of the snapshots 
of the 50 replicates (See A3.10). 
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Figure 2.28 Binding interactions between TS10 residues and TRF1TRFH.  
 
2.12.11 TS11–TRF1 Binding Interactions 
 
Following PCA analysis of the TS11 peptide, two clusters were identified at 
the equilibrium state. Both have approximately the same percentage of 
occupancy (50% for each of the clusters), meaning that the snapshots of the 50 
replicates at the equilibrium state have two main conformations (See A3.11). 
Therefore, the figures shown in this section represent both of the 
conformations, overlapped. 
 
Mutating A261 of TIN2 into Arg in TS11 produces a significant change in 
ΔGbinding value of TS11–TRF1 complex, with an increase of -10 kcal/mol than 
that of TS01–TRF1 complex. A search for salt-bridges between TRF1 protein 
and TS11 peptide revealed four, which are R261–E106, R265–D139, R266–
K265 
N261 
N263 
E106 
D139 
S267 
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E192 and R267–E146. In addition, a strong H-bonding observes between the 
backbone N-H group of R261 and the side-chain carboxylic acid group of 
E106 (Figure 2.29). 
 
A) 
 
B)                                                                 C) 
 
 
Figure 2.29 Binding interactions between R261 of the TS11 peptide and the TRF1TRFH 
protein. A) A snapshot showing the interactions of the R261 residue of TS11 analogue 
with TRF1TRFH protein. B) Salt-bridge between the guanidinium side-chain of R261 
and the carboxylic acid group side-chain of E106. C) H-bonding between the main-
chain N-H groups of R261 and the carboxylic acid group side-chain of E106.  
E106 
R261 
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As illustrated in Figure 2.30, both TS11 clusters have virtually the same 
conformation and binding interactions as the crystal structure; however, the 
F259 side-chain in the B conformation (yellow) changes conformation and is 
not close to the hydrophobic groove and the side-chain of R268 in the A 
conformation (red) has changed position and lost the H-bond contact with 
E146 of TRF1. 
 
 
Figure 2.30 Overlapping the crystal structure of TRF1–TIN2 and the 2 conformations 
of TRF1–TS11. The dark blue sequence is the TIN2 crystal structure. The red (A) and 
yellow (B) sequences represent the 2 cluster conformations of TS11. 
	
2.12.12 TS12–TRF1 Binding Interactions 
 
The TS12 peptide differs from TS10 only in the F258Y mutation. ΔGbinding of 
this complex system decreases by around 4 kcal/mol compared to TS01–TRF1 
complex and 1 kcal/mol relative to TS10–TRF1 complex. Despite preserving 
F258 
R267 
A261 R261 
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all TS10–TRF1 complex interactions in the TS12–TRF1 complex and 
producing salt-bridges (K265–D139 and R266–E192), this system displays 
lower binding free energy. This observation is most likely related to F258Y, as 
F258 of TS10 entirely preserves a hydrophobic contact but Y258 of TS12 
disrupted the hydrophobic interactions. Furthermore, and unlike TS02–TRF1, a 
slight change in the conformation results in the abolishment of H-bonding 
between the phenoxyl group of Y258 and the side-chain amide group of Q127 
(Figure 2.31). PCA analysis shows virtually one cluster for the snapshots (See 
A3.12). 
 
 
 
Figure 2.31 Binding interactions between TS12 analogue and TRF1 protein. A) 
Hydrophobic contact of Y258 of TS12 peptide with the TRF1 residues. B) 
Superimposed TS12–TRF1 complex (green) and TS02–TRF1 complex (yellow) 
shows the different conformations of Y258 in each peptide, dispelling the H-bond in 
TS12–TRF1 complex. 
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2.12.13 TS13–TRF1 Binding Interactions 	
Mutating V268 into Leu in the TS13 peptide results in increased ΔGbinding value 
to -89 kcal/mol in TS13–TRF1 complex. During MD simulations, TS13 
peptide was shown to maintain three salt-bridges with the TRF1 protein 
(R265–D139, R266–E192 and R267–E146), identical to TS01–TRF1 salt-
bridge elements. As shown in Figure 2.32, the conformations of V268 in TS01 
and L268 in TS13 molecule are quite similar. The cause of increased binding 
free energy is presumably related to non-specific improvements in the van der 
Waals and electrostatic forces between the TS13 peptide and the TRF1 protein. 
PCA analysis indicates four clusters, but Figure 2.32 represents one of the 
clusters, which has 40% occupancy in the equilibrium state (See A3.13). 
 
 
 
 
 
 
 
 
 
 
Figure 2.32 Superimposition of TS01–TRF1 and TS13–TRF1 to determine the 
differences in conformation of V268 and L268. 
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2.13 Fluorescent Probe Design 	
Prior to synthesis of the TIN2 peptide, the optimal site for attachment of the 
fluorescein molecule (See Chapter 4) was investigated through computational 
modelling. Typically, peptides are tagged at defined positions such as the C- or 
N-terminus 145,209. In this project, because peptides synthesis commenced from 
the C-terminus, the N-terminus was selected as the most straightforward 
conjugation position. MD simulations were undertaken to determine whether 
5-carboxyfluorescein (5-FAM) caused any interference in peptide–protein 
interactions, but the tagged molecule was shown to be outside of the interaction 
region (Figure 2.33). Moreover, ΔGbinding of TRF1-labelled TIN2 was 
calculated using MM-GBSA method to realise any changes happen in the free 
energy of binding between the peptide and the TRF1 protein; it was -84.7 
kcal/mol, which was approximately the same value as TRF1–TIN2 (-85.07 
kcal/mol).  
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Figure 2.33 Fluorescein molecule conformation during MD simulations after tagging 
of the N-terminus part of TIN2 peptide in the TRF1–TIN2 system. 
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3. Total Chemical Synthesis of the Peptide Ligands  
3.1 Introduction 	
In chapter two, the design and investigation of TIN2 and 53 of the peptide 
analogues, and the prediction of their binding free energies have been 
described. Based on the in silico results, a selection of TIN2 and 12 of the 
analogues (13 compounds in total) were synthesised. The aim of synthesising 
TIN2 analogues is to perform competitive binding assays (biophysical assays) 
with TRF1 protein. 
 
In this chapter, the principles and methods of peptide synthesis are summarised 
in Section 3.2. A consideration of the solid-phase synthesis, solid supports, 
linker resins, activating reagents and factor(s) behind selecting a specific linker 
resin and activating reagent in this project is described in Section 3.3. Section 
3.4 is focused on establishing the solid-phase peptide synthesis of the TIN2 
peptide and its analogues, and on a chemical method to label TIN2 with a 
fluorescent probe. Finally, in Section 3.5, the purification method, yields and 
analyses of the produced peptides are presented. 
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3.2 Peptide Synthesis 	
Peptides are produced by making amide bonds between two or more amino 
acids. The peptide or amide bond is formed through linking the α-carboxyl 
group and the α-amino group of two adjacent amino acids 210. There are two 
essential synthetic methods for assembling peptides chemically: the first is the 
classical or solution-phase synthesis (SPS) and the second is solid-phase 
peptide synthesis (SPPS). Both methods have advantages and disadvantages 
relative to each other. Drawbacks of the SPS technique compared with SPPS 
are:  it is labour-intensive because there is no automation to remove the product 
from the solution mixture; it takes longer because of the complexity of the 
assembly procedure and the difficulty of the purifications; there are frequent 
solubility problems, particularly with increasing size of the peptides 211; and 
the yields are lower 212. On the other hand, the advantages of SPS over SPPS 
are: lower production costs for large-scale manufacturing; and a higher chance 
of producing a pure compound because the intermediate products are purified 
after each bonding step and any side reactions can be easily identified 213,214. 
To a large extent, SPS has been replaced by SPPS in the majority of 
laboratories. Nevertheless, manufacturers still find SPS useful for the assembly 
of peptide in large quantities 215. 
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3.3 Solid-Phase Peptide Synthesis 	
Between 1950 and 1960, Bruce Merrifield developed SPPS, a fast and simple 
method for assembling peptides. Inclusion of the term ‘solid phase’ embodies 
the use of a supporting polymer attached to the growing peptide, which allows 
for washing, deprotection and the removal of byproducts and reagents. 
Therefore, this method does not require purification, such as recrystallisation 
of intermediates to remove impurities 216.  
 
Generally, SPPS is classified into two types according to the chemical groups 
protecting the α-amino group of the amino acids. The first method is 
Boc/benzyl SPPS; here, the α-amino group of the amino acid is protected by 
the tert-butoxycarbonyl (Boc) group, which is sensitive to acids 217. The second 
method is the Fmoc/tBu approach during which the fluorenyl-9-
methyloxycarbonyl (Fmoc) group protects the α-amino group and is sensitive 
to bases, such as piperidine 218. In the Fmoc approach, 20% v/v piperidine in 
dimethylformamide (DMF) can be used to deprotect the α-amino group of the 
amino acids. In contrast, in the Boc technique, acids, like trifluoroacetic acid 
(TFA) are required to deprotect the α-amino groups. The use of milder 
chemicals in the Fmoc method of SPPS makes it safer than, and therefore 
preferable to, the Boc approach. Another advantage of the Fmoc method over 
that of Boc is the orthogonal nature of Fmoc 219: the Fmoc temporary 
protecting group is deprotected under basic conditions whereas the side-chain 
protecting groups and the peptide–resin linkage are deprotected by an acid 220. 
For these reasons, Fmoc SPPS was used in this study.  
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The process of peptide building starts from the C-terminal, which grows to the 
N-terminal of the peptide sequence 221. As illustrated in Scheme 3-1, the 
starting point of this technique is the linker resin; it possesses a functional 
group that can make an ester or amide covalent bond with the α-carboxyl group 
of the first amino acid introduced in the synthesis (See Section 3.3.1 for the 
chemical composition of the linker). Coupling of the first amino acid is crucial 
for the success of SPPS because it can have a big impact on the peptide yield. 
An activating reagent is required to activate the α-carboxyl group of the amino 
acid, which accelerates the covalent bond construction and prevents side 
reactions 222,223. After coupling, DMF is used to wash and remove excess 
amino acid, byproducts and reagents from the resin. Next, the Fmoc-protected 
α-amino group of the amino acid that is now attached to the linker resin is 
deprotected using 20% v/v piperidine/DMF. Subsequently, the next carboxy-
activated amino acid is attached to the growing sequence. This cycle is 
repeated until the desired peptide is produced. After producing the peptide 
sequence, the α-amino protecting group is removed by 20% v/v 
piperidine/DMF, while the side-chain protecting groups and the linker resin are 
cleaved by an acid, such as TFA 220,221.  
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Scheme 3-1: The steps of synthesising peptides using Fmoc SPPS method.  
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Scheme 3-2 represents the steps of Fmoc cleavage from the α-amino group: the 
first step is the deprotonation by piperidine and the formation of a 
cyclopentadiene ring; dibenzofulvene is then separated from the amino acid 
and then forms a dibenzofulvene–piperidine adduct. The produced adduct 
absorbs ultraviolet (UV) light at 350 nm and is therefore a valuable tool for 
monitoring α-amino group deprotection of amino acids by simple UV 
spectrophotometry 224. 
 
 
Scheme 3-2: Mechanism of Fmoc deprotection and dibenzofulvene–piperidine adduct 
production from the α-amino group of the amino acids in the SPPS method.  
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3.3.1 Resin Materials and Linker Types for SPPS 	
Selecting an appropriate resin and linker is fundamental for successful peptide 
synthesis. Resin is composed of insoluble polymer, such as polystyrene. The 
resin swells extensively in solvents such as dichloromethane (DCM) and DMF, 
allowing penetration of the reagents and construction of a peptide sequence 
inside or on the particles 225. Resins are connected to the peptides through 
linkers; they should be chemically stable and must not react with different 
solvents and reagents 217,226. The most common resin comprises polystyrene 
supports; these are spherical beads of two size ranges, 35–75 microns and 75–
150 microns 221. Other types of resins are polyamines and polyethylene glycols 
(PEG) resin 227. A PEG resin has been developed recently, known as 
ChemMatrix®, which can be used for the production of many long and 
complex peptides 228. 
 
Linkers are the connectors between the resin, i.e. polymeric support and the 
peptide chains. Their primary function is to anchor the C-terminal part of the 
peptide structure reversibly through a reaction with the α-carbonyl group of the 
C-terminal amino acid. The second function of the linkers is to protect the C-
terminus of the peptide during the assembly process. Various types of linkers 
are commercially available; the type can determine not only the functional 
group of the peptide C-terminal, but also the chemicals used to cleave the 
peptide from the resin. As illustrated in Table 3-1, different types of linkers can 
provide different C-terminal functional groups of the peptides, such as 
carboxylic acid, or amide, ester 229 and thioester groups 230. Most of the peptide 
linkers release a peptide with the C-terminal carboxylic acid (e.g. Wang resin) 
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or amide group (e.g. Rink amide resin) (Scheme 3-8), both of which require 
acidic conditions for their cleavage 220,221,229,230.  
 
Table 3-1 Commonly used linkers that produce peptides with different C-terminal 
functional groups. 
	
Linker name C-terminal 
functionality 
Structure 
 
Rink amide linker 
 
Peptide amide 
 
 
Siber linker 
 
Peptide amide 
 
 
Wang linker 
 
Peptide acid  
 
2-chlorotrityl chloride 
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3.3.2 Coupling Reagents in SPPS 
 
Coupling or activating reagents are chemicals used to activate the α-carboxylic 
acid of the amino acids in SPPS in order they could react with the α-amino 
group of the growing peptide sequence. The coupling reaction to form a 
peptide bond is through increasing electrophilicity of the α-carbonyl group. 
The reaction can be achieved by replacing the hydroxyl group of the α-
carbonyl group with an electron-withdrawing group. There are different 
chemical classes of activating reagents, such as carbodiimides and onium 
(aminium/phosphonium)-based activating reagents 220,231. Choosing an 
appropriate coupling reagent is one of the critical factors for succeeding with 
SPPS 232. Carbodiimide reagents such as dicyclohexylcarbodiimide (DCC) and 
diisopropylcarbodiimide (DIC) are the first class of reagents applied in peptide 
chemistry (Figure 3.1). When they react with the α-carboxyl group of amino 
acids, a highly reactive O-acylisourea intermediate compound is produced, 
which can easily be attacked by a nucleophilic α-amino group of the amino 
acids. 
 
 
 
Figure 3.1 Structures of DCC and DIC activating reagents. 
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C
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The major drawback of carbodiimides is the production of the highly reactive 
O-acylisourea, which leads to racemisation and the yield of side-products, such 
as N-acylurea (Scheme 3-3). In addition, DCC produces dicyclohexylurea that 
has poor solubility in organic solvents 221,233.  
 
 
 
Scheme 3-3: Coupling reaction when using only Carbodiimides activating reagent 
(adapted from El-Faham and Albericio 2011). 
 
Hence, N-hydroxy triazole reagents were introduced as additive compounds 
with carbodiimides to improve the efficiency of reactions, as they produce 
corresponding active esters 231,234. Tertiary amine groups of the triazole 
activating reagents can facilitate formation of the active ester 235. One of the 
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produce an active ester (Scheme 3-4). However, a main disadvantage of these 
reagents is their explosive nature 236,237.  
 
Scheme 3-4: Coupling reaction using DCC and HOBt as activating reagents. 
 
The newer and most widely used coupling reagents are onium 
(aminium/phosphonium) reagents. They are more powerful and safer reagents 
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as they retain the same reactivity; in addition, their positively charged 
phosphorus centre can prevent peptide termination and cyclisation 238.  
 
Recently, the Oxyma activating reagent, ethyl 2-cyano-2-(hydroxyimino) 
acetate has been developed as a non-explosive alternative of to the N-hydroxy 
triazoles (HOBt and HOAt), which can be used as an additive with 
carbodiimides (Figure 3.2) 237. Oxyma can be considered as a powerful 
replacement for benzotriazole-based additives due to a number of desirable 
characteristics: first, it is highly soluble in widely different solvents; second, it 
poses significantly lower thermal risks compared with benzotriazole 
compounds such as HOBt. Finally, it can significantly inhibit racemisation 
237,240. 
a)                                                                 b) 
                                  
 
 
Figure 3.2 The structures of  a) Oxyma and b) Pyoxim activating reagents. 
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In 2010, Subiros-Funosas et al. introduced an Oxyma-based phosphonium salt 
activating reagent known as PyOxim: O-[(cyano (ethoxycarbonyl)methyliden)-
amino]-yloxytri(pyrrolidino)phosphonium hexafluorophosphate 234. This 
compound is a good choice for the SPPS: first, it combines the elegant 
characteristics of Oxyma based reagents and phosphonium-based reagents; 
second, it produces peptides with a significantly lower probability of 
epimerisation or racemisation; third, it is more reactive than the earlier reagents 
231; fourth, it is safer and has a lower thermal response compared to the 
benzotriazole-based compounds 237; fifth, it has greater solubility in organic 
solvents such as DMF and DCM than benzotriazole activating reagents; and, 
finally, its allergenic potential is minimal 234. Therefore, PyOxim was selected 
as an activating reagent for the peptide assembly in this project. 
 
The mechanism of action of PyOxim is illustrated in Scheme 3-5. The 
carboxylate anion reacts with the phosphonium cation of PyOxim to produce 
the acyloxyphosphonium intermediate, which in turn is attacked by the 
released Oxyma anion to yield an Oxyma amino acid ester and the byproduct, 
phosphonium oxide. Finally, aminolysis of the Oxyma active ester results in 
producing the desired peptide bond 240. 
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Scheme 3-5: Mechanism of the coupling reaction between two amino acids, catalyzed 
by the PyOxim activating reagent. 
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3.4 Synthetic Strategy of the TIN2 Peptide Analogues 	
The chemical assembly of the TIN2TBM peptide and the selected 12 peptide 
analogues was based on the computational results. Using the molecular 
modelling calculations, the ΔGbinding values between the peptide analogues and 
TRF1 protein were predicted and compared with the wild-type TRF1–TIN2 
complex system. Details of the peptide analogues selection and the binding 
free energies were discussed in Sections 2.5 and 2.6. The TIN2 peptide and its 
analogues, which are linear peptides, were produced through applying the 
Fmoc/tBu SPPS method. The method depends on using an orthogonal-
protecting-group strategy in which an acid removes the side-chain protecting 
groups and the linker support, while a base releases the α-amino-protecting 
groups. 
 
All the synthesised peptides consisted of either 12 or 13 amino acid residues, 
except the labelled wild-type (TS01-L), which was composed of 13 amino acid 
residues with β-alanine (β-Ala) and the 5-FAM molecule (Scheme 3-6): β-Ala 
used as a linker between the N-terminal residue (Ser256) and the fluorescein 
molecule to separate 5-FAM from the interaction region of the peptide and the 
protein (for more details, see Section 2.13). The fluorescein molecule is a 
suitable reagent in the fluorescence-based assays. After assembly of the peptide 
sequence with β-Ala, the N-terminal of TIN2 was labelled using 5-FAM. The 
purpose of tagging the peptide with the 5-FAM molecule was to monitor the 
protein–peptide interactions 241. The mechanism of labelling TIN2 by the 5-
FAM molecule is illustrated in Scheme 3-6. 
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Scheme 3-6: Mechanism of tagging the N-terminal part of the TIN2 peptide by the 5-
FAM molecule, using DIC and HOBt as coupling reagents. 
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3.4.1 Condensation of Fmoc-Amino Acids with Rink Amide 
Novagel 
 
The first step of assembling the TIN2 peptide and its analogues was the 
reaction between the linker and the α-carboxyl group of the C-terminal amino 
acid residue. Rink amide Novagel was selected as a resin linker in order to 
produce the peptide amide. The structure and coupling mechanism of the linker 
with an amino acid is explained in Scheme 3-7, which shows that the reaction 
is identical to the coupling of amino acids. After activation of the α-carboxyl 
group of the amino acid by the PyOxim reagent (Section 3.3.2), the 
nucleophilic functional group of the Rink amide linker (amino group) attaches 
the α-carbonyl of the activated amino acid to produce an amide bond.  
		Scheme	 3-7:	 Coupling	 reaction	 of	 Rink	 amide	 Novagel	 with	 α-carbonyl	group	of	an	amino	acid. 
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Hence, prior to coupling of the resin linker with the amino acid, the resin was 
swollen in the DMF overnight. The first Fmoc-amino acid and PyOxim were 
then dissolved in 0.6 ml DMF, followed by the addition of 2 equivalent (eq.) of 
N,N-diisopropylethylamine (DIPEA). The mixtures were loaded onto the 
swollen Rink amide Novagel in the reaction column and stirred gently for 3 
hours at room temperature. 
 
All the amino acids used were protected: α-amino groups were masked by the 
Fmoc group as a temporary protecting group, and side-chain functional groups 
were masked by semi-permanent protecting groups, such as tert-butyl (tBu) 
and trityl (Trt) that were not affected by reaction conditions during assembly of 
the peptide chains.  
 
3.4.2 Peptide Assembly 	
After coupling the first amino acid with the resin, the temporary α-amino 
protecting group (Fmoc) was removed (deprotection) using 20% v/v piperidine 
in DMF for 7 min (3 ml min-1) in a semi-automated peptide synthesiser. As 
illustrated in Scheme 3-2, monitoring the Fmoc deprotection semi-
quantitatively was achieved through UV absorption of the dibenzofulvene–
piperidine adduct at 350 nm.  
 
Subsequently, an excess of the next carboxy-activated amino acid was added to 
the growing peptide sequence (Scheme 3-5). After 3 hours, via the use of the 
semi-automated peptide synthesiser, washing and deprotection were performed 
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to remove the excess reagents and to cleave the Fmoc group, respectively. 
Each washing was achieved using 3 ml min-1 DMF and lasted for 7 min.  
 
For each coupling reaction, before loading the next amino acid, a solution of 
the carboxy-activated Fmoc-amino acid was prepared, which consisted of 4 eq. 
Fmoc-amino acid, 4 eq. PyOxim, 8 eq. DIPEA and 0.6 ml DMF. All of the 
steps discussed above were repeated until the desired sequences were 
produced. After assembling the desired peptides, the resin-peptides were 
washed with DMF, filtered, and washed with DCM and hexane, and finally, 
dried in vacuo.  
 
3.4.3 Cleavage of the Linear Peptides  	
In order to deprotect and release the linear peptide analogues, the peptide-
linker solid support and the semi-permanent protecting groups were cleaved 
using a TFA cocktail. Thus, the cocktail was composed of 95% TFA, 2.5% 
TIPS and 2.5% water 220. The reaction was allowed to proceed for 3 hours at 
ambient temperature. The mechanism of cleaving the produced peptides from 
the Rink amide linker is shown in Scheme 3-8. The peptide products were 
filtered, evaporated using a rotary evaporator and triturated using diethyl ether, 
which produced a precipitated thin film of the peptide.  
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Scheme 3-8: Rink amide Novagel cleavage from the produced peptide through 
acidolysis. 
 
3.5 Purification and Analyses of the Linear Peptides 
 
The crude and purified peptides were analysed using reverse-phase high 
performance liquid chromatography (RP-HPLC) and mass spectrometry (MS). 
Analysis of the produced peptides using MS showed that all the m/z values 
corresponded to the (M+3H+) species (Table 3-2).  
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Table 3-2 Summary of the yield, RP-HPLC retention time (tR), crude purity and both 
calculated and measured MS for the peptide analogues. 
                                                                                                    MS 
Name Sequence Yield 
(%) 
tR 
(min) 
Crude 
purity 
(%) 
 
 
Calculated 
(M+3H+) 
Observed  
TS01 S256-H-F-
N-L-A-P-L-
G-R-R-R- 
V268 
 
96 5.9 78 507.9333 507.9683 
TS01-L 5FAM-βA-
S256-H-F-
N-L-A-P-L-
G-R-R-R- 
V268 
 
93 7.4 78 651.3233 651.3334 
TS02 S256-H-Y-
N-L-A-P-L-
G-R-R-R- 
V268 
 
94 5.4 83 513.2900 513.2959 
TS03 S256-H-F-
L-L-A-P-L-
G-R-R-R- 
V268 
 
98 6.4 82 507.6400 507.6575 
TS04 S256-H-F-
N-L-T-P-L-
G-R-R-R- 
V268 
 
96 5.9 91 517.9633 517.9702 
TS05 S256-H-F-
N-L-A-P-L-
G-R-P-R- 
V268 
 
98 6.3 89 488.2766 488.2768 
TS06 H257-F-N-
G-A-P-L-G-
R-P-R-V268 
 
96 5.0 95 440.5800 440.5880 
TS07 H257-F-N-
L-N-P-N-G-
K-R-S-L268 
 
94 5.1 81 466.9166 466.0143 
TS08 H257-F-N-
L-N-P-N-G-
R-R-R-V268 
 
86 5.0 83 493.6033 493.6815 
TS09 H257-F-N-
L-N-P-L-G-
K-R-S-L268 
 
96 6.3 78 465.5966 465.6921 
Chapter Three                                        Total Chemical Synthesis of the Peptide Ligands 
	129 
TS10 H257-F-N-
L-N-P-N-G-
K-R-S-V268 
 
98 4.9 93 461.2466 461.3439 
TS11 S256-H-F-
N-L-R-P-L-
G-R-R-R-
V268 
 
91 5.6 71 536.3133 536.3444 
TS12 H257-Y-N-
L-N-P-N-G-
K-R-S-V268 
 
96 4.5 80 466.5766 466.6737 
TS13 S256-H-F-
N-L-A-P-L-
G-R-R-R- 
L268 
94 6.0 68 512.6333 512.6854 
	
 
Furthermore, 2D 1H-1H correlation spectroscopy (COSY) nuclear magnetic 
resonance (NMR) analyses were used to characterise the wild-type TS01 and 
the analogue TS11. In this study, COSY NMR was chosen because of the 
overlapping multiplet signals. Figure 3.3 shows COSY NMR for TS01, which 
confirmed the presence of all of the secondary amide protons and their 
correlation with the adjacent α protons.  
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Figure 3.3 2D 1H-1H COSY NMR spectrum of the TS01 peptide. All of the NH 
signals of the secondary amides are in the circle and the different coloured lines 
demonstrate the correlation of the proton signals in each amino acid residue. 
	
COSY NMR also confirmed the amino acid residues of TS01 from the 
observations of the cross peaks of the NH signals for each residue and their 
correlated proton signals of the residue (Table 3-3). However, the method 
could not confirm Pro262 and Ser256 because Pro possesses a tertiary amide 
bond and Ser was at the N-terminal of the peptide. In addition, it could not 
precisely characterise the Arg residues due to the presence of three Arg 
residues in the peptide molecule. 
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Table 3-3 Proton chemical shifts for the amino acids of the TS01 peptide having the 
secondary amide signals. 
Residue 
 
NH 
 
α H 
 
β H 
 
γ H 
 
δ H 
 
Val268 
 
7.64 
 
 4.11 (1H) 
 
1.95 (1H) 
 
0.92 (6H) 
  
 
 
Arg 
 
7.88 
 
 
 
4.32 (1H) 
 
1.41, 2.00  
(2H) 
1.94, 1.96  
(2H) 
4.00, 4.08  
(2H) 
 
 
Arg 7.93 4.31 (1H) 1.50 (2H) 1.5, 1.49 (2H) 3.11 (2H) 
 
 
Arg 7.94 4.18 (1H) 1.46 (2H) 1.48 (2H) 3.07 (2H) 
 
 
Gly264 8.04 3.70 (2H)    
 
 
 
Leu 8.07 4.26 (1H) 1.57 (2H) 1.56 (1H) 0.82 (6H) 
 
 
Ala261 8.19 4.47 (1H) 1.19 (3H)   
 
 
Leu 8.11 4.28 (1H) 1.68 (2H) 1.70 (1H) 0.84 6H) 
 
 
Asn259 8.65 4.64 (1H) 2.46, 2.58 (2H)   
 
 
Phe258 8.26 4.57 (1H) 2.72, 2.98 (2H)   
 
 
His257 8.59 4.62 (1H) 3.08 (2H)   
 
 
Moreover, COSY NMR was performed to characterise the structure of the 
TS11 peptide. According to the correlation map of the 2D COSY spectrum 
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(Figure 3.4), TS11 analogue signals were virtually identical to TS01 signals; all 
of the secondary amides were recognised from their α-proton cross signals. The 
proton chemical shifts for the different amino acids of the compound are given 
in Table 3-4. 
 
 
 
 
Figure 3.4 1H-1H COSY NMR spectrum of the TS11 peptide analogue. Coloured 
lines represent cross peaks of each amino acid. 
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Table 3-4 Proton chemical shifts for each amino acid of the TS11 peptide. 
Residue 
 
NH 
 
α H 
 
β H 
 
γ H 
 
δ H 
 
Val268 7.65 4.10 (1H) 1.93 (1H) 0.84 (6H)  
Arg 7.88 4.34 (1H) 1.44, 1.99 
(2H) 
1.44 (2H) 4.32 (2H) 
 
 
Arg 7.99 4.19 (1H) 1.43 (2H) 1.43 (2H) 4.19 (2H) 
 
 
Arg 8.00 4.36 (1H) 1.40, 1.69 
(2H) 
1.51 (2H) 4.33, 4.31 
(2H) 
 
G264 8.04  3.80 (2H) 
 
 
   
L263 8.14 4.27 (1H) 1.47 (2H) 1.47 (1H) 0.82 (6H) 
 
 
Arg 8.11 4.26 (1H)) 1.48 (2H) 1.47 (2H) 3.08 (2H) 
 
 
Leu 8.16 4.44 (1H) 1.53 (2H) 1.53 (1H) 0.82 (6H) 
 
 
Asn259 8.64 4.66 (1H) 2.39, 2.58 
(2H) 
 
 
  
Phe258 8.26 4.56 (1H) 2.75, 3.04 
(2H) 
 
 
  
His257 
 
8.56 
 
4.60 (1H) 
 
2.51 (2H) 
 
  
 
 
 
 
Specifically, the secondary amide proton signal at δH = 8.19 ppm and its cross 
signals at δH = 4.47 and 1.19 ppm for α and β protons, respectively, were 
assigned to Ala261 in TS01. In contrast, the secondary amide signal was 
Chapter Three                                        Total Chemical Synthesis of the Peptide Ligands 
	134 
shown at δH = 8.11 ppm and its cross signals at δH = 4.26, 1.48, 1.47 and 3.08 
ppm, respectively (Table 3-4) was assigned to Arg261 residues, which is 
specifically present in the analogue TS11. 
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4. Biophysical Evaluations for the Protein–Peptide 
Complexes 
 
4.1 Introduction 
 
Direct detection of receptor–ligand interactions plays a vital role in the study of 
biological systems and in new drug development processes because it can be 
used to determine the distribution of the receptors and identify their subtypes, 
to discover endogenous ligands, and to screen for and find new chemical 
entities as drug candidates 242. The aim of using the receptor-ligand binding 
assay in this research has been to find a new molecular entity. Diverse 
biophysical approaches are available to investigate binding interactions and 
affinities between ligands and receptor proteins, such as the radioligand 
binding assay 243, isothermal titration calorimetry (ITC) 244 and fluorescence 
polarisation (FP) assay 245,246.  
 
Each type of the receptor–ligand binding assay is characterised by several 
advantages and drawbacks. For example, ITC is a reliable technique for 
determining the binding thermodynamics between receptors and ligands, such 
as peptide–proteins interactions. This method does not require the ligand’s 
labelling; however, it does consume a considerable amount of the ligand and 
has a low throughput capability 244,247. Regarding radioligand binding assay, 
the most significant advantages of these binding assays are their 
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reproducibility, ease of use and the precision of the receptor-ligand binding 
affinities which is achieved because the labelling of the ligands by radioactive 
compounds does not interfere with the receptor-ligand binding interactions 248. 
However, the disadvantages of radioligand assays are the requirement to 
separate bound and unbound ligands, the use of extremely hazardous 
radioactive chemicals, the associated waste disposal problems and the 
requirement for special laboratories. Additionally, this method is expensive and 
relatively slow 242. Due to the disadvantages of radioactive assays, non-
radioactive assays have been developed, which are based on optical methods. 
These methods are usually preferred to the radioactive assays because they are 
less health hazardous, less expensive and create less environmental pollution. 
The FP assay is an example of a non-radioactive biophotonic technique, which 
is widely applied to the identification of the ligand-receptor bindings 242. In this 
project, FP assays were performed to recognise binding interactions between 
the peptide analogues and the TRF1 protein. 
 
4.2 Introduction to the FP Assay 	
The term fluorescence polarisation refers to a process of monitoring molecular 
rotations and the factors that modulate their orientations when small molecules 
interacts with macromolecules like protein or DNA molecule. The method can 
be applied in different fields, for example, for detecting receptor–ligand 
interactions, DNA–protein interactions, enzyme assays and competitive 
immunoassays 249,250. The FP assay is used essentially as a binding assay 
between a receptor and ligand in order to identify the binding affinity of the 
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k	+	1	k	-1	
ligand analogues to the receptor (competitive binding assay) or infrequently to 
obtain the dissociation constant (Kd) of the ligands. Our goal of using the FP 
assay is to identify the binding affinity between the TRF1 protein and the TIN2 
peptide, and then the competitive bindings of the peptide analogues with the 
TRF1–TIN2 complex. Theoretical aspects and calculations of the receptor-
ligand binding affinities are explained in the following equations (a colon 
represents a non-covalent bond). 
 
Reversible interactions between two molecules are illustrated in Equation 4.1, 
which is a binding between the receptor [R] and the labelled ligand [FL] to 
form a complex. 
 
[R] + [FL]       [R:FL]                                             Equation 4.1 
 
where k+1 and k-1 are the rate constants. The forward rate is k+1[R][FL], and the 
backward rate is k-1[R:FL]. At equilibrium condition, both forward and 
backward rates are constant. Kd demonstrates the quantity of the ligand that 
saturates half of the binding sites, and it can be consider as an affinity of the 
interactions. At equilibrium, Kd is the ratio k -1/k+1, as shown in Equation 4.2. 
 
Kd =   k–!k!! =  FL [R][R: FL]                                                                        Equation 4.2 
 
When the ligand analogue molecule [A] is added to the complex [R:FL], two 
different receptor ligand complexes are produced, as the analogue [A] 
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displaces a number of the labelled ligands [FL]; the ratio of displacement 
depends on the affinity and concentration of [A]  (Equation 4.3). 
 R + FL + A                                R: FL + R:A                                  Equation 4.3   
    
An inhibition curve can be generated when keeping the concentrations of [R] 
and [FL] constant, while varying the concentration of [A]. Through the 
inhibition curve, the inhibitory concentration 50% value (IC50) can be obtained, 
which represents the concentration of [A] that displaces 50% of [FL] bound 
with [R] 242,251. 
 
For calculating the IC50 of the peptide ligands in the competitive binding assay, 
GraphPad Prism was applied. The titration curve was fitted using the log of the 
concentrations of the inhibitors versus response-variable slope (using four 
parameters) (Equation 4.4). 
 
P = min+ (max−min)(1+ 10 !!!"  ! !)                                                       Equation 4.4 
 
where cp is the log of concentration of the peptide analogues, r is the log of 
IC50, P is the FP reading results, min is the minimum value of the sigmoidal 
curve, which represents the FP of the free-labelled peptide, max is the 
maximum value of the sigmoidal curve, which represents the FP of the labelled 
peptide bound to the TRF1 protein and H is the Hill slope, which is the slope 
factor.  
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4.3 Principles of the FP Assay 	
The FP assay starts with the attachment of a fluorophore to a small molecule 
(typically < 1500 Da). When a fluorophore-labelled molecule is free and 
excited by plane-polarised light, it will emit a long a different plane from the 
excitation light during the excitation lifetime of the fluorophore. In contrast, 
when a fluorophore labelled molecule binds with a high MW protein (typically 
> 10 kDa) and is excited by a plane-polarised light, it will to a large extent emit 
the identical polarised light. The emitted light is measured in two different 
planes: the first is the same plane of the excitation light; the second is 
perpendicular to the first plane. According to these observations, the cause of a 
depolarising free–labelled molecule is the rapid Brownian molecular 
reorientation during the excitation lifetime, whereas after it has bound with a 
protein, there is a decrease in the mobility of the labelled molecule during the 
excitation lifetime, which causes the emission of polarised light. In conclusion, 
the rate of the emitted polarised signal is inversely proportional to the rate of 
molecular rotation (Figure 4.1) 241 252.  
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Figure 4.1 The difference of emitted light between an unbound labelled ligand and a 
bound labelled ligand with a receptor during the FP assay. 
 
FP assays can be explained through Equation 4.6, which calculates 
polarisations (P) through vertically and horizontally polarised emissions:  
 𝑃 =  !∥!!!!∥!!!                                                                                    Equation 4.6                                
          
where, 𝐼 ∥ is intensity with the polariser parallel and  𝐼 ⊥  is intensity with the 
polariser perpendicular 253. Usually, measured P is in the range of 0.01-0.3; 
therefore, it is multiplied by 1000, which is a millipolarisation (mP) unit. 
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4.4 Characteristics of the Fluorophore Molecule 	
Currently, the FP technique is widely applied and many studies has been 
focused on developing new chemical classes of fluorophores to increase their 
solubility, improve their physical properties, optimise their brightness 
(intensity of fluorescence = molar extinction coefficient x quantum yield) and 
enhance their photostability 78. Therefore, to achieve a successful FP assay, a 
fluorophore molecule should have: a high quantum yield, a high extinction 
coefficient (ε) to increase sensitivity in aqueous media for detection, good 
photostability, a high excitation wavelength to inhibit autofluorescence and 
suitable molecular size. Furthermore, using a spacer between the ligand and the 
fluorophore molecule is essential to reduce the likelihood of inducing steric 
hindrance caused by the attachment of the bulky fluorophore molecule. Finally, 
the position of tagging fluorophores needs to be in a location that does not 
interfere with the receptor–ligand interaction 242. 
 
4.5 Advantages and Disadvantages of the FP Assay 	
The FP assay has a number of advantages over other methods when it is used 
to identify receptor–ligand interactions. First, it can be easily automated for use 
in ultra-high-throughput screening (uHTS) 250,254. Second, the assay is 
relatively inexpensive because the plate reader can be used for different types 
of HTS assays 255,256 and miniaturisation can decrease the cost of the assay 257. 
Third, it is unlike other fluorescence assays in only needing one labelling step. 
Fourth, it is a homogenous assay (mix-and-measure) because it does not 
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require separation of bound and free ligands, while radiological assays do 
require this separation and therefore entail filtration, centrifugation and dialysis 
before the samples can be read, which is time-consuming and may disturb the 
reaction equilibrium 242. Fifth, the FP assay has significantly lower health risks 
and fewer safety issues. Finally, the chemicals can be kept for a long period of 
time 252. 
 
However, the FP assay does have several drawbacks. The first concerns the 
size of interacting molecules. Typically, the size of the ligand is < 1500 Da and 
the size of the receptor > 10 kDa; nevertheless, a ligand size of up to 5000 Da 
could be used if the receptor has a very large MW 241,257. The second drawback 
is that the labelled fluorophores may involve interactions between the ligand 
and the receptor 242,257. Finally, the demand for protein is higher in an FP assay 
relative to a radioligand assay because of the need to titrate proteins against a 
fixed concentration of the ligand; however, it still requires less amount of 
protein compared with the ITC technique 251.  
 
4.6 FP Assay of the TRF1–TIN2 Peptide Analogues 	
Before performing the FP competitive binding assays between the TRF1 
protein and the TIN2 peptide analogues, the method was developed and 
optimised by: choosing a suitable fluorophore molecule as well as a site of 
labelling fluorophore to the TIN2 peptide; investigating the sensitivity of the 
plate reader to the fluorophore-labelled TIN2; and identifying the required 
concentration of TRF1 protein for the assays. 
Chapter Four                    Biophysical Evaluations for the Protein–Peptide Complexes 
	143 
4.6.1 Fluorophore Selection for the FP Assay 	
Different types of fluorophore molecules have different excited state lifetimes, 
and choosing a fluorophore with an appropriate excitation lifetime for a 
specific type of FP assay can be considered to be one of the critical factors for 
a successful FP assay 250. Theoretically, to achieve FP measurements between 
the ligand and the receptor, the binding should be between a low MW ligand 
and a much higher MW receptor (substrate), while in practice, as discussed 
above, the bindings are typically between ligands of approximately ≤ 1500 Da 
and receptors of approximately ≥ 10 kDa; this limitation is due to the short 
excited-state half life of the fluorophore molecules, which need a consistency 
between the fluorescence lifetime of the fluorophore and the rotation of the 
labelled ligand-receptor complex 258. Fluorophore molecules such as 
Fluorescein and rhodamines have lifetimes of approximately 4 ns which can 
allow an obvious FP separation between the free-labelled ligand and the 
labelled ligand-receptor complex when the size of both molecules are within a 
range discussed above. In this study, the MW of the peptide analogues was 
approximately ≤ 1500 Da and the MW of the TRF1 protein was approximately 
50 kD. The selected fluorophore was 5-carboxyfluorescein (5-FAM) because 
its excitation lifetime is 4 ns, which was consistent with the MW of the ligands 
and receptor. In addition, the maximum absorption and emission of the most 
plate-reader filters are at 492 nm and 518 nm, respectively; the EnVision® plate 
reader, which was used in this FP assays has an excitation wavelength at 480 
nm and an emission wavelength at 535 nm. Finally, 5-FAM is inexpensive 
compared with the other fluorophores 259,260.  
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4.6.2 Selecting the Fluorophore Tagging Site 	
The 5-FAM molecule can be labelled at the N-terminal, C-terminal or inside 
the peptide; however, the label should be in a position such that it cannot 
interfere with the peptide-protein binding site. Furthermore, tagging a flexible 
region of the peptide or having a long linker between the peptide and 5-FAM 
may affect the FP measurement 241. Therefore, based on the structural data, the 
N-terminal of the TIN2 peptide was selected, as it is outside the binding area of 
the TRF1–TIN2 complex 192. Also, β-Ala was chosen as a linker between 5-
FAM and TIN2 to ensure that 5-FAM was positioned safely outside of the 
binding region. MD simulations were then carried out to confirm that the 
labelled compound could not interfere with the binding interactions between 
the TRF1 protein and the TIN2 peptide (details in Section 2.13). 
 
4.6.3 Detection Sensitivity of the Instrument for the Labelled 
TIN2 Peptide 	
One of the vital steps before starting the FP assays was to determine the 
sensitivity of the plate reader for the synthesised fluorescent tracer (TS01-L) in 
order to select the minimum concentration of it, which could be detected by the 
plate reader 241,261. This step was achieved by using different concentrations of 
TS01-L, and identifying the concentration above which there was no further 
change in the polarisation signal and which was above the sensitivity of the 
instrument. As demonstrated in Figure 4.2, different concentrations of TS01-L 
were applied, starting at 10 µM and going down to 10 nM. The signals of 
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concentrations below 100 nM (30 nM and 10 nM) different from the other 
concentrations: the mP readings increased with decreasing concentration, 
which indicated these concentrations were below the detection limit of the 
instrument. Thus, the lowest fluorescent detection limit of the multi-well plate 
reader for the TS01-L compound was 100 nM and therefore, this concentration 
of the labelled tracer was identified as a fixed concentration for the future FP 
assay. The selected concentration should not be higher than twice the Kd value 
(Kd = 0.31 µM) because it may lead to stoichiometric titration and decrease the 
sensitivity of the assay 192,241. The selected concentration was close to the Kd 
value. 
 
 
 
 
 
 
 
 
 
Figure 4.2 The polarisation signals (mP) for the different concentrations of TS01-L.  
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4.6.4 Determining the TRF1 Concentration  	
After confirming the TS01-L concentration, the next step in developing the 
assay was to determine the lowest possible concentration of TRF1 that should 
be used in the experiment to avoid wasting valuable material, nevertheless, 
high enough to ensure that most of TS01-L is bound before adding 
competitors. This step was achieved by maintaining a fixed concentration of 
the labelled probe (TS01-L) and measuring changes in the polarisation signals 
whilst titrating with different concentration of the TRF1 protein 241,261. The 
aims of this measurement were not only to find the optimum protein 
concentration for the future assays, but also to demonstrate the protein-peptide 
binding interactions. In this experiment, the different concentrations of TRF1 
protein (1 nM–30 µM) were titrated against a fixed concentration of TS01-L 
(100 nM); and the polarisation readings were plotted against the TRF1 
concentrations to determine at what point the curve reached a plateau, this 
point being due to a direct binding of the all labelled ligand with the protein 
(Figure 4.3A).  
 
The data were then replotted using the log of the TRF1 concentrations, and 
were expressed as a sigmoidal curve (Figure 4.3B). The baseline of the curve 
represents the free TS01-L; the plateau (220 mP) represents the total binding of 
TS01-L with TRF1; between these points there is increasing polarisation due to 
increased binding between TS01-L and TRF1. 
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A) 
 
B) 
 
 
Figure 4.3 Direct binding of 100 nM TS01-L with different concentrations of TRF1 
protein. (A) FP versus TRF1 concentrations. (B) FP versus log of TRF1 
concentrations. 
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The sigmoidal binding curve shown in Figure 4.3B was used to choose the 
optimum concentration of the TRF1 protein. The selected concentration needed 
to be within a range of 50–80% of increasing polarisation measurements from 
the free-labelled peptide to the completely bound state (plateau) because, on 
the one hand, selecting protein concentrations < 50% would not show an 
obvious assay window when the labelled peptide was displaced by the 
unlabelled competitor compounds, and on the other hand, concentrations > 
80% would not be sensitive to competitors 241. Therefore, 1 µM of the TRF1 
protein was determined for the assays, which corresponded to 79% of 
increasing polarisation from the baseline to the plateau. 
 
4.6.5 Competitive Binding of TS01 and TS01-L with the TRF1 	
After determining the concentrations of the fluorescent tracer and the protein, a 
standard competitive binding assay was undertaken between the labelled and 
the unlabelled TIN2 peptide with the TRF1 protein. This assay was applied to 
confirm that the TIN2 peptide was interacting with a specific TRFH domain of 
TRF1 and that the FP assay was working properly. The assay is based on 
measuring the decrease of mP directly as the concentration of the unlabelled 
peptide – which is added to the mixture of the labelled peptide and the protein 
– is increased. The reason of decreasing mP is that increasing the concentration 
of the unlabelled peptide leads to increase displacement of the bound labelled 
peptide from the protein. To achieve this assay, different concentrations of 
TS01 (10 nM–300 µM) were titrated against a fixed concentration of TS01-L 
and TRF1 protein (100 nM and 1 µM, respectively) in the plate wells. By 
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increasing the concentration of TS01 added to the complex of TS01-L and 
TRF1, the polarisation signals were decreased due to displacement of TS01-L 
by the TS01 peptide. The sigmoidal curve shows the polarisation signal starts 
to inhibit from increasing the TS01 concentration at 100 nM and it displaces all 
of the TS01-L at around 300 mM (Figure 4.4). 
 
 
 
Figure 4.4 Competitive binding assay between the labelled and unlabelled TIN2 
peptide with TRF1 protein. 
 
4.6.6 Competitive Binding Assay of the Labelled TIN2-TRF1 
with the Peptide Analogues  	
After the successful competitive FP assay of TS01-L and TS01 with the TRF1 
protein, all of the peptide analogues (12 peptides) were screened to obtain their 
binding affinities. Each peptide analogue was titrated against the mixture of 
TS01-L (100 nM) and TRF1 protein (1 µM). Decreasing mP signals for each 
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peptide assay were observed as the concentration of the peptide analogue 
increased because TS01-L was gradually being displaced by the peptide 
analogues. However, different concentrations of the various peptide analogues 
were required to displace TS01. As shown in Figure 4.5, reducing FP 
intensities were different for the different peptide analogues while using the 
same concentration scale; it is reasonably certain that these results were due to 
the diverse potencies of the peptide analogues. 
 
 
 
Figure 4.5 Competitive binding assay of TS01 and the 12 peptide analogues with the 
complex of labelled TIN2 and TRF1 protein. 
 
The results of the FP assays for each competitive binding assay were 
demonstrated by a sigmoidal curve: the top of the curve denoted the total 
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showed the concentration at which half of the TS01-L was displaced by the 
competitor ligand, which was IC50. In pharmacology and medicinal chemistry, 
IC50 is commonly used to indicate the potency of a compound or drug 
antagonist in vitro, as it is a quantitative measurement, i.e. the concentration of 
a compound that will inhibit 50% of the biological process being considered. 
Hence, IC50 was obtained for each of the peptide analogues to investigate the 
inhibitory activity of the analogues and obtain an early lead compound. All the 
IC50 results are presented in Table 4-1. However, the assays were performed in 
triplicate (Section 6.3.4), the standard errors of mean for the peptide analogues 
TS07 and TS12 are not exist because IC50 of these analogues was obtained in 
one of the experiments owing to the uncompleted sigmoidal curves in the 
remaining two assays. 
 
The IC50 of the peptide analogues were compared with TS01 because the latter 
is a wild-type compound. According to the modelling results, both of the 
compounds TS05 and TS06 were predicted to be negative controls, as they had 
significantly lower ΔGbinding values compared with TS01; here also, it has been 
clearly demonstrated that they had dramatically higher IC50 values (625 µM 
and 928 µM, respectively).  
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Table 4-1 Results of IC50 for the TIN2 analogues obtained from the FP assays. 
Compound Name IC50 (µM) Log IC50 (M) 
 
TS01  5.04 ± 0.3 -5.30 ± 0.03 
 
TS02  3.97 ± 0.1 -5.40 ± 0.01 
 
TS03  41.41 ± 3.8 -4.39 ± 0.04 
 
TS04  5.81 ± 0.3 -5.24 ± 0.02 
 
TS05  625.00 ± 27.8 -3.15 ± 0.06 
 
TS06  948.20 ± 23.5 -3.02 ± 0.01 
 
TS07 
 
 428.30 -3.368  
TS08  268.70 ± 10.5 -3.57 ± 0.02 
 
TS09  6.24 ± 0.6 -5.21 ± 0.05 
 
TS10  681.95 ± 9 -3.17 ± 0.01 
 
TS11  1.40 ± 0.1 -5.85 ± 0.03 
 
TS12  118.00 -3.93  
 
TS13 5.04 ± 0.7 -5.436 ± 0.07 
 
   
 
Only two peptide analogues had lower IC50 values compared with TS01, these 
being TS02 (IC50 = 3.97 µM) and TS11 (IC50 = 1.4 µM). TS02 had a slightly 
higher binding affinity than TS01, while TS11 was significantly more potent 
than the wild–type, as obviously verified in the sigmoidal curve (Figure 4.6). 
All of the other peptide analogues had either approximately similar or lower 
binding affinities compared with TS01. Therefore, we can conclude that 
according to the FP results, TS11 is the only peptide analogue with a 
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significantly higher binding affinity relative to TS01 and can be considered as 
an early lead compound. 
 
 
 
Figure 4.6 Competitive binding assay of the peptides TS01, TS02 and TS11 with the 
mixture of TS01-L and TRF1 protein. (blue curve = TS01; red curve = TS02; green 
curve = TS11). 
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5. Conclusions and Future Work 
	
The essential aim of this study was destabilising PPIs in the telomeres of the 
cancer cells. Choosing this target rather than telomerase or telomeric DNA (G-
quadruplexes) was based on the literature data. Telomerase inhibitors have a 
delayed onset of action and they could produce senescence only in p53 active 
cells 40,41,262. In contrast, G-quadruplex ligands could overcome the problem of 
delayed onset of action of telomerase inhibitors because they may directly 
disrupt and destabilise the shelterin proteins of telomeres 41,50,51,263. In addition, 
in vivo results demonstrated the significant selectivity and sensitivity of the G-
quadruplexes for the cancer cells 42. Hence, directly inhibiting the PPIs of the 
shelterin components may be an appropriate choice and a new method of 
targeting cancer cells. 
 
Inhibiting PPIs between TRF1 and TIN2 proteins was the target chosen in this 
work because they are crucial for the stability of telomeres. TRF1 is essential 
to maintain the consistency and chromosomal stability of the shelterin 
components 22. Furthermore, according to Pal et al. (2015), overexpressing 
TRF1 and TRF2 have been recognised in the renal cancer cells; therefore, 
silencing their expression have been achieved, which led to reduce the number 
and proliferation of the treated cells significantly compared with the control 
cells. This observation was explained to be related to the cell cycle arrest, 
consequently, telomere destabilisation and apoptosis of the cancerous renal 
cells 57. A recently published article by Garcia-Beccaria et al. (2015) reported 
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the potential effect of TRF1 inhibition on lung cancer cells when p53 was 
inactivated and the high degree of selectivity for cancer cells 59. 
 
Peptide molecules have been selected to target the PPIs between the TRF1–
TIN2 complex. A library of TIN2 peptide analogues (53 compounds) has been 
designed in silico to compete against TIN2 protein efficiently on TRF1, inhibit 
PPIs and destabilise the telomeres. Then, 10 ns MD simulations were carried 
out and the MM-GBSA method was used to calculate the binding free energy 
of each peptide analogue–TRF1 complex system. MM-PBSA/GBSA is one of 
the most common methods for the prediction of drug–target binding affinities 
in drug design projects; however, its main weakness is calculating absolute 
binding affinity values because of the difficulty in predicting entropy changes.  
 
Typically, entropy can produce ΔGbinding values closer to the experimental 
values, but when calculated in MM-PBSA/GBSA method, it may dramatically 
overestimate the ΔGbinding values 264,265. Hence, predicting the absolute values 
of the binding affinity may be unrealistic when utilising MM-PBSA/GBSA 
methods, whereas their accuracy can be significantly improved when 
neglecting entropy issues and determining relative affinities of similar ligands 
or conformers 157,183,266. In addition, for relative binding free energy 
predictions, MM-GBSA seems often to be more accurate than MM-PBSA 181. 
 
Predicted values of ΔGbinding for a wide range of candidate peptide–protein 
complex systems varied over a broad range of over 50 kcal/mol (ΔGbinding value 
for P04 = -102.31 kcal/mol while for P25 = -50.37 kcal/mol) (Table 2-2).  
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It was impracticable to investigate and test all of the peptide analogues. 
Therefore, 13 peptides were selected from the library of peptide analogues to 
perform extensive computational analysis and optimisation of their binding 
free energies, chemical synthesis and biophysical assays. The selected peptides 
consisted of the wild-type TIN2 peptide as a reference compound, two peptide 
analogues as estimated negative controls, three peptide analogues produced 
from TIN2–Apollo cross-matching mutations, and seven peptide analogues that 
have been predicted to have significantly higher binding free energy compared 
with the wild-type and might compete effectively with TIN2 peptide. 
 
Replicate MD simulations for the wild-type system led to an interesting 
observation, which was significantly different ΔGbinding value between 
replicates (the difference was 10 kcal/mol). After that, one question that needed 
to be addressed was whether the ΔGbinding values predicted from the single MD 
simulations are sufficiently accurate to depend on? There are two likely causes 
for the poor convergence of the MD simulations; it might be related to the 
trapping of the system in local minima for a long period of simulation time 
and/or insufficient sampling of the conformational space.  
 
In order to improve the accuracy of the results, MD simulations were repeated 
50 times for all of the complex systems (using the same protocol and starting 
structure, but different initial velocities) and the average ΔGbinding values for the 
replicates were calculated. Then, the protocol for the calculation of binding 
free energies of the complex systems were optimised, which was started by 
testing the statistical distribution of the replicate values for each system (Figure 
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2.11); subsequently, the required number of replicates for each system was 
calculated through using the sample size equation, which were different 
according to their margin of error (Table 2-4).  
 
After calculating average ΔGbinding value for the complex systems, they were 
compared with the wild-type value as a reference values; most of the ΔGbinding 
values were within the margin of error for the wild-type peptide, except 
compounds TS05, TS06, TS08 and TS11, which had significantly different 
binding affinity values. Both TS05 and TS06 had significantly lower values, 
which were predicted to be negative controls, while TS08 and TS11 were 
expected to be lead compounds. 
 
Then, the optimum time of MD simulations was determined through two 
different approaches. The first was calculating ΔGbinding at each time point of 
the MD simulations for the 50 replicates; this strategy was tested just for the 
wild-type system because it was expensive computationally. According to this 
approach, the system was equilibrated after approximately 4 ns of MD 
simulations. The second was calculating RMSD for all of the replicates of the 
complex systems; for each peptide–protein system, the average RMSD value of 
the replicates at each time point was taken. The RMSD was calculated for all 
peptides atoms and all TRF1 residues within 5 Å of the ligand, because the 
greatest binding interactions were in that distance range. As shown in Figure 
2.11, the complex systems approached equilibration after approximately 4–5 ns 
MD simulations; however, a number of the systems trend with respect to time 
were to increase RMSD gradually, which means the systems were not yet 
completely equilibrated. 
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Subsequently, the 12 designed 13-mer peptide analogues and the TIN2 peptide 
were synthesised using Fmoc SPPS. Rink amide Novagel was used as a resin 
linker to produce the peptide amide, which can decrease the charge of the 
peptides, increase cell permeability and increase resistance against enzymatic 
degradations. PyOxim was used as an activating reagent, as it is a great choice 
for SPPS because it can significantly inhibit racemisation, improve reactivity, 
has less explosive capability and is highly soluble in organic solvents. 
 
The last stage of this project was applying FP as a biophysical assay to obtain 
the IC50 of the peptide analogues. The reasons for selecting this assay, as 
discussed in Chapter 4, were utility to identify protein–peptide interactions, 
easy automation to use in HTS, relative economy because a plate reader 
instrument can be used for different tests and miniaturisation of the assay, 
homogenous assay and significantly fewer safety problems comparing with 
radiolabelled assays. Furthermore, we could overcome the main limitations 
related to this assay (the size difference between the ligand and the receptor) 
because of the huge gap between the size of the peptides and the protein: the 
size of the peptide analogues did not exceed 1600 Da and the size of TRF1 is 
approximately 50 kDa. Moreover, TIN2 was suitable to be labelled by 5-FAM 
and according to the molecular modelling results, it would not interfere with 
the interacting regions of TRF1–TIN2. Finally, abundant and pure TRF1 
protein was prepared for the assay. 
 
This assay was developed to screen for peptide analogues against TRF1TRFH–
fluorescent tracer (TS01-L) mixture, which was the first demonstration of an 
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FP assay for TRF1 protein and then it can be used in high-throughput (HT) 
format. The assay developed here was applied to identify a lead compound. 
The initial development of the assay was time-consuming as usual; however, 
the developed methodology of this assay could be used for the future screening 
of chemical libraries against TRF1–TIN2 interactions and easily automated.  
 
After optimising the methodology for the assay and before screening the 
peptide analogues, the unlabelled wild-type peptide (TS01) was titrated against 
the mixture of TRF1 and the labelled wild-type peptide (TS01-L) to confirm 
binding of TS01 with the TRFH domain of the TRF1 protein and that the assay 
was working properly; this titration is termed a “Gold-standard assay” 241. 
Subsequently, a competitive binding assay for the peptide analogues against 
the mixture of TRF1 and TS01-L was done, which led to obtaining IC50 of the 
peptide analogues. The lowest IC50 values were obtained from two peptide 
analogues with a single residue mutation, which were TS02 (TIN2-F258Y) and 
TS11 (TIN2-A261R) with 3.97 µM and 1.4 µM, respectively, and they had 
lower IC50 compared with TS01 (IC50 = 5.04 µM). However, TS11 had a 
significantly higher binding affinity than TS01, as it is approximately five-fold 
more potent than TS01 (Table 5-1); hence, it can be considered as an early lead 
molecule.  
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Table 5-1 Predicted and experimental affinity of the TIN2 peptide analogues. 
Compound Sequence IC50 (µM) Average predicted 
ΔGbinding (kcal/mol) 
TS01 S256-H-F-N-L-A-P-L-G-
R-R-R- V268 
 5.04 ± 0.3 -85.07 ± 0.72 
TS02 S256-H-Y-N-L-A-P-L-
G-R-R-R- V268 
 3.97 ± 0.1 -84.61 ± 0.81 
TS03 S256-H-F-L-L-A-P-L-G-
R-R-R- V268 
 41.41 ± 3.8 -82.69 ± 0.77 
TS04 S256-H-F-N-L-T-P-L-G-
R-R-R- V268 
 5.81 ± 0.3 -87.98 ± 0.95 
TS05 S256-H-F-N-L-A-P-L-G-
R-P-R- V268 
 625.00 ± 27.8 -60.99 ± 0.77 
TS06 H257-F-N-G-A-P-L-G-
R-P-R-V268 
 948.20 ± 23.5 -51.42 ± 0.68 
TS07 H257-F-N-L-N-P-N-G-
K-R-S-L268 
 428.30 -81.95 ± 1.03 
TS08 H257-F-N-L-N-P-N-G-
R-R-R-V268 
 268.70 ± 10.5 -94.94 ± 1.11 
TS09 H257-F-N-L-N-P-L-G-
K-R-S-L268 
 6.24 ± 0.6 -88.92 ± 0.86 
TS10 H257-F-N-L-N-P-N-G-
K-R-S-V268 
 681.95 ± 9 -82.96 ± 1.26 
TS11 S256-H-F-N-L-R-P-L-G-
R-R-R-V268 
 1.40 ± 0.1 -95.49 ± 1.21 
TS12 H257-Y-N-L-N-P-N-G-
K-R-S-V268 
 118.00 -81.99 ± 1.2 
 
TS13 S256-H-F-N-L-A-P-L-G-
R-R-R- L268 
5.04 ± 0.7 -89.00 ± 0.7 
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As illustrated in Table 5-1, the in silico and experimental results show that 
most of the amino acid residue mutations lead to inhibition of the binding 
affinity between the ligands and the TRF1 protein because of changes in the 
conformations of the peptides that affect other binding interactions, or as a 
result of the entropy penalties. The only two mutations that produced positive 
results are the F258Y and A261R in TS02 and TS11, respectively.  
 
The second aim of this study was to investigate and optimise the accuracy of 
ΔGbinding by implementing MM-GBSA methods. The results of single and 
average (optimised) predicted binding free energy for the peptide analogues 
were reported in Chapter 2 and the experimental results were reported in 
Chapter 4. To reveal the accuracy of the single and average predicted results, 
the correlation between each set of the predicted values and the experimental 
values was tested. The results of the correlational analysis are displayed in  
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Figure 5.1 Correlation between ΔGbinding results and experimental results. (A) 
Correlation between single ΔGbinding value of the peptide analogues and their IC50. (B) 
Correlation between average ΔGbinding results of the peptide analogues and their IC50 
results. 
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the predicted binding free energy values, the coefficient of determination (r2) 
significantly increase and improve correlation from 0.08 to 0.40 between the 
predicted ΔGbinding values and the experimental data in the form of IC50 values. 
The above can explain the general accuracy of the predicted values; however, 
after dissecting the predicted and experimental value of each peptide, various 
relative relationships can be found. For example, both of the negative controls 
peptide analogues (TS05 and TS06) have significantly lower predicted and 
experimental binding affinities compared with those for TS01 (Table 5-1), 
which is due to mutating the critical residues that could highly interact with 
TRF1 residues. In addition, predicted and experimental binding affinity values 
in TS06 are significantly lower than those for TS05 because, as well as 
mutating R266P, it has a second mutation: L260G. Another example is TS11; 
according to the molecular modelling results, it has the highest predicted 
binding affinity (-95.49 kcal/mol) and it is identical in the experimental result, 
as it has the highest binding affinity (IC50 = 1.4 µM). These examples show the 
significantly high accuracy of the computational results. 
  
In contrast to the above examples, some of the peptide analogues’ 
computational and experimental results are significantly different. The most 
obvious example is TS08, for which the results are not very encouraging, as the 
predicted ΔGbinding value is -94.94 kcal/mol, which is significantly higher than 
TS01, but the experimental binding affinity is significantly lower than TS01, 
which mean that there is not any correlation between the predicted and 
experimental results (Table 5-1). 
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Overall, the findings of this research support what is stated in the literature, 
that both computational and experimental investigations in drug design projects 
could be used in parallel to enhance the success rate of the projects 82,267,268. 
However, the predicted binding free energy between the receptor and ligand 
was not such accurate to match the experimental data and still may not be a 
reality. In this study, it is clear that the in silico results can be relatively 
correlated with the experimental values because all of the computational values 
are overestimated. In addition, the computational and experimental values of 
the several analogues like TS07, TS08 and TS10 are not correlated (Figure 
5.1). 
 
Nevertheless, it is apparent that the prediction of binding affinity in most 
projects is within the acceptable range, and that the continuous development of 
the computational programme and capacity are also required to correct the 
penalties and improve the accuracy through improving the force field 
parameters and undertaking higher sampling of the conformational space. As 
demonstrated in this project, accuracy of the predicted ΔGbinding values was 
significantly improved compared with the experimental results, after 
optimising the computational ΔGbinding values through 50 replications of the 
MD simulations to obtain average values (Figure 5.1). However, multiple MD 
simulations are expensive at present and require the use of specific 
supercomputer centres: this may improve in the future, however, if more 
powerful computers become available. 
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Further studies 
 
The promising results of the work presented in this thesis have the potential for 
further exploration and investigation. The essential goal of the project was 
obtaining a peptide analogue of the TIN2 peptide that could inhibit PPIs 
between TRF1–TIN2. The compound TS11 was identified, which is a peptide 
analogue of TIN2; it has significantly higher binding affinity than TIN2 and 
could be considered as an early lead compound. However, the peptide analogue 
requires chemical optimisation of the potency, pharmacokinetics and 
physicochemical properties.  
 
Optimisation could be achieved through various ways, such as mutating amino 
acid residues to improve binding affinity, trying to truncate unnecessary group 
or residues in order to decrease the size of the molecule, adding unnatural 
amino acids and cyclising the peptide analogues so as to increase the stability 
and cell permeability.  
 
In our investigations, a library of peptide analogues was designed through 
mutation of the TIN2 sequence residues. However, only the peptide analogues 
TS02 and TS11 were capable of improving ΔGbinding. Hence, future 
experiments could mutate F258Y and A261R to combine the favourable 
interactions of both residues and significantly increase ΔGbinding. Furthermore, 
mutating P262 of the TIN2 peptide to Phe (P262F) may improve free binding 
energy as according to the crystal structure and MD simulations, P262 has not 
binding interaction with the TRF1 residues and its side-chain fairly close to the 
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F142 of TRF1 (Figure 5.2). However, P262F was designed (P03) and ΔGbinding 
was inhibited -3.5 kcal/mol, but it was applied for the single MD simulations 
and experimental assays were not performed. 
 
 
Figure 5.2 Conformations of the P262 and F141 in the TRF1–TIN2 crystal structure. 
 
Amino acid residues S256, H257 and V268 can be deleted, as S256 has an 
unfavourable effect on the binding affinity with TRF1. In addition, per-residue 
decomposition results show that H257 and V268 contributions to the binding 
free energy are minimal (-1.32 and -0.82 kcal/mol, respectively) (Figure 2.10). 
The ΔGbinding value of truncated S256 (P06) was determined, which improved 
the binding free energy by approximately -11 kcal/mol (Table 2-2). In addition, 
deletion of both S256 and V268 in compound P26 improved ΔGbinding to -6.5 
kcal/mol. However, these are single MD simulation results and their accuracy 
is unspecified. Truncating the residues leads to significant decrease in the sizes 
P262	
F142	
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of the peptide analogues (approximately 300 Da), crucial to improve the 
pharmacokinetic properties and reduce manufacturing cost. 
 
The major limitation of peptide drugs, particularly the natural peptides, is their 
low residence time in the blood and rapid metabolism by the protease enzymes. 
This could be overcome by using various strategies that do not affect the 
biological activity of the molecule. For example, changing the entire peptide 
residues from L to D configuration, which is known as retro-inverso strategy 
269. This technique involves inversion of all of peptide bonds to form a retro-
inverso peptide. It may be one of the approaches to improve stability of the 
peptide analogues, as the resulting peptide cannot be recognised by proteases 
and thus maintains biological activity.  
 
In addition, cyclising of the TIN2 peptide analogues could be a promising 
strategy as it constrains flexibility of the peptide analogues, reduces the 
entropic penalties and improves the peptide’s stability by decreasing 
susceptibility to proteolytic enzymes 133. As shown in Figure 5.3, the S256 and 
L263 side-chains are virtually free from interactions and the distance between 
them is 4.7 Å; closing this ring could constrain the main interacting region of 
TIN2 (F-X-L-X-P), which could be a promising approach for optimising the 
molecule. This can be achieved through mutating L263K and S256D to form a 
covalent bond between the side-chains of K263 and D256. 
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Figure 5.3 The TRF1–TIN2 crystal structure showing the conformations and the 
distance between the side-chains of S256 and L263. 
	
The second goal of the project was optimising predicted ΔGbinding values 
calculated from the MM-GBSA method. After optimising the values and 
improving the correlation significantly, future work would be repeating the 
same approach on different systems to confirm the validity and reliability of 
the approach. 
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Recommendations for further research work 
 
Optimising binding affinity in early drug development is a fundamental and 
challenging step. Improving potency is increasing ΔGbinding of the ligands 
through favourable increase in enthalpy and entropy. It is normal when 
introducing new functional groups or amino acid residues during lead 
optimisation to get unwanted enthalpic or entropic penalties, but recognising 
the causes of those penalties may accelerated the process of optimisation 187. 
 
More importantly, before mutating any residues of the peptides or introducing 
new functional groups, it is essential to consider that the interacting atoms of 
the peptides are located at the correct angle and distance from the 
corresponding atoms of the amino acid residues in TRF1 protein in order to be 
sure that any enthalpic gain could overcome enthalpic penalty owing to 
desolvation of polar groups. However, it is apparent that improving enthalpy 
through mutating residues to construct a new H-bond or salt-bridges may not 
be sufficient to increase affinity because improving favourable enthalpy is 
always at the cost of unfavourable entropy, and large ligands such as peptides 
are usually entropy dominated 270. Therefore, it will be important to consider 
conformational changes when wanting to establish a new or stronger binding 
interaction between the peptide analogues and the TRF1 protein and 
minimising structural effects by performing the peptides mutation in a well-
structured region of the peptides and TRF1 protein. 
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In this study, almost of the mutations were made to increase hydrophilicity, but 
always adding hydrophilic residues may lead to unfavourable entropy 186. 
Therefore, if mutations are to increase the peptides hydrophobicity in the 
future, it may improve binding affinity significantly because of providing 
favourable entropy 187. 
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6. Experimental 
6.1 Molecular Modeling 
6.1.1 Systems Preparation 	
The starting coordinates of the TRF1–TIN2 complex (solved at 2.0 Å 
resolution) was downloaded from the Protein Data Bank (PDB) website 
(http://www.rcsb.org, access code 3BQO 192). The file was edited to retain a 
monomer of the complex structure. Then, mutations were carried out for the 
selected amino acids of the TIN2 peptide to produce the peptide analogues. 
Mutations were performed using the UCSF Chimera 1.6 package from the 
Resource for Biocomputing, Visualization, and Informatics at the University of 
California, San Francisco 271. Subsequently, the monomer complexes (Protein–
Peptide) were prepared for MD simulations with AMBER suite version 12 272 
and the ff99SB force field 273. Counter ions (Na+) were added to neutralise the 
complex systems. The next step was immersing the Protein–Peptide complexes 
in an octahedral box of TIP3P water molecules that extended 10 Å outside of 
the complex in all dimensions 274. 
 
6.1.2 Systems Minimisation 	
After preparing and parameterising the complex systems, minimisations were 
achieved through two steps, and for each step, two different minimisation 
algorithms were applied. The first and the faster one was steepest descent 
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minimisation, which was used to quickly reduce unfavourable clashes. The 
next minimisation algorithm was conjugate gradient, which was performed to 
minimise systems energy after the steepest descent as its more efficient. In 
terms of the minimisation steps, restrained and the unrestrained minimisation 
were performed to relax the complex structures. Firstly, all of the water and 
ions were relaxed, while the protein–peptide coordinates were restrained to 
their original values, and then, unrestrained minimisation was applied to all of 
the system. The restrained minimisation procedure was 2000 cycles (500 
cycles of steepest descent and 1500 cycles of conjugate gradient minimisation). 
The whole system minimisation was 3000 cycles (1000 cycles of steepest 
descent and 2000 cycles of conjugate gradient minimisation). 
 
6.1.3 Molecular Dynamic Simulations 	
After minimisations, equilibrating MD simulations were performed in two 
stages: solute-restrained and then unrestrained. All simulations were performed 
using the pmemd module in Amber 12 272. For all simulations, the SHAKE 
algorithm was used to constrain bond lengths involving hydrogen atoms 275. 
The time step was 2 femtoseconds (fs), and Langevin dynamics were carried 
out to control the temperature with a collision frequency of 1.0 ps-1 276. For the 
restrained 2 ns MD simulations, a constant volume periodic boundary and a 10 
Å cutoff were used. Furthermore, the systems were gradually heated from 0 to 
300 K over 200 picoseconds (ps) as a pre-equilibration period. Random initial 
velocities were generated from a Boltzmann distribution. 
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For the subsequent unrestrained equilibration MD simulations, the temperature 
was kept at 300 K and a 10 Å cutoff was used. Furthermore, a constant 
pressure periodic boundary was applied (1 atmosphere) with isotropic position 
scaling to maintain constant pressure dynamics. The relaxation time of the 
pressure was 2 ps. Finally, snapshots were taken every 10,000 steps (every 20 
ps) of 10 ns MD simulations, thus producing 500 frames for each MD 
simulation 277. While preliminary MD simulations were run using local 
facilities, the UK national supercomputing services HECToR 
(http://www.hector.ac.uk) and ARCHER (http://www.archer.ac.uk) were used 
for the later replicate MD simulations. 
 
6.1.4 Trajectory Analysis Techniques 
6.1.4.1 Predicted Binding Free Energies 	
The MM-PBSA/GBSA method was used to estimate ΔGbinding values for all of 
the 13 Protein–Peptide complexes using the standard AMBER python scripts 
(MMPBSA.py) 278. Calculations were performed using all of the frames in each 
system trajectory file (10 ns, 500 frames). Water molecules were stripped off 
with an infinite cut-off. Four compatible topology files were created for each 
complex system, which were: solvated complex, non-solvated complex, 
receptor and ligand file 277. To predict binding free energy using MM-GBSA 
method, water and counterions were stripped, the generalized Born method 
(igb =5) was used 279, and 0.1 M salt concentration was assumed. Data analysis 
and visualisation were performed using GraphPad Prism V6.0 (GraphPad 
Software Inc., San Diego, CA; www.graphpad.com). 
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6.1.4.2 Molecular Similarity 	
Molecular similarity was measured by using Root Mean Square Deviation 
(RMSD) to describe the difference or the distance between the reference 
(native state) and the equilibrated structures of superimposed molecules, and 
also to study the equilibration of the system replicates (Equation 7-1) 280. 
 
RMSD =  !!!!!!!!                                                                        Equation 6-1 
 
where N  is the number of atoms and di is the distance between coordinates of 
equivalent atoms in the two superimposed structures. RMSD was performed to 
analyse the trajectory files by applying the ptraj utility of AmberTools 277. In 
addition, ptraj was used to quantify conformational changes versus time and to 
measure the distance between atoms of superimposed structures. 
 
6.1.5 Visualisation Software 	
Visual Molecular Dynamics (VMD) software from the Theoretical and 
Computational Biophysics Group, NIH Resource for Macromolecular 
Modeling and Bioinformatics at the University of Illinois at Urbana-
Champaign was used to visualise structures, trajectories, measure hydrogen 
bonds and salt bridges 281. Furthermore, the PyMOL Molecular Graphics 
System 282 was used to visualise interactions, distances between atoms and 
conformational changes of the Protein–Peptide complex systems.  
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6.2 Peptide Synthesis 
6.2.1  Materials  	
Chemicals for the experiments were purchased from Novabiochem, Sigma 
Aldrich, and MP Biomedicals, and directly used without further purification. 
The solvents, which were either reagent or HPLC grade, were bought from 
Fisher Scientific and Sigma Aldrich. All of the laboratory glassware was oven-
dried overnight prior to use. 
 
6.2.2 Instrumentation  	
Mass spectra were recorded by positive electrospray ionisation using a Waters 
2759 spectrometer. Lyophilisation was carried out on an Edwards Modulyo 
freeze drier. Analytical RP-HPLC was performed using a Waters 510 twin 
pump using an OnyxTM monolithic C18 analytical column (100 x 4.6 mm) at a 
flow rate of 3.0 ml min-1. Eluent detection was monitored by UV absorbance 
using a Waters 486 Tunable Absorbance Detector at 214 nm. Solvent A was 
100% water + 0.06% TFA and solvent B was 90% aqueous acetonitrile + 10% 
water + 0.06% TFA. The linear elution gradient was 10 to 60 %B over 18 min, 
at 3.0 ml min-1. In addition, preparative RP-HPLC was performed on an 
OnyxTM monolithic-C18 Semi-PREP column (100 x 10 mm) at a flow rate of 4 
ml min-1 with an elution gradient of 10 to 60 %B over 19 min. Peptide 
synthesis was carried out using a NOVASYN® GEM manual peptide 
synthesizer. UV absorbance was measured at 355 nm using a Gilson 115 UV 
detector. 
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1H-NMR was performed at room temperature using a Bruker 400 Ultrashield 
operating at 400 MHz. Chemical shifts, denoted by δ were recorded in parts 
per million (ppm) relative to tetramethylsilane (TMS) and coupling constants 
(J) were measured in hertz (Hz). Deuterated solvent used was DMSO-d6 (δH = 
2.50 ppm). Finally, COSY was applied for 1H assignments. 
 
6.2.3 Procedure of the Peptides Assembly 	
The procedure for all peptides assembly was started by placing 0.1 mmol 
(0.156 g) of the Rink amide Novagel in the reaction column, which was then 
swollen with 1.5 ml DMF for 15 hours. The resin was then washed using DMF 
(3 ml min-1, 7 min). The next amino acid was prepared for the acylation 
reaction as follows: 4 equivalent (eq.) of the N-protected amino acid was 
mixed with PyOxim (4 eq.) as an activating reagent; the mixture was then 
dissolved in the minimum amount of DMF (0.6 ml) and DIPEA (8 eq.) added. 
Subsequently, the mixture was added to the washed resin in the reaction 
column. Washing, Fmoc deprotection and a second washing were performed 
after each acylation. Fmoc deprotection was executed using a continuous flow 
of 20% v/v piperidine in DMF (3 ml min-1, 7 min), while the washing processes 
were executed by flowing only DMF (3 ml min-1, 7 min). To perform all the 
washing and deprotection processes, a NOVASYN® GEM peptide synthesizer 
was used and the reactions were monitored thorough UV absorption at 355 nm. 
Each of the consecutive acylation reactions, which lasted 3 hours, was 
performed in the reaction column at ambient temperature. 
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After the final acylation, the peptide–resin was washed using DMF, then 
filtered and washed again using DCM (5 ml) and hexane (5 ml) and dried 
overnight in vacuo. The next step was the cleavage of the resin and the semi-
permanent protecting groups. This was carried out by suspending the peptide–
resin in a mixture of 95% TFA, 2.5% H2O, and 2.5% TIPS (10 ml) for 3 hours, 
and then filtering and evaporation in vacuo to dryness and triturating with 4 ml 
diethyl ether. Finally, the off-white solids were analysed by RP-HPLC and MS.  
 
Regarding TIN2 peptide synthesis, after completion of all the amino acid 
coupling reactions, half of the peptide-resin was separated and β-Ala was 
coupled to the Ser256 residue of the one half peptide sequence; then, the N-
termini of the peptide sequence labelled by the fluorescein molecule (5-FAM). 
In the fluorescein tagging TIN2 reaction step, HOBt (1 eq.) and DIC (1 eq.) 
were used as activating reagents.  
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6.2.4 Produced Peptides 
 
TS01  
 Ser256-His-Phe-Asn-Leu-Ala-Pro-Leu-Gly-Arg-Arg-Arg- Val268-NH2 
 
 
MS: m/z (+ESI) calculated for C67H112N26O15 is 1520.88, found 761.4521 
(M+2H+) and 507.9683 (M+3H+). RP-HPLC 10-60 % B, in 18 min, tR 5.9 min. 
 
TS01-L 
5-FAM-β-Ala-Ser256-His-Phe-Asn-Leu-Ala-Pro-Leu-Gly-Arg-Arg-Arg- 
Val268-NH2 
 
 
 
MS: m/z (+ESI) calculated for C91H127N27O22 is 1950.97; found 976.4952  
(M+2H+), 651.3334 (M+3H+), and 488.7458 (M+4H+). RP-HPLC 10-60 % B, 
in 18 min, tR 7.4 min. 
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TS02 
Ser256-His-Tyr258-Asn-Leu-Ala-Pro-Leu-Gly-Arg-Arg-Arg- Val268-NH2 
 
 
 
MS: m/z (+ESI) calculated for C67H112N26O16 is 1536.87, found 769.4514  
(M+2H+) and 513.2959 (M+3H+). RP-HPLC 10-60 % B, in 18 min, tR 5.4 min. 
 
TS03 
Ser256-His-Phe-Leu259-Leu-Ala-Pro-Leu-Gly-Arg-Arg-Arg- Val268-NH2 
 
 
 
MS: m/z (+ESI) calculated for C69H117N25O14 is 1519.92, found 760.9876  
(M+2H+) and 507.6575 (M+3H+). RP-HPLC 10-60 % B, in 18 min, tR 6.4 min. 
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TS04 
Ser256-His-Phe-Asn-Leu-Thr261-Pro-Leu-Gly-Arg-Arg-Arg- Val268-NH2 
 
 
 
MS: m/z (+ESI) calculated for C68H114N26O16 is 1550.89, found 776.4598  
(M+2H+) and 517.9702 (M+3H+). RP-HPLC 10-60 % B, in 18 min, tR 5.9 min. 
 
TS05 
Ser256-His-Phe-Asn-Leu-Ala-Pro-Leu-Gly-Arg-Pro266-Arg- Val268-NH2 
 
 
MS: m/z (+ESI) calculated for C66H107N23O15 is 1461.83, found 731.9208  
(M+2H+) and 488.2768 (M+3H+). RP-HPLC 10-60 % B, in 18 min, tR 6.3 min. 
 
 
 
 
 
N
H
H
NN
H
H
NN
H
H
N
O
O
NH
O
NH
O
HN
O
O
O
NN
H
H
NN
H
H
NN
H O
O
O
O
O
N
HN
H2N
O
HO
NHH2N NHH2N
NHH2N
NH2
NH2 OHO
NH2N
H
H
N
NH
NN
H
H
NN
H
NH
NH2
O
O
O
O
O
O
N
H
NN
H
H
NN
H
H
N
O
O
O
O
O
O O
NH2
O
N
NH
2HN
OH
HN
NH2
HN
Chapter Six                                                                                                                  Experimental 
	181 
TS06 
Ser256-His-Phe-Asn-Gly260-Ala-Pro-Leu-Gly-Arg-Pro266-Arg- Val268-NH2 
 
 
MS: m/z (+ESI) calculated for C59H94N22O13 is 1318.74, found 660.3820  
(M+2H+) and 440.5880 (M+3H+). RP-HPLC 10-60 % B, in 18 min, tR 5.0 min. 
 
TS07 
 Ser256-His-Phe-Asn-Leu-Asn261-Pro-Asn263-Gly-Lys265-Arg-Ser267- 
Leu268-NH2 
 
 
 
MS: m/z (+ESI) calculated for C61H98N22O16 is 1394.75, found 698.2541  
(M+2H+) and 466.0143 (M+3H+). RP-HPLC 10-60 % B, in 18 min, tR 5.1 min. 
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TS08 
Ser256-His-Phe-Asn-Leu-Asn261-Pro-Asn263-Gly-Arg-Arg-Arg-Val268-NH2 
 
 
 
 
MS: m/z (+ESI) calculated for C63H103N27O15 is 1477.81, found 493.6815 
(M+2H+) and 370.6317 (M+3H+). RP-HPLC 10-60 % B, in 18 min, tR 5.0 min. 
 
TS09 
Ser256-His-Phe-Asn-Leu-Asn261-Pro-Leu-Gly-Lys265-Arg-Ser267-Leu268-
NH2 
 
 
MS: m/z (+ESI) calculated for C63H103N21O15 is 1393.79, found 697.7742 
(M+2H+) and 465.6921 (M+3H+). RP-HPLC 10-60 % B, in 18 min, tR 6.3 min. 
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TS10 
Ser256-His-Phe-Asn-Leu-Asn261-Pro-Asn263-Gly-Lys265-Arg-Ser267-
Val268-NH2 
 
 
MS: m/z (+ESI) calculated for C60H96N22O16 is 1380.74, found 691.2517 
(M+2H+) and 461.3439 (M+3H+). RP-HPLC 10-60 % B, in 18 min, tR 4.9 min. 
 
TS11 
Ser256-His-Phe-Asn-Leu-Arg261-Pro-Leu-Gly-Arg-Arg-Arg- Val268-NH2 
 
 
 
MS: m/z (+ESI) calculated for C70H119N29O15 is 1605.94; found 803.7291 
(M+2H+), 536.3444 (M+3H+) and 402.6352 (M+4H+). RP-HPLC 10-60 % B, 
in 18 min, tR 5.6 min. 
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TS12 
Ser256-His-Tyr258-Asn-Leu-Asn261-Pro-Asn263-Gly-Lys265-Arg-Ser267- 
Val268-NH2 
 
 
 
MS: m/z (+ESI) calculated for C60H96N22O17 is 1396.73, found 699.2429 
(M+2H+) and 466.6737 (M+3H+). RP-HPLC 10-60 % B, in 18 min, tR 4.5 min. 
 
TS13 
Ser256-His-Phe-Asn-Leu-Ala-Pro-Leu-Gly-Arg-Arg-Arg- Leu268-NH2 
 
 
 
MS: m/z (+ESI) calculated for C68H114N26O15 is 1534.90, found 768.2478 
(M+2H+) and 512.6854 (M+3H+). RP-HPLC 10-60 % B, in 18 min, tR 6.0 min. 
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6.3 Fluorescence Polarisation Assay 
6.3.1 Materials and Instrumentation  	
The essential materials used in the FP assays were: TRF1 protein stock 
solution (41.7 µM in 50% TED350 protein dilution buffer and 50% v/v glycerol 
pH 8.5); TS01-L stock solution (3 mM in water); and stock solutions of each of 
the peptide analogues (3 mM in water). An EnVision® Multilabel Plate reader 
2104 (Perkin Elmer) was used for reading the plates, these being black opaque, 
flat-bottomed, 96-well microplates (Thermo scientific Sterilin, Catalogue No. 
611F96BK). The reader used EnVision® version 2.12 data-capturing software 
(excitation wavelength was set on 480 nm and the emission wavelength was set 
on 535 nm); and GraphPad Prism Software was applied for analysing the 
results. 
 
6.3.2 Detection Sensitivity of the Instrument for TS01-L 
Increasingly diluted concentrations of TS01-L were prepared from the 3 mM 
stock solution, starting from 10 µM with subsequent dilutions down to 10 nM. 
Dilutions were performed in 0.5 ml eppendorf tubes and 100 µl was aliquoted 
to each well of the 96-well plate. In addition, 100 µl from both the 5 nM 5-
FAM (the solvent was water) and the TED350 buffer were aliquoted to each of 
the wells to act as gain detector and blank (to correct background 
fluorescence), respectively. Subsequently, the plate was loaded onto the 
EnVision® plate reader; the software automatically measured the plate 
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dimensions, but the gain and blank were manually adjusted. The plate was then 
read and FP measured for the samples. All of the saved data were exported to 
Graphpad software, which plotted the average of the measured FP of the wells 
for each point as a function of the peptide concentration.  
 
6.3.3 Determining the Concentration of TRF1 for the Assays 	
The concentration of TRF1 protein was optimised for the FP assays through 
measurement of its direct binding with TS01-L. Concentrating of the TRF1 
protein was the first step of this process because normally the highest 
concentration of the protein for the assay needs to be approximately 30–100 
µM so as to determine a plateau region and produce a complete binding curve 
241. For this step, 700 µl (7 aliquots each containing 100 µl) of TRF1 protein 
were put in Falcon™ 15 ml conical centrifuge tubes (Fischer Scientific). The 
glycerol concentration was diluted from 50% to 5.5% by adding 5.664 ml of 
TED350 buffer pH 8.5. After 5 hours centrifugation of the protein, the 
concentration had increased to 86 µM. NanoDrop was used to measure TRF1 
concentration. For the TRF1 centrifugation, a Vivaspin 20 ml spin concentrator 
(5,000 Da MW cut-off, Sartorius) in an Allegra® 25R centrifuge (Beckman 
Coulter) was used; it was operated at 2 ℃ and 4100 revolutions per minute 
(rpm).  
 
From the concentrated TRF1 protein solution, dilutions to 33.3 µM and 11.1 
µM (200 µl from each) were prepared. Eleven eppendorf tubes (0.5 ml) were 
then prepared as follows. The first tube received 180 µl of the 33.3 µM TRF1 
solution. The second tube received 180 µl of the 11.1 µM TRF1 solution. Eight 
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of the remaining eppendorf tubes each received 160 µl of TED350 buffer pH 
8.5, followed by each of them receiving 20 µl of different TRF1 concentrations 
(50% glycerol) as follows: 30 µM, 10 µM, 3 µM, 1 µM, 300 nM, 100 nM, 30 
nM and 10 nM. The last eppendorf tube received 180 µl of TED350 buffer 
containing 5.5% glycerol pH 8.5 (negative control). Subsequently, 20 µl of 1 
µM TS01-L solution were aliquoted to each of the eleven-eppendorf tubes, 
which led change glycerol concentration in each of the tubes to a 5%. All of 
the tubes were mixed through pipetting. The next step was to aliquot 200 µl 
from each sample into two wells (100 µl/well) of the 96-well plate. The 
samples were incubated for 30 min at room temperature and protected from 
light. The plates were then loaded onto the plate reader and measured as 
described in Section 6.3.2. The FP values were corrected through subtracting 
the measured control values. 
 
6.3.4 Competitive Binding Assay  	
These assays were achieved in two steps. First, a competitive assay between 
the labelled (TS01-L) and unlabelled TIN2 (TS01) with TRF1 was performed, 
and second, competitive binding assays between the mixture of TS01-L and 
TRF1 with all of the 13 peptides were performed. The stock solution of TRF1 
protein was diluted from 41.7 µM to 10 µM through collecting 12 aliquots of 
the protein (1.2 ml) in Falcon™ 15 ml conical centrifuge tubes (Fischer 
Scientific) and adding 3.804 ml of the buffer (50% TED350 and 50% glycerol) 
pH 8.5; the final volume of the protein solution was 5.004 ml. All of the 
dilutions were undertaken in an icebox, after which 5 ml of 1 µM TS01-L were 
Chapter Six                                                                                                                  Experimental 
	188 
prepared as a stock solution using water as a solvent. The next step was to 
make up 5 ml of 5 nM 5-FAM, again using water as a solvent.  
 
For each of the peptide analogues, starting with the 3 mM stock solution, 
increasingly diluted solutions (down to 100 nM) were prepared; afterwards, 40 
µl of each analogue concentration was aliquoted into separate 0.5 ml eppendorf 
tubes corresponding to the analogue concentration. Next, 40 µl of each of the 
TRF1 and TS01-L solutions and 280 µl of TED350 buffer pH 8.5 were added to 
each 0.5 ml eppendorf tube. Three extra eppendorf tubes had been prepared: 
the first contained only 360 µl TED350 buffer and 40 µl TS01-L (to act as a 
positive control); the second contained only the prepared 5 nM of 5-FAM (to 
act as the gain); and the third contained the TED350 buffer (to act as a blank to 
correct background fluorescence). The contents of each 0.5 ml eppendorf tube 
were mixed gently through pipetting. Finally, 300 µl from each eppendorf tube 
were aliqouted to three wells (100 µl/well) of the 96-well plate. The 
microplates were incubated for 30 min at room temperature and protected from 
light. After loading the plates to the EnVision® plate reader, the software 
automatically measured the plate dimensions, but the gain and blank were 
manually adjusted. The plate was then read and the FP measured for the 
samples. All of the saved data was exported to Graphpad software, which 
plotted the average of the measured FP of the three wells for each point as a 
function of the peptide concentration. The FP values were corrected through 
subtracting measured control values. Experiments were performed in triplicate. 
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Appendix 
A1 TRF1 Expression and Purification 
 
The hTRF1 expression and purification were performed to collect a pure TRF1 
protein for the experimental assays. The protocol was taken from the PhD 
thesis of Emily Golding 283, and the work was undertaken by me with the 
assistance and supervision of Dr Olivier Rannou. The construct (hTRF1 
pET28aHis6), which was prepared before, used for the protein expression. 
Then, to purify the protein, immobilised metal affinity chromatography 
(IMAC) and size exclusion chromatography (SEC) were carried out. Finally, 
dialysis was performed. 
 
A1.1 TRF1 Expression 
 
10 µl of XL1 blue competent cells, which contained the construct, was 
transformed into a 20 ml plastic tube contained 10 ml Luria Broth (16 g/l 
Casein Digest Peptone, 5 g/l NaCl, 10 g/l yeast extract) and 10 µl (10 mg/ml) 
kanamycin antibiotic. It incubated overnight at 30 ℃ and 180 rpm to grow the 
cells. Then, 2 ml was withdrawn and centrifuged at 12000 rpm for 1 min; the 
supernatant layer was removed. This step was repeated 7 times. Next, the 
plasmid DNA was separated from the precipitated cells using GeneJET 
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plasmid miniprep kit (Thermo Scientific). Subsequently, 10 µl of the plasmid 
DNA was transferred into 200 µl of BL21 (DE3) strain of competent E. coli 
cells, mixed gently, incubated for 30 min in the ice, put in the water bath for 45 
seconds at 42 ℃ and then to the ice for 2 min. After that, the cells were 
smeared onto Luria broth (LB)-agar plates contained chloramphenicol 34 µl/ml 
and kanamycin 30 µl/ml; the incubation was carried out for 24 hours at 37 ℃. 
The colonies appeared were selected to inoculate 4 plastic tube cultures; each 
of the cultures contained 10 ml LB, chloramphenicol and kanamycin. The 
cultures were grown overnight in a shaking incubator at 37 ℃. Add 10 ml 
from the overnight cultures to each of the 4 flasks (starter culture), which were 
prepared before and consisted of 500 ml of fresh LB salt (15.5 g broth in 
water); then, 0.5 ml chloramphenicol, 0.5 ml kanamycin and 1 drop of 
antifoam agent were added. The starter cultures were grown to optical density 
(O.D.)595 0.66, after which 0.5 ml of 1 M isopropyl β-D-1-
thiogalactopyranoside (IPTG) was added. Next, the flasks were incubated for 5 
hours at 30 ℃ and 180 rpm, followed by centrifugation at 4000 rpm and 4 ℃ 
for 20 min.  
 
The pellet was collected and the supernatant was discarded. Thereafter, 150 µl 
of the cocktail protease inhibitor and 40 ml of TED350 pH 8.5 buffer (50 mM 
Tris-HCl pH 8.5, 1 mM EDTA, 1 mM DTT, 300 mM NaCl) were added to the 
pellet. The sample was sonicated at 20 amplitude microns for 30 seconds using 
a MSE Soniprep 150 sonicator. The sonication was repeated for 6 times and 
after each sonication put the sample in the ice. After lysis of the cells, it was 
centrifuged at 4000 rpm and 4 ℃ for 40 min. The supernatant layer was 
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separated and filtered by syringe and filter 0.2 µM (Sartorius) in order to 
remove impurities. The expressed TRF1 protein was identified through sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) (Figure A.1). 
 
             M      1 
Figure A.1. SDS-PAGE of hTRF1 before purification. 1 is the 
protein and M is the marker. 
 
 
 
 
A1.2 TRF1 Protein Purification 
A1.2.1 Affinity Chromatography 
Affinity chromatography also termed IMAC was performed for His6-tag 
purification using an AKTA prime purification system. 5 ml HiTrapTM HP 
Chelating columns (GE Healthcare) was (re) charged with Ni2+ using 0.1 M 
NiSO4, following the manufacturers instructions. The column was first washed 
with 0.1 M EDTA, water and 0.1 M nickel. Two different types of buffer were 
used, buffer A (20 mM sodium phosphate buffer pH 8, 500 mM NaCl) and 
buffer B (20 mM sodium phosphate buffer pH 8, 500 mM NaCl and 500 mM 
imidazole). The column was equilibrated with IMAC binding buffer (buffer B). 
Loading clarified supernatant was started with buffer A, which resulted in 
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binding His-tag TRF1 to the nickel of the column, while other impurities were 
eluted. Then, buffer B washed the column and the protein eluted with an 
imidazole gradient 5-500 mM over 120 ml. The process was monitored 
spectroscopically measuring absorption at a wavelength of 280 nm. 4 ml 
fraction collected and was analysed by SDS PAGE (Figure A.2). Samples 
containing purified protein were pooled and stored at 4 ℃. 
 
Figure A.2. SDS-PAGE monitoring hTRF1 (58 KDa) elution from HiTrap TM HP 
Chelating columns.  
	
A1.2.2 Size Exclusion Chromatography 	
Size exclusion chromatography is also known as gel filtration, was performed 
using a Superdex® 75 (HiLoad 26/60 prep grade, GE healthcare) at 2 ml/min in 
TED350 buffer. S75 column was connected to the AKTA prime system to carry 
out gel filtration. TRF1 elution was noted after running 124 ml and collected. 
SDS PAGE was performed for 21 fractions using two gels; the first gel was for 
fractions 1-13 and the second gel was for fractions 14-21 (Figure A.3).  
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Figure A.3. SDS-PAGE monitoring hTRF1 (58 KDa) elution from the HiLoad 26/60 
Superdex 75 prep grade gel filtration column.  
 
A1.3 Dialysis 	
The protein sample in the dialysis tube was placed in a beaker contained 500 
ml TED350 buffer and 50% v/v glycerol in a cold room. The buffer was changed 
3 times during 36 hours. The final concentrated volume of the protein was 10 
ml, which was snap frozen in liquid nitrogen as 0.1 ml aliquots and stored at -
80 ℃. 
 
A1.4 Calculating hTRF1 Concentration 
The concentration of the purified hTRF1 protein was determined by measuring 
an absorbance at 280 nm using the NanoDrop spectrophotometer (Thermo 
Scientific). Sequence of the protein is composed of 449 amino acids and the 
MW is 51327 Da. For calculating molar absorptivity of hTRF1 stock solution, 
ProtParam tool of ExPasy (http://web.expasy.org/protparam/) 284-286 was used 
and the Beer-Lambert law calculated the concentration of it (Equation A.1). 
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A280 = ∑ b c   (Beer-Lambert Law)                                                 Equation A.1 
 
A280 is an absorbance at 280 nm, ∑ is the molar absorptivity in L mol-1 cm-1, b 
is the length of the light path in cm and c is the concentration in molarity. 
 
When, A280 = 1.77, ∑ = 42440 L mol-1 cm-1 and b = 1 cm; hence, c = 41.7 µM, 
or 2.14 mg /ml. 192 
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A2. Amino acid Abbreviations (IUPAC) 	
Abbreviation 
 
 Amino acid name 
Ala  
 
A Alanine 
Arg 
 
R Arginine 
Asn 
 
N Asparagine 
Asp 
 
D Aspartic acid 
Cys 
 
C Cysteine 
Gln 
 
Q Glutamine 
Glu 
 
E Glutamic acid 
Gly 
 
G Glycine 
His 
 
H Histidine 
Ile 
 
I Isoleucine 
Leu 
 
L Leucine 
Lys 
 
K Lysine 
Met 
 
M Methionine 
Phe 
 
F Phenylalanine 
Pro 
 
P Proline 
Ser 
 
S Serine 
Thr 
 
T Threonine 
Trp 
 
W Tryptophan 
Tyr 
 
Y Tyrosine 
Val 
 
V Valine 
β-Ala β-A β-Alanine 
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A3. Principal Component Analysis of the TIN2 Peptide 
Analogues 
 
A3.1 TS01  
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A3.2 TS02 
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A3.3 TS03 
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A3.4 TS04 
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A3.5 TS05 
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A3.6 TS06 
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A3.7 TS07 
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A3.8 TS08 
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A3.9 TS09 
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A3.10 TS10 
 
 
 
 
 
 
 
 
 
                                                                                                                                    Appendix 
	226 
A3.11 TS11 
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A3.12 TS12 
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A3.13 TS13 
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